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Abstract 
Upon vascular injury, platelets instantly adhere to the exposed extracellular matrix 
resulting in platelet activation and aggregation to form a haemostatic plug. This self-
amplifying mechanism requires a tight control to prevent uncontrolled platelet 
aggregate formation that could occlude the vessel. Endothelial-derived nitric oxide 
(NO) and prostacyclin (PGI2) are strong negative regulators that modulate platelet 
adhesion, activation, aggregation, secretion and shape change. In this study the 
effects of NO on Ca2+ dependent and independent pathways of activation were 
investigated. The data produced during the course of this study reveals new insights 
into the mechanisms by which NO regulates platelet responses via the activation of 
the AGC family of Ser/Thr protein kinases. NO inhibited platelet shape change in a 
concentration dependent manner. Platelet shape change is driven by 
phosphorylation of myosin light chain (MLC) and the experimental data shows that 
NO blocked this critical phosphorylation event. Phospho-MLC generated in response 
to platelet agonists occurs through a Ca2+ dependent and RhoA kinase (ROCK)-
dependent mechanisms and NO differentially inhibits both pathways. Activation of 
the ROCK pathway via RhoA leads to the phosphorylation MLC phosphatase 
Threonine696/853, which inhibits enzyme activity. Experimental evidence in this thesis 
indicates that NO, acting through cGMP and protein kinase G, prevents this 
inhibitory phosphorylation of MLCP by at least two mechanisms, (i) inhibiting the 
ROCK pathway that phosphorylates MLCP, and (ii) directly phosphorylating MLCP at 
an independent site, Serine695.  These original observations hint at a novel 
mechanism for platelet regulation by the NO-cGMP-signalling pathway. 
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1.1 Overview 
 
Platelets are critical components of cardiovascular medicine(Heemskerk et al., 
2002). They have roles in the maintenance of haemostasis and also are highly 
involved mediators in pathophysiological processes in cardiovascular disease. This 
includes arterial thrombosis that is the key to the pathogenesis of acute ischemic 
syndromes. Blood vessels that have been affected by metabolic disturbances, 
smoking or high blood pressure develop lipid rich plaques in the walls that on rupture 
leads to activation of the platelets and precipitates clot formation that may occlude 
the lumen resulting in a heart attack (Gregg & Goldschmidt-Clermont, 2003). 
Unregulated platelet aggregation plays a fundamental role in development of 
cardiovascular events and hence controlling the function of these cells is important in 
prevention and treatment of these events(Kumar & Kao, 2009). Anti-platelet drugs 
such as aspirin, di-pyridamole and clopidogrel have been used successfully in 
secondary stroke prevention(Bednar & Gross, 1999) and improving mortality, though 
yielding disappointing results in the long term treatment of chronic stable 
cardiovascular disease (Coccheri, 2010). A possible basis of future treatment is 
centred on pre-existing biological inhibitors, such as novel nitric oxide releasing 
derivatives and combining them successfully with existing therapies (Li et al., ; 
Saavedra et al., 2000). 
1.2 Platelet formation 
 
Blood platelets are small sub-cellular fragments that are derived from the bone 
marrow cells megakaryocytes, which then circulate in blood in the discoid shape. 
Megakaryocytes arise from pluripotent human stem cells (HSCs) that develop into 
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two types of precursors, burst-forming cells and colony-forming cells, both of which 
express the cluster designation CD34 antigen (Briddell et al., 1989). Development of 
both cell types continues along an increasingly restricted lineage culminating in the 
formation of megakaryocyte precursors that develop into megakaryocytes (Ogawa, 
1993). The major function of the megakaryocytes is to produce platelets, a process 
termed thrombopoiesis, which are critical for haemostasis. During its lifespan, a 
mature megakaryocyte can produce up to 10,000 platelets (Long, 1998). 
Thrombopoietin (TPO), the primary regulator of thrombopoiesis, is currently the only 
known cytokine required for megakaryocytes to maintain a constant platelet mass 
(Kaushansky, 2005). TPO is thought to act in conjunction with other factors, 
including interleukins IL-3, IL-6, and IL-11, although these cytokines are not essential 
for megakaryocyte maturation (Kaushansky & Drachman, 2002). Cells committed to 
the megakaryocytic lineage begin to expressCD41 and CD61 (Integrin αIIbβ3), CD42 
(glycoprotein Ib) and glycoprotein V (Roth et al., 1996; Hodohara et al., 2000), 
providing cell surface markers. Megakaryocytes tailor their cytoplasm and membrane 
systems for platelet biogenesis. Before a megakaryocyte has the capacity to release 
platelets, it enlarges considerably to an approximate diameter of 100µm and fills with 
high concentrations of ribosomes that facilitate the production of platelet-specific 
proteins (Long et al., 1982) and undergoes endomitosis to increase in size and ploid 
to a deoxyribonucleic acid (DNA) content in excess of 16n and amassing reserves of 
membrane(Radley & Haller, 1982),granules and cytoskeletal proteins (Schulze & 
Shivdasani, 2004). Upon completion to mature megakaryocytes, they are polyploid 
and no longer proliferate but generate platelets by remodelling their cytoplasm 
(Italiano et al., 1999) resulting in the formation of cytoskeletal tracks, termed 
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proplatelets, which serve as assembly lines for platelet production (Becker & De 
Bruyn, 1976). 
 
Components essential for platelets such as granules, organelles and ribosomes are 
transported from the megakaryocyte body to the protrusions where synthesis and 
release of the platelet occurs (Italiano et al., 1999). Platelet release occurs as these 
proplatelets extrude into the marrow sinusoids (De Botton et al., 2002) or the entire 
megakaryocyte enters the circulation for release (Tavassoli & Aoki, 1981). 
1.3 Blood platelets 
 
As a product of evolution, mammals have evolved the use of sub-cellular fragments 
called platelets as specialised components within the blood to prevent excessive 
blood loss, a process termed haemostasis. However platelets can also perform 
important roles in wound healing and inflammation (Szalai et al., 2006). They are 
present with in the blood at concentration as high as 2-3x108ml; in circulating blood 
platelets are small discs of the dimensions 0.5 x 3.0µm (Bessis et al., 1973). 
Platelets are generated continually and release into the blood stream, then circulate 
for approximately seven days, and can leave the circulation by two major 
mechanisms: (1) consumption at common sites of minor vascular injury and (2) 
phagocytosis by macrophages, predominantly in the spleen and liver (Keith R. 
McCrae, 2006). Generation of small, discoid platelets allows efficient dispersal of clot 
promoting cells within circulation. As consequence of their small size and the 
complex motion of red blood cells, which constitute a large fraction of the blood's 
volume, platelets are pushed to the outer area of the lumen thereby resulting in an 
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intimate relationship with the endothelium and rapid responses to potential sites of 
vascular injury (Crowl & Fogelson, 2010).  
1.4 Platelet Structure 
 
Platelets are anucleate cells, but contain a number of organelles that enable them to 
perform their functions. The outer surface of the platelet is the thicker exterior coat or 
glycocalyx (White, 1971), which is covered with glycoprotein’s (GP) necessary 
receptors for cell-cell and cell-vessel wall interactions to trigger full activation of the 
platelet, principally GP Ib-IX-V complex and integrin αIIbβ3 (the GPIIb-IIIa complex), 
but also a wide range of other receptors. 
 
The lipid bilayer on which the glycocalyx rests is a typical membrane (White & 
Conard, 1973), though it serves an extremely important role in the acceleration of 
clotting, specific to platelets. The bilayer consists of cholesterol-rich lipid islands in 
the resting platelet surface membrane (Del Conde et al., 2005) which following 
platelet activation become associated with the outer layer of the unit membrane, 
bringing anionic phosphatidylserine to the exposed surface and converting pro-
thrombin to thrombin. 
 
The surface connected Open Canalicular System (OCS) is derived from the plasma 
membrane and demarcation membrane system of the megakaryocytes, though is 
not only connected to the platelet surface membrane, it is an extension of the 
surface membrane (Behnke, 1968). The OCS channels are an extension of the 
surface membrane weaving through the cytoplasm. It provides two distinct functions; 
it greatly expands the surface area of the platelet exposed to circulating 
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plasma(Frojmovic et al., 1992) and provide a means for substances to reach the 
deepest recesses of the cell(White, 1972), and serve as channels for the release of 
products stored in secretory organelles during the platelet release reaction(White & 
Krumwiede, 1987). After adhesion to a damaged vascular surface, the platelet 
extends filopodia to bind firmly to the injured area. This is followed by the assembly 
of cytoplasmic actin and spreading of the platelet to cover as much area as possible, 
resulting in a 420% increase in exposed surface area, only possible due to the 
reserve of densely compacted OCS allowing for the expanded surface area of the 
spreading platelet (Escolar et al., 1989). 
 
The Dense Tubular System (DTS) has been indicated to haveCa2+ binding sites and 
enzymes involved in prostaglandin synthesis (Gerrard et al., 1976). Like the OCS, 
channels of the DTS are randomly dispersed in the platelet cytoplasm, though in 
close association with the circumferential band of microtubules, the DTS 
representing residual smooth endoplasmic reticulum of the parent cell. 
 
The area lying just under the membrane is the platelet cytoskeleton, critically 
important to platelet function. The cytoplasmic domains of all transmembrane 
receptors interact in the sub-membrane area, with numerous protein constituents 
regulating the signalling processes of platelet activation. A number of these proteins, 
such as the actin-binding protein filamin, are linked to the GPIb-IX-V complex and 
the cytoplasamic tails of GPIIb and GPIIIa, are associated with calmodulin, myosin, 
and the short actin filaments making up the membrane contractile cytoskeleton. The 
contractile system is involved in the translocation of receptor complexes, including 
GPIb-IXV and GPIIb-IIIa, on the platelet exterior surface. 
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There are two filament systems in the platelet cytoplasm. One is the circumferential 
coil of microtubules, the loss of which is linked to the loss of discoid form (White & 
Krivit, 1967). The other, the actomyosin filament system, is involved in shape change 
(Escolar et al., 1986). The cytoplasmic actin filament cytoskeleton has a function in 
platelet physiology separate from that of the submembrane actin cytoskeleton. In the 
resting cell, it serves as the matrix on which all organelles and other structural 
components are suspended and maintained separate from each other and the cell 
wall (Escolar et al., 1986). 
 
Following platelet activation in suspension or on surfaces, the cytoplasamic 
actomyosin cytoskeleton has a unique role in contractile physiology. It constricts the 
circumferential microtubule coils and drives the α-granules and dense bodies into 
close association in platelet centres (White, 1968) and prolonged stimulation 
resulting in the secretion of granule and dense body contents via channels of the 
OCS (Escolar et al., 1986) leaving behind a dense, central mass of actomyosin. The 
constriction of the activated platelet thus influences the release of secondary 
mediators from internal organelles; α-granules, dense bodies and lysosomes, of 
which α-granules are the most numerous of the platelet organelles (Reed, 2004). 
There are usually 40 to 80 α-granules per platelet; they are round to oval in shape 
and 200 to 500nm in diameter, with their interior substructure divided into zones.  
 
Human platelet dense bodies are smaller than the α-granules and fewer (Berger et 
al., 1996), there being four to eight dense bodies per platelet which are rich in 
adenine nucleotides, including adenosine triphosphate (ATP) and adenosine 
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diphosphate (ADP), and serotonin. The last of the main storage granules are 
lysosomes, which are spherical in form and slightly smaller than α-granules.  
Their contents, together with products stored in α-granules and dense bodies, can be 
released when platelets are exposed to strong, sustained stimulation. 
1.5 Platelet activation and thrombus formation 
 
Platelets activation is critical in thrombus formation and can be summarised into 
three overlapping stages; initiation, extension, and perpetuation. 
1.6 Platelet adhesion to vessel wall 
 
At the sites of vascular injury, the sub-endothelial extracellular matrix (ECM) is 
exposed to constituents within the circulating blood, triggering activation. The ECM 
contains a number of proteins that can contribute to the capturing of platelets 
including collagen, collagen-bound von Willebrand factor (vWF), laminin and 
fibronectin. The most important of these are collagen and vWF. The mechanisms of 
platelet adhesion at the sites of injury are determined by the rheological conditions. 
Under low shear conditions, collagen alone is able to immobilise and activate 
platelets, though under the conditions of high shear found in the arterial circulation, 
vWF plays an essential role in adhesion and activation of platelets. Blood flows with 
a greater velocity in the centre of the vessel then near the wall, thereby generating 
shear forces between layers of fluid becoming maximal at the wall (Eskin et al., 
2006). The drag which opposes platelet adhesion increases with the shear rates 
depending on the vessels. Under high shear rates present in small arteries the initial 
tethering to the site of injury is mediated by GPIb-IX complex on the platelet surface 
and VWF bound to collagen(Savage et al., 1998). The binding of GPIb to VWF is 
insufficient to mediate strong or stable adhesion; though it enables the maintenance 
  
8 
 
of platelet contact with the damaged area enabling the characteristic ‘rolling’ along 
damaged surfaces (Figure.1.1). This allows the platelet to establish contact with the 
thrombogenic collagen via its GPVI. The GPVI receptor binds directly to collagen 
through the specific Gly-Pro-Hyp peptide repeat sequence triggering the clustering of 
receptors and an activatory signalling cascade through tyrosine kinases(Knight et al., 
1999). These signalling events termed inside-out signalling leads to the conversion 
of platelet integrins from low to a high affinity state, allowing them to form stable 
adhesion with the ECM. Inside-out signalling can be initiated through platelet 
adhesion or via the different G-protein subfamilies. Upon damage to the sub-
endothelial layers, collagen and VWF are exposed leading to the engagement of the 
GPVI and the GPIb-IX-V complex upon the platelet triggering inside-out signalling, 
with collagen been able to induce shape change, aggregation and secretion 
(Packham et al., 1977). Binding of collagen to GPVI, the major platelet collagen 
receptor to mediate cellular activation (Nieswandt & Watson, 2003) allows the 
clustering of the receptor and its associated Fc receptor γ chain. This leads to the 
activation of PLCγ2 via Syk(Moroi & Jung, 2004) and subsequently inducing the 
formation of secondary messengers DAG and IP3, activating PKC and elevating 
cytosolic Ca2+ levels (Grosse et al., 2007), while been supported by collagen binding 
to α2β1 simultaneously (Holtkotter et al., 2002). Together this results in strong 
integrin activation and release of stored mediators (Nieswandt & Watson, 2003) 
VWF binding to the GPIb-IX-V complex can also activate the αIIbβ3 integrin. 
 
In addition, several members of the integrin family facilitate platelet interactions with 
adhesive proteins. Integrins are heterodimeric cell surface molecules which consist 
ofα and β subunit. Eight β-type subunits are known and have been shown to be 
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highly homologous to one another. Further, 14 α-type subunits have been identified, 
which also demonstrate similarities. Each β-subunit can form a non-covalent 
complex with anα-subunit to form a functional adhesive protein receptor. The most 
widely expressed integrin on platelets is the integrin αIIbβ3 with up to 40,000 copies 
expressed on the membrane of one resting platelet. The numbers of αIIbβ3 integrins 
are increased during platelet activation to up to 80,000 copies per cell. The integrin 
αIIbβ3 primarily binds to the plasma protein fibrinogen.  In the context of platelet 
adhesion inside-out signalling leads to the activation of α2β1, which can then forma 
high affinity interactions with collagen(Moroi et al., 2000). 
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Figure.1.1 Platelet adhesion and aggregation on the ECM 
 
The GPIb-vWF interaction mediates platelet tethering thereby enabling GPVI 
interaction with collagen. This triggers the shift of integrins to a high-affinity state and 
release of ADP and TXA2. In parallel, tissue factor (TF) locally triggers thrombin 
formation which also contributes to platelet activation (Varga-Szabo et al., 2008b). 
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1.7 Extension of the platelet plug 
 
Following the formation of the platelet monolayer upon exposure to collagen and 
vWF further platelets are recruited to this monolayer. This is the recruitment of 
circulating platelets to the adhered platelets at the wound site, termed aggregation. 
Key to the extension of the platelet plug beyond the monolayer adhered directly to 
collagen is the presence of local accumulations of soluble agonists that are secreted 
from platelets, such as ADP and TXA2and by the local generation of thrombin upon 
the surface of activated platelets. In order for platelet aggregation to occur 
fibrinogens as well as divalent cations are required. Platelet activation by one or 
more of the above agonists leads to the rapid activation of the integrin αIIbβ3. Once 
activated, each integrin heterodimer is able to bind one fibrinogen molecule in the 
presence of divalent cations, such as Ca2+. In the absence of Ca2+ fibrinogen no 
longer binds to its receptor and platelet aggregation does not occur. Further, it has 
been demonstrated that integrin clustering can lead to integrin activation and 
fibrinogen binding (Hato et al., 1998; Li et al., 2001; Li et al., 2004). Initial fibrinogen 
binding to the integrin αIIbβ3 is reversible, which can lead to the disaggregation of 
platelets, as would be the case if Ca2+ were removed. However, fibrinogen binding 
undergoes a time dependent stabilisation which results in irreversible fibrinogen 
binding and irreversible aggregation (Bennett & Vilaire, 1979).  αIIbβ3can also bind 
with multimeric VWF, fibronectin and thrombospondin(Ma et al., 2007). Once bound 
to its ligand, fibrinogen,αIIbβ3 generate intracellular signals, achieved through a short 
β-subunit cytoplasmic tail (Tadokoro et al., 2003).This type of signalling refers to 
intracellular signalling events that do occur downstream of activated integrins (Shattil 
& Newman, 2004). 
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1.7.1 Platelet activation by soluble agonists 
 
As highlighted in the previous section recruitment of platelets into the growing 
aggregate requires the use of potent autocrine and paracrine signalling pathways 
though secretion of the soluble mediators (Figure.1.2) once platelet adhesion has 
been initiated. The receptors involved in their detection are typically members of the 
G-Protein Coupled Receptor (GPCR) family, which are ideally suited to the process 
as they are able to bind their ligands with a high affinity. Agonist binding to the 
surface-accessible domains of GPCR cause a conformational change that activates 
the G proteins constitutively associated with the intracellular surface of the 
receptor(Hamm, 2001). The amplification of the original signal triggered by the 
agonist upon the receptor is another key feature due in part to its use of the guanine 
nucleotide exchange factors, allowing the receptor to activate multiple G-proteins 
and also other classes of G-protein and potentially other effector pathways ensuring 
the rapid activation and recruitment of platelets into the growing thrombus. 
 
GPCR are membrane proteins that have an extracellular N-terminus, an intracellular 
C-terminus and seven transmembrane domains(Palczewski et al., 2000). G proteins 
interact with the cytoplasmic domains of the receptor with a specificity determined by 
the receptor domain itself and by the sequence of the α-subunit of the G protein. The 
G proteins are heterotrimers comprising α, β, and γ subunits. The α-subunit contains 
a guanine nucleotide binding site, which is present in the off state by the occupation 
of the site with guanosine diphosphate (GDP). Upon receptor activation GDP is 
exchanged for guanosine triphosphate (GTP), thus altering the conformation of the 
α-subunit and leading to the exposure of the sites on both the Gα and Gβγ for 
interaction with downstream effectors(Ford et al., 1998). The duration of activation of 
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the G protein is intrinsically regulated by the action of the GTPase upon the GTP 
loaded α-subunit. Hydrolysis is accelerated by the presence of a regulator of G 
protein signalling (RGS) with the acylation of Gα and prenylation of Gβγ allowing the 
subunits to remain bound to the membrane until the GTP from the Gα has been 
hydrolysed and ultimately return the heterotrimer to the inactive state awaiting further 
activation (Ross & Wilkie, 2000). 
 
Human platelets express four families of G proteins that are referred to by the 
designation of the α-subunit, and there are ten forms of the Gα that fall within the Gsα, 
Giα, G12α and the Gqα families. These include at least one member of the Gs family, 
four members of the Gi family (Gil, Gi2, Gi3 and Gz) which stimulate and inhibit cAMP 
formation by adenylyl cyclase. Three further of the Gq family (Gq, G11, and G16) which 
stimulate β isoforms of phospholipase C(Offermanns et al., 1997), and two G12 
members (G12 and G13) which regulate the platelet cytoskeleton(Offermanns et al., 
1994; Klages et al., 1999). The Gβγ isoforms are less well understood than the α-
subunit, and their contribution to selective activation of platelets, though the 
abundance of G protein types is necessary to support the differing actions of 
numerous agonists (Yang et al., 2002). 
 
GPCR responding to platelet agonists differ in the strength of their response and 
their preferences for intracellular effector pathways, using a distinct mechanism to 
achieve full activation. Receptors for thrombin, protease activated receptors (PAR-1 
and PAR-4), ADP (P2Y1 andP2Y12) and TxA2 (TP) cause activation of 
phospholipase C (PLC) leading to hydrolysis of phosphatidylinositol-4-5-
bisphosphate (PIP2) in the membrane and subsequent secondary messengers 
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elevate cytosolicCa2+ concentration by activating Gq(Offermanns et al., 1997). The 
ADP and epinephrine receptors, P2Y12 and α2A-adrenergic receptors are coupled to 
Gi2 or Gz which can regulate the inhibition of adenylyl cyclase(Yang et al., 2000; 
Yang et al., 2002) and activation of phosphatidylinositol 3-kinase (PI3K) and 
downstream effector the serine/threonine kinase Akt(Vanhaesebroeck et al., 2001; 
Cantley, 2002). Thrombin and TxA2 activation can also cause the rearrangement of 
the actin cytoskeleton defining platelet shape change through the RhoA/Rho-kinase 
mediated pathway regulated by the G12/G13 family, in which activated G13 binds and 
activates Rho-specific guanine nucleotide exchange factors (Offermanns et al., 
1994; Hart et al., 1998). 
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Figure.1.2 Overview of platelet activation 
 
Most platelet agonists activate platelets via G protein coupled receptors on the 
platelet surface. Critical responses include Gq mediated activation of phospholipase 
Cβ isoforms to allow an increase in cytosolic Ca2+, activation of phospholipase A2 
and protein kinase C, and G12 mediated activation of Rho family members to support 
rearrangement of the platelet cytoskeleton (shape change). The increase in cytosolic 
Ca2+ is initially caused by the IP3triggered release of Ca2+ from within the dense 
tubular system of the platelet, which in turn triggers Ca2+ influx across the platelet 
plasma membrane. TP = thromboxane receptor (Brass, 2003). 
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1.8 Platelet Aggregation 
 
The accumulation of platelets into a thrombus is based on multiple ligands 
(fibrinogen, fibronectin and VWF), receptors (GPIbα and αIIbβ3) and platelets in 
different activation states (Jackson, 2007). The major integrin mediating platelet 
aggregation is αIIbβ3, binding to fibrinogen and VWF. The structural arrangement of 
these ligands, fibrinogen being dimeric and the multimeric structure of VWF allows 
the formation of cross-bridges with other platelets and generation of a platelet 
aggregate. In the quiescent platelet the αIIbβ3 integrin is in an off state, though upon 
activation and intracellular signalling process the cytoplasamic part of αIIbβ3 is 
converted into an active state (inside-out signalling) resulting in the binding of 
fibrinogen and VWF thus mediating platelet aggregation (Sehgal & Storrie, 2007). 
 
The formation of reversible platelet aggregates results in the platelet activation and 
formation of stable aggregates as the space between aggregating platelets provides 
an enclosed environment for accumulation of soluble agonists such as thrombin, 
ADP and TxA2. These agonists inducing activation, shape change and secretion of 
granule products act via GPCR, resulting in inside-out signalling of αIIbβ3.  
 
The requirement of Ca2+ elevation via the Gq mediated signalling for agonist induced 
αIIbβ3 has been demonstrated on Gq deficient platelets, which fail to aggregate in 
response to thrombin, ADP and TxA2 due to the lack of PLC activation (Offermanns 
et al., 1997) though not solely based on Gq activation. A role for Gi mediated 
signalling in αIIbβ3 activation is shown by its deficiency in platelets, with a reduced 
response to thrombin and ADP (Jantzen et al., 2001). Thus Gq and Gi are required in 
order to induce platelet activation. 
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Through the activation of Gq and Gi, CalDAG-GEFI, guanine nucleotide exchange 
factor activates Rap1 (Dupuy et al., 2001), Rap1 absence results in decreased αIIbβ3 
activation and decreased platelet activation (Crittenden et al., 2004). Studies on 
platelets lacking the G13 coupled protein confirm its mediation over the activation of 
αIIbβ3 and RhoA/Rho-kinase pathway, indicate their role in platelet aggregation 
(Missy et al., 2001; Schoenwaelder et al., 2002). 
 
Although the precise signalling mechanisms are as yet unclear, it has been 
demonstrated that rapid platelet aggregation requires the heterotrimeric G-proteins 
Gq, G12/13 and Gi to achieve efficient αIIbβ3 activation. 
1.9 Perpetuation 
 
Further signalling events are necessary to stabilise the platelet plug, preventing 
disaggregation and break-up of the clot. Perpetuation occurs at this point when 
platelets are in close enough contact and for a sufficient duration allowing contact 
dependent signalling possible, which can only occur once platelet aggregation 
begins. Estimations of the width required to allow molecules on the platelet surface 
to bind to each another range from zero to 50nm(Skaer et al., 1979). This takes the 
form of contact dependent signalling mechanisms. When multivalent adhesive 
proteins bind activated αIIbβ3 on adjacent platelets, this involves outside-in signalling 
through the integrin (Phillips et al., 2001), which can associate with cytoskeletal 
structures in thrombin aggregated platelets (Phillips et al., 1980). The β3 domain of 
activated αIIbβ3 is essential for any thrombus formation (Hodivala-Dilke et al., 1999) 
and deficiency or absence of its ligands fibrinogen, VWF and fibronectin result in 
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slow and unstable thrombus formation. They are necessary for anchoring the platelet 
mass, thus preventing the release of the thrombus further downstream and 
embolism forming (Ni et al., 2000; Ni et al., 2003). The gaps between platelets within 
the thrombus also allow the accumulation of platelet derived molecules. In addition to 
the continual release of ADP and TXA2, platelets also shed surface proteins. This 
exodomain shedding of CD40 ligand and thereby the accumulation in the inter-
platelet gaps promotes thrombus stability by binding to activated αIIbβ3(Andre et al., 
2002). The stability of the thrombus is also mediated by other adhesion and 
signalling receptors besides αIIbβ3, such as platelet endothelial cell adhesion 
molecule-1 (PECAM-1), junctional adhesion molecules (JAM), endothelial cell 
specific adhesion molecule ESAM, CD226 and Eph kinases/ephrins and Gas 6 on 
the platelet surface (Brass et al., 2005). The close contact of the platelets enables 
these interactions, allowing the ligands of one platelet to interact with the receptor of 
an adjacent platelet regulating the growth of the platelet thrombus and stability. 
 
1.10 Platelet Pro-coagulant Activity 
 
Thrombus formation is linked to the activation of the coagulation cascade resulting in 
its final stabilisation by a fibrin network, platelet adherence and aggregation at the 
site of injury localise subsequent pro-coagulant events.  
The coagulation cascade is composed of the contact activation pathway (intrinsic), 
and the tissue factor (TF) pathway (extrinsic); both activate a final common pathway 
of factor X, thrombin and fibrin formation (Figure.1.3). 
 
  
19 
 
The blood coagulation cascade is propagated through the formation of enzymatic 
complexes composed of a vitamin K-dependent serine protease and a non-
enzymatic cofactor protein that are assembled on the membrane surface in a Ca2+ 
dependent manner (Mann et al., 1990).  
Coagulation is initiated upon damage to the endothelium lining, when sub endothelial 
TF, an integral membrane protein, is exposed to blood flow (Weiss et al., 1989). TF 
can also be expressed under pathological conditions on the surface of activated 
monocytes or endothelial cells (Carlsen et al., 1988; Camera et al., 1999). The TF 
pathway can be considered the fuse that ignites coagulation with a small amount of 
thrombin (Orfeo et al., 2005). 
 
The serine protease factor VIIa (activated factor VII), circulating in blood at sub-
nanomolar concentrations (Eichinger et al., 1995), binds to tissue factor to form 
extrinsic Xase, which activates the zymogens, factor IX and factor X, to their 
corresponding serine proteases factor IXaβ and factor Xa(Bom & Bertina, 1990). 
Subsequent to formation of a TF/factor VIIa complex, the limited amounts of factor 
Xa produced assemble into prothrombinase via a Ca2+ dependent interaction with 
membrane bound factor Va initially to generate picomolar amounts of thrombin 
(Kalafatis et al., 1994). Upon formation, thrombin significantly amplifies and also 
sustains the coagulant response. Thrombin also recruits more platelets to the 
growing thrombus and sustains coagulation. Thrombin activates additional factor V 
to factor Va, as well as factor VIII to factor VIIIa to thereby allow continued 
prothrombinase and intrinsic Xase formation and function(Butenas et al., 1997).  
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Thus, membrane-bound factor VIIIa binds factor IXaβ in a Ca2+-dependent manner 
forming intrinsic Xase(Tans et al., 1991), which activates factor X 50 to 100 times 
faster than the factor VIIa-TF complex (extrinsic Xase)(Ahmad et al., 1992). The 
thrombin, continuously produced via prothrombinase, amplifies its own generation by 
activating factor XI (Gailani & Broze, 1991) and continuing to activate additional 
platelets and factors V and VIII (Pieters et al., 1989). Further activation of platelets 
leads to secretion of α-granule contents and coagulation factors leading to platelet 
pro-coagulant activity by the surface exposure of phosphatidylserine supporting the 
formation of thrombin and by facilitating the assembly of prothrombinase, tenase and 
coagulation factors on the surface of the activated platelet (Heemskerk et al., 2002).  
 
Thrombin now converts fibrinogen to fibrin(Mosesson, 1992) and factor XIII (Naski et 
al., 1991), forming a loose mesh, the building block of the haemostatic plug, with 
thrombin acting upon factor XIII to form covalent bonds that cross link the fibrin 
polymers that form from the activated monomers to stabilising the dense mesh and 
allowing the formation of a stable thrombus(Brummel et al., 1999). 
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Figure.1.3 Intrinsic and extrinsic systems of the coagulation cascade 
 
Interaction between clotting factors (XII, XIIa, XI, XIa, IX, IXa, VII, VIII, X, Xa, and 
XIIIa) and the platelet membrane. (Modified from Fuster V, Stein B, Ambrose JA, et 
al: Atherosclerotic plaque rupture and thrombosis: evolving concepts. Circulation 
1990; 82[Suppl II]: II-47-II-59.) 
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1.10.1 Calcium signalling in platelets 
 
The activation pathway for all agonists converge downstream to increase the 
intracellular Ca2+ concentration (Rink & Sage, 1990). The increase in cytosolic Ca2+ 
upon platelet activation derives from two sources; namely from intracellular stores, 
such as the endoplasmic reticulum (ER)/ dense tubular system (DTS) and acidic 
stores, though also from extracellular compartment. The major Ca2+ store in platelets 
is the DTS; its Ca2+ concentration is in the micromolar range and approximately ten 
thousand times higher than in the cytosol. This results in the leakage of Ca2+ though 
it is continually pumped back into the ER/DTS via the sarcoplasmic/endoplasmic 
reticulum Ca2+ ATPase (SERCA) (Papp et al., 1991). Cytosolic Ca2+ elevation occurs 
as a result of the release of the Ca2+ cation from the intracellular stores and influx 
from the outside medium(Figure.1.4). The key element involved in this elevation is 
the activation of cell surface receptors coupled to Gq that lead to the stimulation of 
phospholipase C (PLC), leading to the hydrolysis of phosphatidyl-1,4-
bisphosphate(PIP2) into 1,2-diacyl-glycerol (DAG) and inositol-1,4,5-trisphosphate 
(IP3), causing Ca2+ release and activating protein kinase C (PKC), together 
implicating Gq in both processes (Somlyo & Somlyo, 1994). IP3 in turn induces Ca2+ 
release from the ER/DTS by binding to its channel pore receptor, the IP3 receptor 
(IP3R) in the stores. As the internal store becomes depleted specific plasma 
membrane Ca2+ channels open allowing extracellular Ca2+ to enter the cytosol 
further increasing the Ca2+ concentration and also to refill the now depleted internal 
stores. The mechanisms and channels for Ca2+ entry are poorly understood though 
are critical for full activation of the platelet (Nesbitt et al., 2003). This process is 
termed store-operated Ca2+ entry (SOCE) and is a major pathway for Ca2+ entry after 
store depletion (Putney et al., 2001).  
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Figure.1.4 Platelet calcium 
Upon receptor activation different phospholipase (PL) C isoforms hydrolyze 
phosphatidilinositol-4, 5-bisphosphate (PIP2) to inositol-1, 4, 5-trisphosphate (IP3) 
and diacyl-glycerol (DAG). IP3 releases Ca2+ from the intracellular stores and in turn 
STIM1 opens Orai1 channels in the plasma membrane, a process called store-
operated calcium entry (SOCE), whereas DAG mediates non-SOCE through 
canonical transient receptor potential channel 6 (TRPC6). Additionally, a direct 
receptor-operated calcium (ROC) channel, P2X1, and a Na+/ Ca2+ exchanger 
(NCX)contribute to the elevation in [Ca2+]i. The counteracting mechanisms involve 
sarcoplasmic/endoplasmic reticulum Ca2+ ATPases (SERCAs) and plasma 
membrane Ca2+ ATPases (PMCAs), which pump Ca2+ back into the stores or 
through the plasma membrane out of the cell, respectively. IP3R, IP3receptor; ATP, 
adenosine triphosphate; ADP, adenosine diphosphate; GPVI, glycoprotein VI; FcRγ, 
Fc receptor γ chain; FcγRIIa, Fc γ receptor IIa;CLEC-2, C-type lectin-like receptor 2; 
PI3-K, phosphatidylinositol 3-kinase; Syk, spleen tyrosine kinase. Due to 
controversies about the localization and role of TRPC1 in the literature, this protein is 
not depicted in the figure (Varga-Szabo, 2009). 
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1.10.2 Store-Operated Calcium Entry 
 
In non-excitable cells, as seen in platelets, the IP3 mediated Ca2+ release from the 
internal stores and their depletion triggering Ca2+ entry from the extracellular 
environment is referred to as store-operated calcium entry (SOCE)(Parekh & Putney, 
2005). This itself does not represent a distinct channel type or mechanism (Guo & 
Huang, 2008), though numerous potential mechanisms(Figure.1.5) have evolved on 
the molecular link between the Ca2+ stores release and SOCE (Putney, 2007). 
 
1.10.3 Role of STIM 
 
Grosse et al (Grosse et al., 2007) were the first to demonstrate that the stromal 
interaction molecule 1 (STIM 1)  is key to Ca2+ signalling. Stim 1 is a single 
transmembrane spanning protein containing two N-terminal EF hand (Ca2+-binding 
motifs composed of two helixes (E and F) joined by a loop, Ca2+ is bound by the loop 
region) domains situated in the ER lumen and bindsCa2+. In resting platelets these 
EF hands are occupied by Ca2+, though upon activation and depletion of Ca2+ stores, 
the EF hand are no longer occupied and STIM 1 redistributes to puncta to interact 
with channels in the plasma membrane (Dziadek & Johnstone, 2007). Mice 
expressing the mutant EF domain in the Stim 1 protein displayed increased bleeding 
and pre-activation of platelets in circulation due to elevated basal Ca2+ levels 
(Grosse et al., 2007), while genetic deletion of STIM 1 impaired platelet activation 
and adhesion (Varga-Szabo et al., 2008a).  
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1.10.4 Role of ORAI 
 
Human and mouse platelets were shown to express all three isoforms of the Orai 
channel family (Orai 1-3), with Orai 1 being the predominant isoform. Orai 1 is a four 
membrane spanning channel with intracellular N and C termini and was identified as 
an essential component of SOCE by the analysis of T cells from severe combined 
immuno deficiency patients (Feske et al., 2006) and is impaired in platelets lacking 
Orai 1 (Braun et al., 2009) and from mice expressing the loss of function mutation of 
Orai 1 (OraiR93W) (Bergmeier et al., 2009). Sustained increases in cytosolic Ca2+ are 
critical for the ability of platelets to switch from an adhesive state to a coagulant, 
phosphatidylserine (PS) state (Bevers et al., 1982; Heemskerk et al., 2002); in the 
absence of Orai 1, platelets fail to maintain elevated Ca2+ levels necessary for PS 
exposure. 
1.10.5 Role of TRPC 
 
The transient receptor potential (TRP) proteins are proposed as components of 
SOCE and non-SOCE channels, which assemble into tetramers to form a channel. 
The TRP family can be divided into seven subfamilies, of which the canonical TRPs 
(TRPC) are the best described. TRPC members comprise seven channel proteins 
(TRPC 1-7), which are divided on the basis of their amino acid similarity. TRPC 1 
and 2 are almost unique, TRPC 4 and 5 have about 64% similarity and TRPC 3, 6 
and 7 are the most closely related members, having 75% sequence identity. 
Heterotetrameric association is known to occur within the TRPC 3, 6 and 7 subgroup 
and TRPC 1 is able to complex with -4 and -5 (Hofmann et al., 2002) and may 
associate with TRPC 3 and -7 also (Zagranichnaya et al., 2005). The strongest 
evidence of TRPCs been a component of SOCE is TRPC 1, as it is known to 
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contribute to SOCE in many cell types, such as smooth muscle, endothelial cells and 
platelets upon agonist stimulation (Rosado et al., 2002; Venkatachalam et al., 2003). 
Further studies indicate that Stim 1 proteins can interact and cause the activation of 
TRPC (Huang et al., 2006). TRPC channels are also reported to interact with Orai 
proteins (Liao et al., 2007), both Stim 1 and Orai 1 appear to be associated within a 
complex that contains the TRPC1 channel (Ong et al., 2007), suggesting that all 
three proteins interact to form a SOC. 
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Figure.1.5 Store-operated calcium entry (SOCE) in platelets 
 
In platelets, distinct subtypes of surface receptors activate two major isoforms of 
PLC; G-protein coupled receptors (GPCRs) activate PLCβ through Gq, whereas 
integrins and receptors coupled to an immunoreceptor tyrosine-based activation 
motif (ITAM) activate PLCγ2 through Syk. Receptor agonist binding results in 
calcium store release through inositol 1, 4, 5-trisphosphate receptors (IP3R) in the 
endoplasmic reticulum (ER) membrane. This disrupts the calcium binding of the EF 
hand domain of STIM1 in the ER lumen and leads to the activation and redistribution 
of STIM1 to plasma membrane (PM) near puncta where it opens Orai1, the major 
store-operated calcium (SOC) channel in the PM, to allow calcium entry (Varga-
Szabo, 2009). 
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1.11 Shape change 
 
Platelet shape change is one of the earliest responses induced by a physiological 
agonist, as it this precedes spreading, aggregation and secretion. Resting, discoid 
platelets are transformed upon encountering the ECM, which is characterised 
morphologically by spheration, rearrangement of the cytoskeleton, the folding of the 
membrane and extension of lamellipods and pseudopods or filopods(Fox, 1993). 
Shape change depends on the cytoplasmic dynamics of the actin polymer (Fox & 
Phillips, 1981) and actin accessory proteins, which mediate severing, capping and 
cross-linking into a gel by filamin, while others are bundled by α-actinin and fimbrin 
generate morphological changes(Figure.1.6). 
 
In the resting platelet the short actin filaments are capped by CapZ and surrounded 
by a large pool of actin monomers bound to profilin. Upon activation by either direct 
contact with the damaged area or soluble agonist, a rapid intracellular signal 
transduction cascade occurs and resulting in a large influx of Ca2+ into the cytosol. 
This Ca2+ activates gelsolin to remodel the cytoskeleton by cleaving the capped 
filaments into fragments, now capped by gelsolin(Fox et al., 1987; Sun et al., 1999). 
The same pathway leading to the elevation of cytosolic Ca2+ also leads to a rise in 
PIP2 levels though at a slower rate, which then inactivates gelsolin and CapZ thus 
removing them from actin and exposing the barbed filament ends(Weber et al., 
1991). 
 
The freely exposed barbed filament ends generated by severing and uncapping are 
rapidly lengthened by the monomeric actin pool with recruitment of the actin 
monomers and the assembly of actin filament at the barbed ends with profilin, 
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providing the force for protrusive activity in platelets and driven by the generation of 
barbed ends(Hartwig, 1992). Some of these elongated actin filaments are cross-
linked into a gel by filamin, while others are bundled by α-actinin and fimbrin, thereby 
allowing the extension of lamellipodia and filopodia enabling spreading across the 
damaged area, and platelet adhesion via integrins. The length of the actin filament is 
also heavily influenced by the vasodilator stimulated phosphoprotein (VASP) 
regulating the formation of filopods(Mejillano et al., 2004). 
 
With the decline of PIP2 signalling CapZ returns to the ends of the actin filaments, 
rendering them stable against depolymerization and locking the platelet into its 
spreading form. Once tethered to actin, cytoplasamic myosin II using ATP is the 
molecular motor that applies the contractile force allowing sliding the long actin 
filaments relative to one another, causing contraction of the platelet and pulling the 
edges of the wound together. During the platelet shape change, new actin filaments 
are formed thus leading to the formation of the submembranous actin filament 
network and the extension of the filopodia. Simultaneously actomyosin contractile 
processes are stimulated resulting in the organelles, namely the dense and α-
granules dispersed throughout the cell being centralised, termed internal contraction 
(White & Burris, 1984) and plays a role in driving granule secretion. 
 
Finally with the depolymerization of the circumferential microtubule coil the 
characteristic change from discoid to a spherical form platelet is achieved.  
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Figure.1.6 Platelet activation and subsequent shape change 
 
(A) Platelet activation is a controlled sequence of actin filament severing, uncapping, 
elongation, recapping, and cross-linking that creates a dramatic shape change in the 
platelet. (B) Scanning electron micrograph of platelets prior to activation. (C) An 
activated platelet with its large spread lamellipodium. (D) An activated platelet at a 
later stage than the one shown in C, after myosin II-mediated contraction (Alberts et 
al., 2002). 
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1.12 Platelet Secretion 
 
Following platelet binding to the damaged sub-endothelial matrix and subsequent 
internal signalling, a controlled release reaction takes place. Platelet activation 
causes shape change, secretion of their intracellular granules and subsequent 
aggregation with one another (Gordon, 1976). Internal granules fuse with the outer 
membrane, thereby ejecting their contents via exocytosis. Bio-active molecules, 
acting in a para- and auto-crine manner quickly feed back, increasing activation of 
nearby platelets, magnifying secondary secretion and resulting in the amplification of 
the platelet activation process (Figure.1.7). 
 
Platelets contain at least three types of granules, distinguished as alpha (α), dense 
(δ) and lysosomes (λ) granules (White JG. 1994), which upon activation are secreted 
into the external medium (Ciferri et al., 2000). The α-granules contain chemokines, 
growth factors and both pro- and anti-thrombotic molecules (Reed, 2004), and 
contain over two hundred and eighty different proteins (Maynard et al., 2007). Dense 
granules contain fewer proteins, though an increased composition of membrane 
anchored proteins, histamine and serotonin. Lysosomes are composed mainly of 
enzymes such as serine peptidases, carbohydrases and phosphatases (McNicol & 
Israels, 1999). The controlled release of different granular contents can selectively 
modulate the microenvironment of the damaged area though switchable release 
reaction functions to choose between pro- and anti-regulatory cargo secretion 
(Italiano & Battinelli, 2009). The mediation of granule secretion is dependent upon 
the syntaxin family of membrane integrated soluble NSF attachment protein 
receptors (SNARE) cargo regulatory proteins, which are mobilised upon cytosolic 
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Ca2+ elevation and PKC concentration changes (Flaumenhaft, 2003) and their 
interaction and activation with the Munc18 family proteins (Houng et al., 2003). 
SNARE syntaxin 2 acts on dense granules (Chen et al., 2000) and syntaxin 4 and 2 
act on α-granules (Flaumenhaft et al., 1999). These syntaxin molecules are t-
SNAREs, been bound to the plasma membrane an function as a target for the 
vesicle specific or v-SNARE (Ren et al., 2007). 
 
Platelet shape change, which precedes platelet secretion, generates the contractile 
force necessary to allow for the centralisation of granules, necessary for the fusion of 
granules with each other, the OCS and the plasma membrane. The contractile force 
and cytoskeletal rearrangement required for the secretion is supported by the 
phosphorylation of the MLC mediated by the Ca2+ and Rho dependent pathways 
(Suzuki et al., 1999). Platelet secretion in response to thrombin is severely impaired 
upon disruption of the above pathway in platelets lacking G13(Moers et al., 2003). 
 
1.12.1 Role of Adenosine Diphosphate 
 
ADP is stored in dense granules at high concentration, which upon release activates 
platelets in an auto and paracrine manner. ADP activates platelets by the G-protein 
coupled receptors P2Y1 and P2Y12(Murugappa & Kunapuli, 2006). P2Y1 couples to 
Gq(Savi et al., 1998), while P2Y12 is coupled to Gi(Jantzen et al., 2001) and both 
receptors are required for full platelet activation upon exposure to ADP (Jantzen et 
al., 1999). In the absence of P2Y1, platelets do not undergo shape change (Leon et 
al., 1999) and in the absence of P2Y12 an impaired aggregation response in mice 
(Fabre et al., 1999). The deficiency of these receptors results in significantly 
prolonged bleeding times and the formation of unstable thrombi (Andre et al., 2003).  
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1.12.2 Role of Thromboxane A2 
 
TxA2 acts in an autocrine manner only, due to its short half-life and thereby its 
effectiveness is restricted locally. TxA2is synthesised from arachidonic acid by the 
conversion by cyclooxygenase-1, which is targeted by aspirin and thromboxane 
synthase. The TxA2 receptor (TP) which can also be activated by prostaglandin 
endoperoxides couples to Gq and G12/13(Knezevic et al., 1993; Offermanns et al., 
1994). Absence of the receptor results in prolonged bleeding times and non-stable 
thrombi (Thomas et al., 1998).  
 
1.12.3 Role of Thrombin in Platelet Activation 
 
Thrombin formation is initiated by the exposure of tissue factor to plasma coagulation 
factors following injury to the endothelium. Thrombin formation also takes place upon 
the surface of the activated platelets (Heemskerk et al., 2002), providing a 
mechanism in which platelets can activate the coagulation cascade. In addition, the 
presence of thrombin facilitates the activation of platelet, which is rapidly inactivated 
after its formation. Activation of platelets by thrombin is mediated via cleavage and 
activation of protease activated receptors (PAR) (Coughlin, 2005). In turn this 
receptor activate Gq, G12 and in some cases the Gi family, leading to the activation of 
PLCβ, PI3K and the monomeric GTP binding proteins Rho, Rac and Rab1, also 
leading to the elevation of cytosolic Ca2+(Offermanns et al., 1994; Klages et al., 
1999). The action of thrombin in this process is supported by the released ADP and 
TxA2 binding to their respective receptors.  
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Four members of the PAR family have been identified; PAR 1 and PAR 4 are 
present on the human platelet (Kahn et al., 1999). Receptor activation begins with 
the cleavage of the N-terminus of the receptor, which then exposes a new N-
terminus that serves as a tethered ligand activating the receptor. This conformational 
change in the PAR receptor leads to the initiation of signalling across the plasma 
membrane to promote the exchange of GDP for GTP on the associated G proteins. 
PAR1 mediates platelet activation at low thrombin concentrations, though PAR4 
requires 10 to 100 fold higher concentrations due to the lack of a hirudin-like 
sequence close to the C-terminal cleavage site that facilitates receptor cleavage by 
thrombin (Kahn et al., 1998), though PAR4 activation maybe more sustained (Covic 
et al., 2000).  
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Figure.1.7 Various stages of platelet activation 
 
Schematic representation of the main platelet activation pathways, soluble mediators 
and vessel-related mechanisms involved in platelet adhesion, activation, and further 
aggregation. AA indicates arachidonic acid; ADP, adenosine diphosphate; ATP, 
adenosine triphosphate; vWF, von Willebrand factor; PAR, protease-activated 
receptor; PG, prostaglandin; TP, thromboxane receptor; TXA2, thromboxane A2 
(Tubaro et al., 2011). 
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1.13 Role of Myosin IIA 
 
Platelets contain only one type of non-muscle myosin, the heavy chain isoform, 
myosin IIA (Maupin et al., 1994), which interacts with the actin to develop the 
contractile unit. Myosin II molecules are composed of three pairs of peptides; two 
heavy chains of 220kDa and two 20kDa regulatory light chains that regulate myosin 
II activity and two 15kDa essential light chains that stabilize the heavy chain 
structure. The functional action of the myosin IIA is controlled by the phosphorylation 
of the heavy and light chains, which upon phosphorylation assemble into filaments 
required for the interaction with actin (Scholey et al., 1980). The phosphorylation of 
the 20kDa regulatory Myosin Light Chain (MLC) is essential to allow myosin to move 
along the actin, thus providing the contractile force (Sellers et al., 1985) and develop 
the actin activated adenosine triphosphatase (ATPase) activity (Adelstein & Conti, 
1975), whilst phosphorylation of the heavy chain would prevent the myosin IIA 
filament formation (Dulyaninova et al., 2005). The myosin necessary for contractile 
force is distributed throughout the platelet; though upon agonist stimulation via 
thrombin it relocates to the centre (Painter & Ginsberg, 1984), binding to cytoskeletal 
structures, and assembles into filaments (Fox & Phillips, 1982; Fox, 1993). Thereby 
it facilitates cytoskeletal rearrangements, folding of the surface membrane and 
internal contraction centralising the secretory granules and GPIb-IX whilst driving 
granule secretion (McNicol & Israels, 1999), all observed during shape change 
(Siess, 1989; Kovacsovics & Hartwig, 1996). 
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1.13.1 Role of Myosin Light Chain in Platelet Shape Change 
 
The regulation of the myosin light chain (MLC) phosphorylation at serine 19 on the 
20kDa proteins increases the ATPase activity of myosin in the presence of actin 
(Somlyo & Somlyo, 2003) by controlling the conformation of the myosin heads 
(Wendt et al., 2001) and assembly the myosin into filaments (Scholey et al., 1980). 
 
Platelet stimuli such as TXA2 and thrombin have been shown to activate Gq and 
G12/13 pathways(Shenker et al., 1991; Offermanns et al., 1994; Ushikubi et al., 1994). 
MLC phosphorylation is thereby mediated by a Ca2+ dependent (Gq)and, aCa2+ 
independent pathway (G12/13) (Bauer et al., 1999; Paul et al., 1999). The Ca2+ 
dependent pathway effects MLC phosphorylation via the Ca2+/calmodulin dependent 
MLC-kinase (MLCK), while the Ca2+ independent pathway is mediated by the Rho-
kinase (activated by the small GTP binding protein RhoA), which can directly 
phosphorylate the MLC and the regulator of MLC phosphorylation MLC-phosphatase 
(MLCP)(Figure.1.8). This thereby inhibits the catalytic subunit of the enzyme 
responsible for regulation of the phosphorylation state of the MLC leading to further 
increases in phosphorylation and ultimately shape change (Kimura et al., 1996). 
1.13.2 Regulation of Myosin in blood platelets 
 
Contractile tension necessary for the changes in the actin cytoskeleton is regulated 
by myosin and the phosphorylation of the MLC. The phosphorylation state of MLC is 
under the control of two enzymes, MLC kinase (MLCK) and MLC phosphatase 
(MLCP), and the relative activity of these enzymes will control phosphorylation of the 
light chain. Phosphorylation of the MLC on Ser19 leading to the contractile response 
is induced by agonists that signal through Gq coupled receptors. Activation of the 
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receptor leads to an increase in cytosolicCa2+ and subsequent formation a of Ca2+-
calmodulin complex that then activates the MLCK (Nairn & Picciotto, 1994). The 
principal mediator of cytoskeletal tension is the GTPase RhoA and its downstream 
effector Rho associated kinase (ROCK). GTP binding and hydrolysis switches the 
RhoA between its GTP bound active state and GDP bound inactive state(Etienne-
Manneville & Hall, 2002). RhoA has been shown to regulate smooth muscle 
contraction through modulating MLCP activity, via its downstream effector ROCK. 
The ROCK inhibitor Y27632 suppressed force activated by TXA2 analog U46619 with 
parallel decreases in MLC phosphorylation(Tsai & Jiang, 2006). In endothelial cells 
through the phosphorylation and deactivation of the myosin binding subunit of 
myosin phosphatase (MYPT1) at the equivalent platelet inhibitory sites Thr696 and 
Thr853 results in the loss of MLCP ability to dephosphorylate MLC and along with the 
direct phosphorylation of the MLC, leads to force generation and shape change 
(Ruiz-Loredo et al., ; Kimura et al., 1996). Particularly thrombin has been shown to 
inactivate MLCP via ROCK in endothelial cells (Essler et al., 1998). 
1.13.3 Role of RhoA/Rho-Kinase 
 
Agonists that can activate Gq also activate G12/13, both capable of activating RhoA. 
Three main classes of Rho GTPase, Rho, Rac1 and Cdc42 regulate actin 
cytoskeleton dynamics (Leung et al., 1996). The RhoA inactive form (RhoA.GDP) is 
present in the cytosol when bound to guanine nucleotide dissociation inhibitor (GDI). 
Activation of RhoA by either Gq or G12/13 is mediated by Rho specific guanine 
nucleotide exchange factors (Rho GEF) promoting the exchange of inactive form 
(GDP bound) for the active form (GTP bound). The GEF proteins share a common 
structural motif that includes the RGS (regulator of G protein signalling), Dbl 
homology (DH) responsible for the exchange of GDP for GTP, and pleckstrin 
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homology (PH) domains (Kaibuchi et al., 1999). When in the GTP bound 
conformation, RhoA interacts and activates the downstream effector Rho-kinase. 
The effector of RhoA, Rho-kinase(Matsui et al., 1996)is a serine/threonine kinase, 
which possesses an amino terminal kinase domain followed by a coiled-coil region 
and other functional motifs at the carboxyl terminus. In the inactive form of Rho-
kinase, the PH and Rho binding domains of Rho kinase bind to the catalytic amino 
region, thus leading to an autoinhibitory loop. Activated RhoA (Rho GTP) binds to 
the Rho binding domain, thus leading to the unfolding of the enzyme, freeing its 
catalytic activity(Riento & Ridley, 2003) and resulting in the spatial regulation of MLC 
phosphorylation in fibroblasts(Totsukawa et al., 2000), which in platelets can occur 
independently of Ca2+(Getz et al.). 
1.13.4 Inhibition of Myosin Phosphatase via Rho-Kinase mediated 
phosphorylation 
 
Myosin light chain phosphatase (MLCP) regulates the phosphorylation of MLC by 
active dephosphorylation of the Ser19 residue, thereby negative regulating actin 
myosin based contractility. Rho kinase phosphorylates the MYPT1 regulatory subunit 
of MLCP and inhibits catalytic activity(Fukata et al., 2001). It is a heterotrimer, 
consisting of a 37-KDa catalytic subunit (protein phosphatase type 1, PP1c), a 
130KDa regulatory subunit (myosin phosphatase target subunit 1, MYPT1) and a 20 
KDa subunit of unknown function (Ito et al., 2004). At the N terminus of the MYPT1 is 
a PP1c binding motif (K/R-I/V-X-F/W) adjacent to seven ankyrin repeats, and upon 
interaction of PP1c with the motif, substrate specificity is altered thus enhancing 
catalytic activity. In smooth muscle and cerebral arterial tone addition of U-46619 
agonist led to the phosphorylation of Thr696and Thr853 on MYPT1 by Rho-kinase 
leading to dissociation and inhibition of the activity of the catalytic subunit and 
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reducing the affinity of MYPT1/MLCP towards myosin, thus allowing phosphorylation 
of MLC Ser19(Velasco et al., 2002; Neppl et al., 2009). 
  
  
41 
 
 
 
Figure.1.8 Ca2+ sensitization and Ca2+dependent pathways 
 
Stimulation of GPCRs leads to the activation of both Ca2+ sensitization and Ca2+ 
dependent pathways. PLC catalyses PIP2 into IP3 and DAG. IP3 increases 
intracellularCa2+ levels and, together with CaM (calmodulin), Ca2+ activates MLCK. 
MLCK then phosphorylates MLC, resulting in smooth muscle contraction. After 
activation by DAG, PKC phosphorylates CPI-17. Phosphorylated CPI-17 has a high 
affinity for the catalytic subunit of MLCP and decreases MLCP activity through 
phosphorylation. Activation of GPCRs also stimulates RhoGEF activity, which 
facilitates the exchange of GTP for GDP on RhoA and dissociates RhoA from 
RhoGDI. The active RhoA-GTP translocates from the cytosol to the plasma 
membrane and activates Rho-kinase. Subsequently, Rho-kinase phosphorylates the 
targeting subunit of MLCP, leading to increased MLC phosphorylation. In addition, 
Rho-kinase has been shown to phosphorylate CPI-17. Meanwhile, RhoGAP 
accelerates the intrinsic GTPase activity of RhoA and promotes hydrolysis of GTP; 
thus, inactive RhoA-GDP re-associates with RhoGDI and relocates to the cytosol 
(Jin &Burnett, 2006). 
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1.14 Regulation of platelet functions 
 
During normal circulation platelets are in a quiescent state as long as the vasculature 
remains intact in vessels, thereby platelets undergo no significant interaction or 
activation during their lifetime. However, upon trauma the main function of platelets 
is to assist in the stopping of haemorrhaging following vascular injury.  
 
Upon exposure to the damaged endothelial cell, this lining triggers platelet adhesion 
via VWF, collagen and fibronectin. Initial tethering occurs via the GP Ib-IX-V on the 
platelet (Figure.1.9)and triggering ‘inside-out’ signalling, activating the high affinity 
state of integrin αIIbβ3allowing binding to divalent fibrinogen or multivalent VWF 
(Savage et al., 2001). In addition exposed collagen is bound via the key GPVI, with 
the state of the damaged area dictating how these receptors interact with each other 
and platelet activity as a whole. The subsequent activation of the platelet causes 
release of additional agonist, such as ADP and thromboxane A2 (TXA2), recruiting 
further platelets to the growing thrombus and aided by the formation of thrombin. 
 
Spontaneous or sustained platelet activation must be limited at all times, preventing 
undesirable obstruction of the lumen of the vessel and limiting the activation to the 
site of injury. There are three primary independent pathways by which the 
endothelium regulates platelet activity; nitric oxide (NO) and prostacyclin (PGI2) are 
continually perfused into the vessels, driven by the pulsatile action of blood flow, 
their inhibitory action occurs through the secondary messengers, cyclic nucleotides 
like cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate 
(cAMP) that play a critical role in platelet inhibition (Schwarz et al., 2001). The third 
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pathway is the endothelial CD39, which reacts with the ADP released from activated 
platelets, hydrolyzing ADP to adenosine monophosphate (AMP) preventing further 
pro-thrombotic platelet activation and mitigating against excessive platelet 
recruitment (Marcus et al., 1997) induced by collagen, ADP, arachidonate, and 
thrombin receptor agonists (Marcus et al., 2001a; Marcus et al., 2001b). Taken 
together the mentioned agents are strong negative regulators of platelet adhesion, 
activation and aggregation. 
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Figure.1.9 Model for platelet-endothelial interactions 
 
The initial contact (tethering) to the ECM is mediated predominantly by GPIb-VWF 
and GPVI-collagen interactions. The GPIb-VWF interaction is essential at high shear 
rates (>500s-1) but may not be required at lower shear rates. In a second step, GPVI-
collagen interactions initiate cellular activation followed by shifting of integrins to 
high-affinity state and the release of second-wave agonists, most importantly ADP 
and TxA2.GPIb-mediated signalling may amplify GPVI-induced activation pathways. 
Cellular activation and up-regulation of integrin affinity is proposed to be a strict 
prerequisite for adhesion. Finally, firm adhesion of platelets to collagen through 
activated α2β1 (directly) and αIIbβ3 (indirectly via VWF or other ligands) results in 
sustained GPVI signalling, enhanced release, and procoagulant activity. In this 
process, α2β1 and αIIbβ3 have partially redundant roles. Released ADP and TxA2 
amplify integrin activation on adherent platelets and mediate thrombus growth by 
activating additional platelets (Nieswandt & Watson, 2003). 
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1.15 Regulation of platelet activation and 
aggregation 
 
In circulation platelets remain in a quiescent state while the endothelium lining the 
blood vessel remains intact. Platelets are key mediators of thrombosis (Libby, 
2002)therefore tight regulation of platelet activation is essential, as excessive 
activation can lead to thrombosis, myocardial infarction and ultimately a stroke 
(Ruggeri, 2002). Therefore there are strong inhibitory signals preventing platelets 
from undesirable activation and limiting it and thrombus formation to the site of the 
damaged sub-endothelial layer. There are three predominant negative regulators, 
through which the endothelium controls platelet reactivity. The endothelial cell 
surface ectonucleotidase CD39interacts with the platelet releasate, neutralising a 
source of prothrombotic platelet by rapidly converting ATP and ADP to AMP, thus 
functioning as a cell-bound ecto-ADPase. It limits the recruitment of additional 
platelets into the growing platelet plug by removing ADP released from the dense 
granules of activated platelets and from damaged erythrocytes and endothelial 
cells(Gayle et al., 1998; Marcus et al., 2001a). Nitric Oxide (NO)(Furchgott & 
Zawadzki, 1980)and prostacyclin (PGI2) (Moncada et al., 1976)are released into the 
lumen of the vessels to inhibit platelet adhesion to the endothelium, activation and 
aggregation as well as having a vasodilatory effect upon the vessel. These agents 
act as global modulators of platelet activity, inhibiting multiple aspects of platelet 
function, although the detailed mechanisms of action remain obscure. 
1.15.1 Nitric Oxide 
 
Nitric Oxide (NO) is a gaseous lipophilic free radical messenger that has been 
implicated in the regulation of blood flow in the vessels (Ignarro, 1999), 
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neurotransmission in synaptic function (Garthwaite, 2008) and anti-thrombotic 
processes in the vasculature (Palmer et al., 1987). The bioavailability of NO is a 
central mediator in maintaining homeostasis via regulating platelet activity and 
preventing the onset of thrombosis. 
 
NO achieves this by preventing platelet adhesion and aggregation to the sub-
endothelium (de Graaf et al., 1992), and upon platelet activation releasing NO, 
thereby limiting excessive recruitment of platelets into the growing thrombus 
(Freedman et al., 1997). 
1.15.2 Nitric oxide synthesis 
 
Nitric oxide biosynthesis is due to the activity of a class of enzymes known as NO 
synthases (NOS) using the amino acid L-arginine(Palmer et al., 1988), present in 
high concentrations in the blood (60-80µM) and in extracellular fluid while been 
present in higher concentrations within cells. NOS first converts L-arginine to an 
intermediate, L-hydroxyarginine and subsequently to NO and L-citrulline which can 
be converted back to L-arginine. The nitrogen for NO is derived from the guanidino 
nitrogen atoms of L-arginine and the oxygen from molecular oxygen. The reaction 
requires a number of cofactors including NADPH, flavin adenine dinucleotide (FAD), 
flavin mononucleotide (FMN) and tetrahydrobiopterin (H4B)(Ignarro et al., 2001).NO 
has different physiological functions and therefore the different isoforms are 
specifically tailored to locations and production where NO is required (Bruckdorfer, 
2005).  
 
NOS exists in at least three different isoforms(Papapetropoulos et al., 1999); 
neuronal (nNOS), inducible (iNOS) and endothelial (eNOS) and there is some 
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evidence that another form of NOS exists in mitochondria (mNOS) (Schild et al., 
2003). The presence of NOS isoforms (eNOS and iNOS) in platelets has yielded 
conflicting reports (Naseem, 2008), though a recent study by Gambaryan et al using 
newly developed techniques demonstrate that the afore mentioned isoforms of NOS 
as proteins are not present in human platelets(Gambaryan et al., 2008).  
1.15.3 S-Nitrosothiols 
 
NO can react with molecular oxygen, haemoglobin, redox metals and the super 
oxide anion. The reaction with oxygen yields a reactive nitrogen oxide species; S-
nitrosothiols (RSNO), which exist as major redox forms in the plasma (Stamler et al., 
1992a)and are formed when oxidised form of NO (N2O3 or ONOO-) reacts with thiols 
and result in the extension of NO half-life allowing time for NO to exert its effects on 
distant targets  (Rassaf et al., 2002). RSNO are present in the vasculature and in 
both high molecular weight, S-nitrosohemoglobin (HbSNO) and S-nitrosoalbumin 
(AlbSNO), the predominant form of RSNO in plasma (Marley et al., 2001), and low 
molecular weight, S-nitrosoglutathione (GSNO)(Stamler et al., 1992a), the most 
abundant intracellular RSNO (Stamler et al., 1992b). Both the high and low 
molecular weight RSNO have the ability to inhibit platelet function, as NO stimulates 
guanylyl cyclase thereby producing intracellular levels of cGMP and attenuate 
platelet function primarily via this mechanism. Release of NO from GSNO occurs via 
enzymatic GSNO reductase activity, by catalytic redox effects of transition metals 
(Cu+, Cu2+, Fe2+) or protein disulphide isomerase(Xiao & Gordge, ; Hogg, 2002).
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1.16 Role of nitric oxide dependent guanylyl 
cyclase 
 
The pulses of NO formed via eNOS diffuse across endothelial layers and into the 
lumen of the vessel, coming first into contact with platelets at the periphery of blood 
flow. NO diffuses into the platelet via the lipid-bilayer into the cytosol whereupon it 
interacts with the enzyme soluble guanylyl cyclase (sGC).The binding of NO to sGC 
leads to the production of cyclic guanosine monophosphate (cGMP) from the 
nucleotide guanosine triphosphate (GTP) substrate, this being the NO dependent 
mechanism of platelet regulation. Cyclic GMP is present in almost all cells(Hardman 
& Sutherland, 1969), and is a secondary messenger which regulates many signalling 
events like activation of protein kinases, ion channels and phosphodiesterases 
(PDEs). 
 
The sGC is a heterodimer composed of α- and β-subunits, of which there are 
differing isometric forms: α1,α2 and β1, β2, though the sGCα1 and β1subunits are the 
ubiquitously expressed and exist in a 1:1 stoichiometry of an α1 and β1 subunits 
(Katsuki et al., 1977). Each sGC subunit is composed of three distinct regions; an N-
terminal haem binding domain, a dimerisation domain and a C-terminal catalytic 
domain. 
 
The catalytic domain is responsible for the conversion of GTP to cGMP(Koesling, 
1999). The dimerisation domain is located in the middle of each subunit allowing 
binding between the individual subunits(Wilson & Chinkers, 1995). The N-terminus 
contains the haem binding domain which mediates the sensitivity of the enzyme to 
NO(Ignarro et al., 1982). Upon binding of NO to the sixth coordinate position of the 
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haem, the bond between a histidine in the β1 subunit (His105) and the iron is broken, 
resulting in a five coordinated nitrosyl-haem complex (Stone & Marletta, 1994). sGC 
is activated by the binding of the free radical form of NO·, which has a high affinity for 
haem moiety/functional group of haem containing proteins (Ignarro, 1989). The 
binding of NO to, and activation of sGC, results in a 200-fold increase in enzyme 
activity from basal, though the half-life of the haem-NO complex is approximately 60-
120 seconds in smooth muscle(Margulis & Sitaramayya, 2000) and as low as 
0.2seconds in platelets and cerebellar cells, thereby allowing precise control over 
stimulation and NO production(Bellamy & Garthwaite, 2001; Russwurm et al., 2002). 
1.17 Mechanisms of cGMP regulation of 
platelet function 
 
Increases in NO/sGC-mediated cGMP levels lead to the activation of a variety of 
signalling cascades which result in the general inhibition of platelet function 
(Schwarz et al., 2001). Cyclic GMP increases the activity of the cGMP-dependent 
protein kinase (PKG) leading to the phosphorylation and inhibition of a number of 
target proteins (Figure.1.10). NO-signalling through sGC seems to primarily affect 
the mobilisation of intracellular Ca2+, and various studies have demonstrated that NO 
exerts it functions by inhibiting Ca2+-dependent platelet signalling (Morgan & Newby, 
1989; Nguyen et al., 1991; Geiger et al., 1994; Le Quan Sang et al., 1996; Pernollet 
et al., 1996). Phosphorylation of the IP3 receptor by PKG results in decreased 
cytosolic Ca2+(Cavallini et al., 1996) and phosphorylation-dependent inhibition of the 
TxA2 receptor causes a reduction in TxA2-depedent platelet activatory 
signalling(Wang et al., 1998). One of the major substrates of PKG is the cytoskeleton 
associated vasodilator sensitive phosphoprotein (VASP), a key protein required for 
the formation of focal adhesions, needed to allow for the polymerisation of actin and 
  
50 
 
formation of lamellipodia(Reinhard et al., 2001), and present in platelets at high 
concentrations (Eigenthaler et al., 1992). It interacts with other cytoskeletal proteins 
to permit shape change in platelets, namely vinculin at the N terminus, profilin in the 
centre and F actin at the C terminus. On VASP there are three phosphorylation sites; 
two serine and one threonine. Upon phosphorylation of Ser157 the apparent 
molecular weight changes from 47 to 50kDa, though the 157 site is most sensitive to 
PKA, the Ser239 site is more sensitive to PKG, while the Thr278 site is less sensitive to 
either of the kinases(Abel et al., 1995), though it can be potentially phosphorylated 
by cAMP-dependent protein kinase as demonstrated in endothelial cells(Blume et 
al., 2007). Depending on the phosphorylation status of these sites, VASP is able to 
regulate actin polymerisation and actin filament bundling(Reinhard et al., 2001), 
thereby preventing full platelet activation and serving as a marker for platelet 
inhibition. 
 
However VASP phosphorylation is not the only effect of PKG on the cytoskeleton, 
another is the reduction of MLC phosphorylation status, due to its crucial regulation 
of the cytoskeleton during platelet shape change(Daniel et al., 1984). PKG interferes 
with the elevation of intracellular Ca2+ critical for the Ca2+/calmodulin dependent 
MLCK phosphorylation of the MLC by inhibiting release from internal stores and 
extracellular Ca2+ entry via phosphorylation of the IP3 receptors(Cavallini et al., 
1996), TRPC, ORAI and STIM pore forming proteins (Hassock et al., 2002; Kwan et 
al., 2004; Authi, 2007; Varga-Szabo et al., 2009) and stimulating the sequestering of 
Ca2+ via PKG specific phosphorylation of the SERCA into the stores (Lincoln et al., 
2001).  
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PKG can reduce the phosphorylation status of the MLC by acting on one or more 
targets in the RhoA pathway, including RhoGEF and RhoA, as well as other 
downstream targets of RhoA such as Rho-kinase and MYPT1. PKG can 
phosphorylate activated, membrane bound RhoA at Ser188(Sauzeau et al., 2000). 
This phosphorylation, as shown in platelets stimulates its translocation back to the 
cytosol thereby inhibiting the activity of its membrane bound targets, such as Rho-
kinase and thereby MLC phosphorylation (Murthy et al., 2003). 
 
Demonstrated in smooth muscle is the action of PKG on MYPT1,on both the 
inhibitory sites (Thr696/853) and the Ser695 site(Wooldridge et al., 2004; Nakamura et 
al., 2007). Phosphorylation by PKG of Ser695 prevents MYPT1 phosphorylation at the 
adjacent Thr696 site via Rho-kinase, thereby blocking Rho-kinase dependent 
inhibition of MLCP activity (Wooldridge et al., 2004). The inhibition of Rho-kinase 
dependent phosphorylation of MYPT1 on Thr853 site returns the affinity of MYTP1 to 
MLC and allows redemption of MLCP activity (Velasco et al., 2002). 
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Figure.1.10 Schematic diagram of cAMP/cGMP signalling network in platelets 
 
The intact endothelium releases prostacyclin (PGI2) and nitric oxide (NO) which bind 
to the prostacyclin receptor (IP-R) and the soluble guanylyl cyclase (sGC), 
respectively. The IP-R stimulates cAMP synthesis by adenylyl cyclase (AC) via 
heterotrimeric Gs protein. NO activates sGC resulting in the synthesis of cGMP. 
Von Willebrand Factor (vWF), thrombin and collagen are probably also able to 
activate sGC, although to a much lesser extent than NO. Cyclic GMP activates 
phosphodiesterases 2A and 5A resulting in the degradation of cAMP and cGMP, 
whereas cGMP inhibits PDE3A. Cyclic AMP stimulates cAMP-dependent protein 
kinase (PKA) which is expressed in two isoforms composed of regulatory subunits 
RIα or RIβ together with catalytic C subunits, or RIIβ and C subunits. C subunit of 
PKA has also been found in association with an NFκB-IκB complex from which it can 
be released by thrombin and collagen signalling. Only the PKGIβ isoform of cGMP-
dependent protein kinase (PKG) is expressed in platelets. C subunits of PKA and 
PKGIβ phosphorylate common substrates which have been grouped according to 
function. Substrate phosphorylation results in an inhibition of platelet activation, 
granule release, adhesion and aggregation (Smolenski, 2012). 
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1.18 AGC Protein Kinases 
 
Protein kinases are key regulatory enzymes which change the properties of a 
substrate via attaching a phosphate group to the Ser, Thr or Tyr residues(Pearce et 
al,.2010). The subgroup of Ser/Thr protein kinases based on their catalytic kinase 
domains, PKA, PKG and PKC were coined as AGC kinases by(Hanks & Hunter, 
1995). The AGC family contains 60 of the 518 human protein kinases(Manning et al., 
2002) which have been highly conserved in eukaryotic evolution. To date fourteen 
AGC kinase domain structures have been determined which all show the typical 
bilobal kinase fold that was first described for PKA(Knighton et al., 1991). The bilobal 
kinase fold contains an amino-terminal small lobe (known as N-lobe) and a carboxy-
terminal large lobe (known as C-lobe) which sandwiches one molecule of ATP to 
serve as the phosphate donor during phosphorylation. 
1.18.1 PKA 
 
The structure of PKA was the first protein kinase structure to be determined(Taylor et 
al., 1990). Human platelets contain micromolar concentrations of PKA(Eigenthaler et 
al., 1992). In its inactive state PKA is a heterotetramer composed of 2 catalytic 
subunits and 2 regulatory subunits. When cAMP binds to the regulatory subunits it 
induces a conformational change in which the catalytic subunits dissociate from the 
complex and phosphorylate their substrates thereby suppressing platelet 
activation(Taylor et al., 1990). The main isoforms of regulatory and catalytic subunits 
expressed in human platelets are RIα, RIβ, RIIβ and Cα, Cβ resulting in the 
formation of PKAI and PKAII holoenzymes(Rowley et al., 2011; Dittrich et al., 2008).  
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1.18.2 PKG 
 
PKG is a cyclic nucleotide-dependent kinase. Elevation of cGMP induces a binding-
dependent activation of PKG leading to the catalytic transfer of the γ-phosphate from 
ATP to a serine or threonine residue on the target protein. This phosphorylated 
protein then mediates the translation of the extracellular stimulus into a specific 
biological function. In contrast to PKA, PKG forms homodimers, the regulatory 
cGMP-binding and catalytic domains of PKG are combined within one molecule that 
dimerises via its N-terminal regulatory region(Hofmann, 2005). PKGs are composed 
of N-terminal, regulatory, and C-terminal, catalytic domains. The N-terminal domain 
contains five regulatory sites:  
(1) The subunit dimerisation site, consisting of an α-helix with a conserved 
leucine/isoleucine heptad repeat 
(2) Autoinhibitory sites, involved in the inhibition of the catalytic domain in the 
absence of cGMP 
(3) Auto-phosphorylation sites, which in the presence of cGMP may increase the 
basal catalytic activity and the affinity of PKGs for cAMP 
(4) A site regulating the affinity and the co-operative behaviour of the cGMP 
binding sites 
(5) The intracellular localization site, which determines the interaction of the 
enzyme with specific subcellular structures 
The regulatory domain contains two cyclic nucleotide binding sites (termed A and B) 
that allow for full activation of the enzyme after specific binding of two molecules of 
cGMP. The catalytic domain is located at the C-terminus of PKGs, contains the 
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binding sites for Mg2+ -ATP and the target protein (Lincoln et al., 1995; Lohmann et 
al., 1997; Pfeifer et al., 1999). 
 
Two different isoforms for soluble PKG have been identified in mammals. The PKG I 
gene is located on human chromosome 10 and codes for the Iα and Iβ isoforms of 
PKG I, which arise by alternative splicing of the N-terminal region (Tamura et al., 
1996). The main isoform expressed in human platelets is PKGIβ. Knockout of the 
PKGI gene in mice revealed a pro-thrombotic phenotype, the inhibitory effects of 
NO-donors on fibrinogen binding, platelet shape change, granule release and 
aggregation were abolished, whereas effects of cAMP-analog where maintained 
indicating that most effects of endogenous cGMP are mediated by PKGI(Massberg 
et al., 1999). A broad range of proteins are phosphorylated by PKG Iβ which are 
involved in the regulation of vascular remodelling, neoangiogenesis(Eigenthaler et 
al., 1999; Lincoln et al., 2006) and mediate smooth muscle cell (SMC) relaxation, 
vasodilatation and platelet shape change(Dangel et al., 2010; Surks et al., 
1999).PKG is also thought to have overlapping effects with PKA and might also be 
involved in regulating long-term potentiation (Zhuo et al., 1994). 
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1.18.3PKC 
 
Protein kinase C (PKC) is a family of serine/threonine protein kinases that play a 
critical role in platelet activation as pharmacological inhibitors of PKC inhibit 
aggregation and secretion by the majority of agonists (Atkinson et al., 2001). Many 
PKC substrates have been identified in platelets including components of the 
secretory machinery and signalling molecules (Wentworth et al., 2006). The family is 
classified into three groups based on mechanism of activation and structural 
similarities (Parker et al., 2004). Conventional isoforms (α, β, γ) contain a 
diacylglycerol (DAG)/phorbol ester-binding C1 domain and a Ca2+ binding C2 
domain, novel isoforms (δ, ɛ, η, θ) also contain C1 domains, but their C2 domains 
are unable to bind Ca2+ and atypical isoforms (ζ and ι/λ) lack a C2 domain and have 
an atypical C1 domain, and are therefore regulated independently of Ca2+ or DAG 
(Konopatskaya et al., 2010). 
 
1.19 Regulation of cyclic nucleotide levels 
 
Regulation of cyclic nucleotides by synthesis via adenylyl cyclase and guanylyl 
cyclase is controlled by degradation through phosphodiesterases (PDE) 
(Figure.1.11). PDEs are a group of enzymes composed of several isoform families 
which hydrolyse the 3’ phosphoester bond on cAMP and cGMP, thus converting 
them to inert 5’ nucleotide metabolites. In platelets there are three types of PDEs; 
the cGMP stimulated PDE2, cGMP inhibited PDE3 and the cGMP specific PDE5 
(Haslam et al., 1999). PDE2 hydrolyses both cAMP and cGMP similarly, though it is 
stimulated by cGMP. PDE3 preferentially hydrolyses cAMP, though it is inhibited by 
cGMP and stimulated via PKA (Macphee et al., 1988). Cyclic GMP can potentially 
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decrease cAMP via PDE2 or enhance via PDE3 a cAMP response. PDE5 is highly 
specific for cGMP hydrolysis, promoted by the cyclic nucleotide and PKG, indicating 
a negative feedback regulation of cGMP levels (Corbin et al., 2000). The overall 
regulatory activity of PDE degradation of cGMP is higher than the PDE activity on 
cAMP(Haslam et al., 1999).  
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Figure.1.11 Regulation and known effector sites of cyclic nucleotides in 
platelets 
 
PKA and PKG mediated inhibition of platelet activation by phosphorylation of 
substrate proteins (heat shock protein (Hsp27), IP3 receptor, small GTPase Rap 1b, 
vasodilator stimulated protein (VASP), actin binding protein (ABP)). Also by cGMP 
mediated inhibition of cAMP hydrolysis by PDE3 (Schwarz et al., 2001).  
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1.20 Aims of the study 
Arterial thrombosis resulting from atheroma associated vascular injury is a major 
cause of death and morbidity in the industrialised world. The critical role of platelets 
in this process is signified by the success of antiplatelet drugs diminishing the 
occurrence of secondary thrombotic events. Primary inhibitory mechanisms are 
mediated by endothelial derived NO, which stimulates soluble guanylyl cyclase 
leading to activation of cGMP dependent pathways; however the mechanisms that 
inhibit platelet function have remained unclear. A critical event in thrombosis is the 
rapid platelet shape change, a process that requires rearrangement of the platelet 
cytoskeleton. Recently identified is MLCP, an enzyme that blocks cytoskeleton 
rearrangement, as a possible target for NO/cGMP signalling in platelets (Roberts et 
al., 2009). This observation may be a critical signalling event that allows NO/cGMP 
to inhibit platelet shape change at the sites of vascular damage. The identification of 
mechanisms that modulate signalling cascades activated by NO may represent a 
novel target for the development of new anti-thrombotic strategies. 
We hypothesise that NO modulates the MLC phosphorylation state through the 
MLCP; this study aims to investigate the mechanism that regulate MLC activity. 
 
The aims of this study were; 
• To dissect the regulation of the MLC phosphorylation state 
• To determine the modulation of RhoA/Rho Kinase mediated inhibition of MLCP 
by NO/PKG 
• To determine the role of phosphorylation in the regulation of platelet MYPT1 
activity by NO/PKG 
• To investigate the influence of NO on CPI-17 mediated inhibition of MLCP 
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2. Methods 
2.1 Methods for the study of platelet function 
2.1.1 Isolation and preparation of human platelets 
 
Venous blood was drawn from patients using a 21-gauge butterfly needle. The initial 
draw of the blood was collected in a 5ml syringe and then discarded due to the 
possible containment of activated platelets from the site of venous intrusion. Whole 
blood was collected from the patient into syringes containing acid-citric dextrose 
(ACD) (Appendix I-1) to act as an anticoagulant at a ratio of 1:5. Whole blood was 
then transferred to centrifuge tubes and spun at 200g for 20minutes, allowing the 
separation of the platelet rich plasma in to a distinct layer from other blood 
constituents. Platelet rich plasma (PRP) was transferred to new centrifuge tubes with 
the addition of 0.3M citric acid resulting in 20µl/ml of PRP and spun at 800g for 12 
minutes. The supernatant, platelet poor plasma (PPP) in these tubes was discarded 
and the pellet was resuspended in wash buffer (Appendix I-1). These washed 
platelets were transferred to another tube and centrifuged for a further 12 minutes at 
800g; the remaining wash buffer was discarded and the pellet resuspended in 1ml of 
Tyrodes buffer (Appendix I-1)producing the washed platelets (WP). In various 
experiments it was necessary the addition of apyrase 1Units/ml, indomethacin 
10µl/ml, acting via inhibition of ADP and TXA2, blocking the secondary aggregation 
and secretory pathway of platelets. When looking specifically at platelets under non-
aggregatory conditions ethylene glycol tetra-acetic acid (EGTA) was added at a final 
concentration of 1mM. 
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2.1.2 Calculation of platelet count 
 
Prepared WP count was analysed via haemocytometer; 5µl of WP were diluted 
1:100 in ammonium oxalate (1% w/v) and subjected to a gentle vortex, and the 
suspension was then pipetted into the haemocytometer and left for 5minutes for the 
platelets to settle. After counting on both sides of the chamber the platelet count was 
corrected for dilutions and expressed as platelets/ml (Appendix I-2).  
2.1.3 Determination of protein content 
 
Quantification of protein in samples was achieved through the use the Bio-Rad DC 
Protein Assay. This reaction was based upon the Lowry assay, with the reaction 
between the protein and the copper in an alkaline medium, leading to reduction of 
Folin by the copper treated protein. The absorbance of the samples, each performed 
in triplicate, was compared to those generated by serial dilutions of known bovine 
serum albumin (BSA) concentrations, and using a wavelength of 750nm in a plate 
reader we determined the protein concentrations present in the samples (Appendix 
I-3). 
2.1.4 Analysis of platelet function via light transmission 
aggregometry 
 
Optical aggregometry permits the production of reliable reproducible and rapid 
measurements of platelet aggregation (Born, 1962). In this method, a light beam was 
passed through a platelet suspension kept there by a miniature stirrer bar and 
detected by a photometer. When the platelets were induced to aggregate via the 
addition of an agonist light transmission through the photometer increases, and this 
was directly proportional to the degree of aggregation achieved. 
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Calibration of the aggregometer was achieved using untreated WP as base line and 
a tube containing Tyrodes buffer alone as 100%, and platelet aggregation assessed 
upon addition of various agonists. WP are suspended in Tyrodes buffer and used at 
a concentration of 2.5x108platelets/ml (Appendix I-4). 
2.2 Analysis of protein phosphorylation 
2.2.1 SDS-PAGE 
 
In Sodium Dodecyl Sulphate (SDS)-Polyacrylamide Gel Electrophoresis (PAGE), the 
proteins are denatured and coated in an overall negative charge, due to the bound 
SDS molecules and thus the basis for their separation was their mass. SDS is a 
strong anionic surfactant and the detergent disrupts all noncovalent interactions in 
the protein, unfolding the polypeptide chain. One molecule of SDS binds through its 
hydrophobic alkyl chain to the polypeptide backbone for every two amino acid 
residues; this then gives the protein a net negative charge that is proportional to its 
mass. The molecular separation of the protein was based on the size of the protein 
and its relative charge since the electrophoretic separation was carried out in 
polyacrylamide gel.  This serves as a molecule sieve where small molecules more 
readily move through the pores in the gel then larger ones. Polyacrylamide was 
chemically inert and was formed by the polymerisation of acrylamide; the pore size in 
these gels was controlled by the concentration of acrylamide used. 
 
The uses of SDS-polyacrylamide gels that contain a gradient of increasing 
acrylamide concentration and decreasing pore size have advantages over uniform 
concentration gels. Gradient gels contain two resolving acrylamide concentrations, 
10% and 18% at a pH of 8.8, prepared using a linear gradient former and a 
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peristaltic pump. This allows a much greater range of protein weights and those of 
very similar size are separated better; large proteins enter the gel and start to 
separate immediately owing to the sieving nature of the gel while smaller proteins 
resolve at the smaller pore size towards the bottom of the gel; those of similar sizes 
therefore separate as two close sharp bands. Additionally the high pH ensures that 
most proteins have a net negative charge and will migrate towards the anode. The 
stacking gel contains large pore size polyacrylamide (3%) at pH 6.8 atop the 
resolving gel containing the loading lanes. This section allows the focusing of each 
protein into narrow bands and ensures that all the proteins enter the resolving gels at 
the same time.  
2.2.2 Sample preparation for SDS-PAGE 
 
Preparation of samples requires addition of 2x concentrate of Laemmeli sample 
buffer containing Tris base which acts as a buffer maintaining the correct pH. 
Glycerol makes the samples denser then the running buffer allowing them to settle 
into the bottom of the lanes, and addition of bromophenol blue allows visualisation of 
the electrophoresis progress. SDS breaks up the secondary and tertiary structure of 
the proteins by adding negative charge to the amino acids, as negative charges 
repel, therefore straighten out the protein thereby rendering the protein immediately 
functionless. The 2-mercaptoethanol was responsible to break the remaining 
disulphide bonds; residual quaternary structure was disrupted by boiling the sample 
for 5 minutes, transforming the samples from the globular to linear proteins ready to 
be used in SDS-PAGE (Appendix I-4). 
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2.2.3 Methods for SDS-PAGE 
 
Preparation of the specific percentage gel was dependent on the protein under 
investigation, by a gradient 10-18% or a single percentage 10% gel. Once the 
correct percentage was chosen it was placed in the gradient mixer and poured with 
the aid of a peristaltic pump (Appendix I-5). Once at the correct level a small volume 
of methanol was pipetted atop the mixture ensuring a level and even surface and the 
resolving gel was left to polymerise for 1 hour. Following removal of the methanol, 
the 3% stacking gel was poured atop and a well forming comb inserted immediately, 
the mixture was left to polymerise for 20 minutes. Once the gel was secured in the 
electrophoresis module, the chamber was filled with running buffer (Appendix I-6) 
and the combs removed, allowing the loading of protein samples 10-30µg and the 
addition 10µl of a biotinylated protein ladder. This allows for greater accuracy when 
analysing the molecular weight of specific protein under investigation after running 
the gel at 120Volts for 2.5 hours. 
2.2.4 Western Immunoblotting 
 
Immunoblotting is a way of visualising the protein of interest using an antibody. For 
this technique the proteins have to be transferred out of the gel where they are 
inaccessible to the antibodies, to a polyvinylidene difluoride (PVDF) membrane. The 
membrane was pre-wetted with methanol for 1minute followed by a 10 minute wash 
with dH2O and stored in transfer buffer until required. Following completion of SDS-
PAGE the resolving gel was isolated from the casting plates, then sandwiched in the 
transfer cassette between sponges, blotting paper and the PVDF membrane kept 
saturated in running buffer while air pockets were removed prior to insertion into the 
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transfer tank, which was itself located in an ice box preventing overheating during 
the process consisting of 100Volts for 2.5 hours. 
 
Following completion of the process of protein transfer after the allotted time, the 
PVDF membrane was removed and washed in TBST (0.1%) for two 5 minute intervals. 
The PVDF membranes were then placed in either 10% (w/v) BSA in TBST (0.1%) or 
5% (w/v) milk for 30 minutes on a shaker leading to blocking of unoccupied binding 
sites on the membrane. The membrane was then washed for 5 minutes in TBST (0.1%) 
before been incubated with the primary antibody (in 2% w/v BSA in TBST (0.1%)) at 
4°C overnight. After this membranes were washed for two 5 minute intervals 
removing remaining primary antibody, then incubated with the appropriate secondary 
antibody (in TBST (0.1%)) for 1 hour. Additional horse radish peroxidase (HRP)-
conjugated anti-biotin antibody (1:10,000) was incubated to reveal the protein 
standard upon detection. After the incubation with the appropriate secondary 
antibody, membranes are washed 4-6 times in TBST (0.1%) removing excess 
remaining secondary antibody before detection with Enhanced Chemiluminescence 
(ECL) (Appendix I-6). Membranes were incubated with ECL for 90 seconds while 
protected from light, then transferred to the exposure cassette and developed in a 
dark room, with the aid of Hyperfilm ECL and developer solutions, which were used 
to visualise the immunoblot. The film was then washed extensively in dH2O before 
been placed in the fixer. 
2.2.5 Stripping and reprobing of membranes 
 
The purpose was to remove previous primary and secondary antibodies present 
upon the PDVF membrane to prevent any undue interference when re-probed using 
different antibodies.  
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The membrane was incubated at room temperature with the stripping buffer for the 
recommended duration of 20 minutes. The buffer was decanted away and the 
membrane was then bathed in TBST (0.1%) to remove residual traces of the corrosive 
buffer and once complete re-incubated with a new primary antibody. 
2.3 Calcium Assay 
2.3.1 Platelet preparation 
 
Initial platelet preparation method was discussed in 2.1.1. PRP was transferred to a 
new centrifuge tube with the addition of20µl/ml of 0.3M citric acid followed by 2µM of 
the fluorochrome Fluo-3 acetoxymethylester and the samples were incubated for 30 
minutes at 37°C. After incubation indomethacin (10µM) was added to the PRP to 
prevent activation via thromboxane A2 and samples were centrifuged at 800g for 12 
minutes. The platelets were then resuspended at 1x108  cells/ml in Ca2+buffer, and 
apyrase (1U/ml) was added to prevent platelet activation via ADP (Appendix I-9). 
2.3.2 Measurement of cytosolic calcium 
 
The fluorescent probe Fura-3 was used to investigate intracellular changes in 
cytosolicCa2+in platelets. The platelet suspension and appropriate Ca2+ buffer were 
incubated at 37°C and each experiment carried out at 1x106 cells/ml. Agonist 
induced increases in intracellular Ca2+ levels in Fluo-3 pre-loaded cells were 
measured at 530nm after excitation at 480nm and recorded using a 
fluorospectrometer (Photon Technology International). Graphs were constructed by 
measuring peak responses to agonist or antagonists and expressed as fluorescence 
intensity (counts per second). 
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2.4 SKOV-3 analysis 
2.4.1 Cell culture 
 
Human ovarian adenocarcinoma cells (SKOV3) were purchased from LGC 
Promochem (Middlesex, UK). The SKOV3 cells were cultured in a flask or a 10cm 
dish with DMEM-F12 medium (Invitrogen, UK) supplemented with 10% fetal calf 
serum, 100units/ml penicillin and 100µg/ml streptomycin, and maintained at 37°C 
under 95% air and 5% CO2. Cells were seeded onto 48-well or 96-well culture plates 
or 6 cm dishes for experiments. 
2.4.2 RT-PCR 
 
Total RNA was extracted using Trizol reagent (Invitrogen). The mRNA was reverse-
transcribed to cDNA using M-MLV reserve transcriptase (RT) (Promega). The primer 
set for PCR was designed across an intron to avoid the genomic DNA 
contamination. Forward and reverse PCR primer sequences are given in Appendix 
V. Non-template or non-RT was set as negative control, and the TRPC mouse brain 
cDNA was used as positive control. Thermal cycling was 95°C (5 min), 40 cycles at 
94°C (30 s), 53–60°C (1-3 min), 72°C (1 min), and 72°C (7 min). PCR products were 
detected on a 2 % agarose gel. 
2.4.3 Antibodies 
 
Rabbit polyclonal anti-TRPC antibodies were generated against the extracellular 
third loop (E3) region near the channel pore or targeting to the C-terminus. The 
specificity of E3-targeting antibodies including anti-TRPC1 (T1E3), anti-TRPC4 
(T45E3), anti-TRPC5 (T5E3) and anti-TRPC6 (T367E3) were tested by ELISA, 
western blotting and functional assays demonstrated in (Xu & Beech, 2001; Xu et al., 
2005b; Xu et al., 2006a; Xu et al., 2006b; Xu et al., 2008a). 
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2.4.4 Immunostaining 
 
Cells were fixed with 4% paraformaldehyde and permeabilised by incubation in -
20°C methanol for 1 minute and 0.1% Triton X-100 in PBS for 1 hour at room 
temperature. For un-permeabilised staining, the steps for methanol and Triton X-100 
were omitted. Non-specific binding sites were blocked by incubation in 1% bovine 
serum albumin (BSA). Cells were then incubated in the appropriate TRPC primary 
antibodies (T1E3 at 1:500 dilutions, T45E3, T5E3 and T367E3 at 1:250 dilution) in 
PBS with 1% BSA at 4°C overnight. Cells were washed three times with PBS and 
then incubated in the secondary sheep anti-rabbit IgG conjugated with FITC (Sigma) 
at a dilution of 1:160 for 3 hours at room temperature. After three washes with PBS, 
cells were mounted with Vectashield mounting medium with DAPI (Vector 
Laboratories). The stainings were photographed using Bio-Rad Radiance 2100 
confocal microscope and acquisition software (Bio-Rad, USA).  
2.4.5 Small interference RNA transfection 
 
The siRNAs for TRPC channels were purchased from Sigma (UK) (Appendix IV). 
TRPC siRNAs were transfected into SKOV3 cells using Lipofectamine 2000 
(Invitrogen). For each 10 cm2 plate surface area, the mixture of 10µl TRPC siRNA 
and 10µl Lipofectamine was incubated for 20 minutes at room temperature to allow 
the mixture of siRNA and Lipofectamine to form complexes. The siRNA and 
Lipofectamine complex was then added to the cells in a dish with 800µl of 
serum/antibiotics-free medium. Some transfections were performed onto cells in 96-
well or 48-well cell culture plate. The final concentration of TRPC siRNAs was 100 
nM. The wells or dishes without siRNA (no siRNA) or with scramble siRNA (Sigma) 
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or non specific pool siRNA were set as negative control in parallel. The Bcl-2 siRNA 
was used as positive control. 
2.4.6 Cell proliferation assay 
 
Cell proliferation was determined using WST-1 assay (Roche). WST-1 is a 
tetrazolium salt and can be cleaved by cellular enzymes, and thus the assay reflects 
the metabolic activity of the cultured cells. The overall cellular metabolic activity 
measured by optical absorption correlates well with the viable cell number in the 
culture dish/well as determined by cell counting. 
2.5 Statistical analysis 
 
All data are expressed as mean±SEM. The statistical significance was analysed 
using ANOVA and student t-test in the Origin 6.0 software (Northampton, MA, USA). 
Significance level was indicated by * (P<0.05), ** (P<0.01), *** (P<0.001). 
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CHAPTER 3 ROLES OF CALCIUM STORES 
AND SIGNALLING PROTEINS 
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3.  Introduction 
3.1 Store-operated calcium entry 
Platelet activation is triggered by a significant number of agonists, including 
thromboxane A2 (TxA2), adenosine-5-diphosphate (ADP) and thrombin. These act on 
different receptors though all triggering an increase in intracellular Ca2+ 
concentration (Rink & Sage, 1990) and leading to activation of the Ca2+/calmodulin 
dependent MLCK which phosphorylates the MLC. In platelets the elevation in 
cytosolic Ca2+ contributes to the various steps of cellular activation, such as the 
phosphorylation of the MLC, reorganisation of the cytoskeleton necessary for shape 
change and secretion (Hathaway & Adelstein, 1979; Kamm & Stull, 2001). Elevation 
in cytosolic Ca2+ can be derived from two main sources; the release from internalised 
stores and the influx of extracellular Ca2+ through the plasma membrane. Agonist 
stimulation leads to the activation of phospholipase C (PLC) isoforms, which 
hydrolyse phosphoinositide 4, 5 biphosphate (PIP2) to inositol 1, 4, 5 trisphosphate 
(IP3) and 1, 2 -diacyl glycerol (DAG). IP3 binds to its receptors on the membrane of 
the intracellular Ca2+ stores and mediates the release of Ca2+ into the cytosol 
(Berridge et al., 2003). This is inhibited by NO/cGMP which prevents the IP3 
mediated intracellular Ca2+ release (Schwarz et al., 2001) a critical step in the signal 
transduction pathway that leads to full platelet activation (Jackson et al., 2003). In 
platelets the major Ca2+ stores is the dense tubular system, upon depletion of the 
Ca2+, it triggers a sustained influx of extracellular Ca2+ know as store operated Ca2+ 
entry (SOCE). The exact underlying signalling proteins in this process have only 
recently been elucidated, such as the stromal interacting molecule 1 (STIM1) 
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identified as a Ca2+ store sensor (Grosse et al., 2007) with Orai 1 and members of 
the canonical transient receptor potential (TRPC) proposed to contribute to the SOC 
in platelets (Rosado et al., 2002; Tolhurst et al., 2008). The present work was 
directed to understanding the roles of SOC in platelets and in particular how this was 
potentially regulated by NO.  The initial aspects of this work was to use immortalised 
ovarian cancer SKOV3 cells to establish the protocols for the assessment of the 
tools used to study the proteins involved in the SOC and apply these to platelets. 
 
Ca2+ signalling is believed to play a central role in the signalling cascades in the 
tumorigenesis and neoplastic progression by controlling gene expression, 
progression through the cell cycle, and DNA synthesis (Berridge et al., 1998), as 
inhibitors of Ca2+dependentsignalling suppress the proliferation of cancer cells in 
vitro and in solid tumours in vivo (Cole &Kohn, 1994; Holmuhamedov et al., 2002). 
Store-operated Ca2+ influx is one of the Ca2+ entry pathways and closely related to 
cell proliferation and apoptosis (Parekh & Penner, 1997). The importance of store-
operated Ca2+ influx in the cancer development has been noticed for many years 
(Weiss et al., 2001; Peng et al., 2003; Kazerounian et al., 2005), however the role of 
TRP channels that act as the molecular constituents or subunits of SOCs or ROCs in 
cancer cell proliferation are largely unknown (Prevarskaya et al., 2007). 
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3.2   Results 
3.2 Role of calcium stores and signalling 
proteins 
3.2.1 Investigation into calcium signalling proteins 
3.2.1.1 Confirmation of TRPC 
The members of the TRPC family of cation permeable channels, have been 
proposed as G protein-coupled receptor-operated Ca2+ channels (ROC) or Ca2+ 
store-operated channels (SOC) (Xu & Beech, 2001; Clapham, 2003; Nilius et al., 
2007). TRPCs are ubiquitously distributed in the body and play essential roles in 
human physiology, such as in the smooth muscle cell proliferation and migration 
(Bergdahl et al, 2005) and contraction (Bergdahl et al., 2003). Store-operated Ca2+ 
influx is one of the Ca2+ entry pathways and closely related to cell proliferation and 
apoptosis (Parekh & Penner, 1997), with the importance of store-operated Ca2+ 
influx in cancer development been noticed for many years (Weiss et al., 2001; Peng 
et al., 2003; Kazerounian et al., 2005). From the TRPC family, platelets have been 
shown to express TRPC6 and TRPC1, and are likely to express other TRPC and 
other SOC constituents (Authi, 2007). In the present study, the immortalised SKOV3 
cells were used as a model for the TRPC expression prior to the application of the 
techniques across to investigate SOC in platelets. 
 
To confirm the expression of TRPCs in SKOV3 cells, the messenger RNA was 
extracted and detected via reverse transcriptase polymerase chain reaction (RT-
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PCR) shown in Figure.3.1.a. The β-actin was used as positive control, and the 
reverse transcript step omitting the reverse transcriptase (no RT) was set as 
negative control. TRPC1, TRPC3, TRPC4 and TRPC6 were positive in human 
ovarian adenocarcinoma SKOV3 cells. Two bands for TRPC1 were detected, which 
suggested the existence of splicing isoforms in the cells (Brinkman et al., 2004). The 
protein expression of TRPC channels in Figure.3.1.b.was probed by western 
blotting.  
 
The protein bands for TRPC1, TRPC3, TRPC4 and TRPC6 were detected using 
anti-TRPC1 (T1E3), anti-TRPC3 and anti-TRPC4 (T45E3) and anti-TRPC6 (T367E3) 
antibodies, respectively. The same size of TRPC6 protein band was detected by 
anti-TRPC6 antibody targeting the N-terminal shown in Figure.3.1.b.ii. SKOV3 cells 
were stained with anti-TRPC1 (T1E3), anti-TRPC3, anti-TRPC4 (T45E3) and anti-
TRPC6 (T367E3) antibodies in Figure.3.1.c. TRPC1 was more evident in the 
cytoplasm of SKOV3 cells, but TRPC3, TRPC4 and TRPC6 were apparent in the 
plasma membrane. The cultured SKOV3 cells had an irregular and very flat cell 
shape and tightly attached onto the coverslips, so it was hard to obtain a Z-section 
with a typical imaging for plasma membrane staining.  
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Figure.3.1 Expression of TRPC channels in SKOV3 cells 
 
(A)Detection of TRPC mRNAs by RT-PCR using the primer set for TRPC1 (T1), 
TRPC3 (T3), TRPC4 (T4), TRPC5 (T5), TRPC6 (T6) and TRPC7 ((T7)(Appendix 
V)). (B) Western blotting detection of TRPC proteins using anti-TRPC1 (T1E3), anti-
TRPC3, anti-TRPC4 (T45E3) and anti-TRPC6 (i) (T367E3) targeting the third 
extracellular loop. (ii) anti-TRPC6 targeting the N-terminal. No band was detected by 
anti-TRPC5 antibody (T5E3) in SKOV3. Two bands were detected by anti-TRPC1 
(T1E3) and competed by antigenic peptide used at 10µM. (C) SKOV3 cells stained 
with anti-TRPC1 (T1E3), anti-TRPC3, anti-TRPC4 (T45E3) and anti-TRPC6 
antibodies at a dilution of 1:500 and the secondary anti-rabbit antibody conjugated 
with FITC (green). No primary antibody was used as control. The nuclei were stained 
by 4', 6-diamidino-2-phenylindole (DAPI, blue). Scale bar is 25µm. The figures are 
representative of more than four independent experiments.  
B 
C 
A 
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3.2.1.2 Confirmation of Stim and Orai 
Studies have shown that TRPCs are not solely responsible for SOC activity; they 
operate as a component of a complex. Recently identified are two conserved 
proteins required for SOC entry. Stim functions as the sensor of endoplasmic 
reticulum (ER) luminal Ca2+ stores, which upon store depletion oligomerises and 
reorganises into puncta close to the plasma membrane leading to Orai activation, the 
pore forming subunit of the SOC channel (Liou et al., 2005; Ong et al., 2007). 
Stim and Orai isoforms mRNA was detected in the SKOV3 cell line. The β-actin and 
GAPDH were used as positive controls in both cases. Stim1, Stim 2 and Orai 1, Orai 
2 and Orai 3 were positive in human ovarian adenocarcinoma SKOV3 cells in 
Figure.3.2. The protein expression of Stim and Orai channels was detected using 
anti-Stim 1, anti-Stim 2 and anti-Orai 1, anti-Orai 2 and anti-Orai 3 antibodies, 
respectively. Stim 1 and Orai 3 were more evident in the plasma membrane of 
SKOV3 cells indicating its presence in pore/channel formation, but Stim 2, Orai 1 
and Orai 2 were apparent in the cytoplasm signifying a function in the ER store (Ong 
et al., 2007).  
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Figure.3.2 Expression of Orai and Stim channels in SKOV3 cells 
 
Detection of Orai and Stim mRNAs by RT-PCR using the primer set for (A) Orai 
1(O1), Orai 2 (O2), and Orai 3 (O3) (C) Stim 1 (S1) and Stim 2 (S2).(B) SKOV3 cells 
stained with anti-Stim 1, anti-Stim 2, antibodies at a dilution of 1:500 and the 
secondary anti-rabbit antibody conjugated with FITC (green). No primary antibody 
was used as control. The nuclei were stained by 4', 6-diamidino-2-phenylindole 
(DAPI, blue). Scale bar is 20µm. (D) SKOV3 cells stained with anti-Orai 1, anti-Orai 2 
and anti-Orai 2 antibodies at a dilution of 1:500 and the secondary anti-rabbit 
antibody conjugated with FITC. No primary antibody was used as control. The nuclei 
were stained by DAPI. Scale bar is 20µm. The figures are representative of more 
than four independent experiments.  
A B 
D 
C 
Stim 1 Stim 2 
Orai 1 Orai 2 Orai 3 
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3.2.1.3 SKOV3 cell proliferation was inhibited by store-operated channel 
blockers 
To investigate the role of SOC in SKOV3 cell growth, SOC blockers were used; 2-
APB is a SOC blocker and a TRPC channel blocker (Flemming et al., 2003; Xu et al., 
2008a). Figure.3.3.a. shows that 2-APB significantly inhibited the SKOV3 
proliferation in a concentration-dependent manner. 2-APB has been shown to inhibit 
gap junctional channels, which might contribute to the anti-proliferative effect 
(Mesnil, 2002; Harks et al., 2003; Leithe et al., 2006; Vinken et al., 2006), therefore 
the SKOV3 cells were pretreated with carbenoxolone, a gap junctional blocker, to 
pharmacologically dissect out the contribution of store-operated channels. 
Carbenoxolone at 200µM and 400µM significantly inhibited the cell proliferation as 
shown in Figure.3.3b however, the anti-proliferative effect of 2-APB was still 
preserved in the presence of carbenoxolone in Figure.3.3.c, suggesting that the 
anti-proliferative effect of 2-APB could be explained by its inhibition on store-
operated channel. To further enforce the active role of SOC in proliferation, a second 
SOC inhibitor was used, SKF-96365, a SOC channel blocker which also targets the 
Stim1/Orai1 pathway (Boulay et al., 1997; Okada et al., 1998; Liou et al., 2005). 
SKF-96365 significantly inhibited the cell proliferation of SKOV3 in a concentration-
dependent manner in Figure.3.3.d, together with 2-APB suggesting the functional 
importance of SOC channels in the regulation of cell growth. 
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Figure.3.3 SKOV3 cell proliferation was inhibited by store-operated channel 
blockers 
 
(A). SKOV3 were incubated with different concentrations of 2- APB for 24hours. The 
cell proliferation was monitored by WST-1 assay and the absorbance was measured 
at a wavelength of 450nm. (B)SKOV3 treated with carbenoxolone for 24hours. (C). 
SKOV3 cells were incubated with carbenoxolone and 2-APB for 24hours. (D). Effect 
of SKF-96365 on SKOV after 24hour incubation. Each experiment had 8 well repeats 
and the data was from three independent experiments. Data=mean±SEM. *** 
P<0.001 vs. untreated. 
  
A B 
C D 
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3.2.1.4 Role of TRPC channels in cell proliferation 
Also applied were the TRPC siRNAs to demonstrate the active role of TRPCs in 
cancer cell proliferation. Shown in Figure.3.4, there was no difference among the 
groups transfected with scramble siRNA, pool siRNA and mock control transfection 
(no siRNA) on SKOV3 cell proliferation. However, the cell proliferation was 
significantly inhibited by the transfection with TRPC1, TRPC3, TRPC4 and TRPC6 
siRNAs for 48 hours with no significant difference between their respective levels of 
inhibition. Bcl-2 siRNA, which targets the anti-apoptotic Bcl-2 gene, was used as a 
positive control, significantly inhibiting cell proliferation. These si-TRPC effects 
suggest that TRPC channels play a key role in proliferation of SKOV3, though there 
is controversy concerning the mode of activation and role in SOC and of particular 
TRPC channel subunits (Parekh et al., 2005). 
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Figure.3.4 Role of TRPC channels in the cell proliferation 
 
SKOV3 cells were transfected with TRPC siRNAs (100nM siRNA for each group) 
using Lipofectamine 2000. Cell proliferation was measured with WST-1 assay after 
48hour transfection. The sham transfection (control), pool siRNA and scramble 
siRNA were negative control. Bcl-2 siRNA was used as positive control. n=16 for 
each group, *** P<0.001. Data is representative of three independent experiments. 
Data = mean±SEM. 
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3.2.2 Role of calcium pathway in platelets 
 
Studies have confirmed an essential role for Ca2+ signalling during aggregate 
formation and thrombus growth in vitro (Nesbitt et al. 2003).One of the first stages 
upon the path to platelet aggregation is the reorganization of cytoskeletal protein 
such as actin and myosin, with the subsequent transition from the resting discoid 
cells to spheroidal cells and the production of pseudopodia (Siess, 1989). It has 
been established that a critical event in shape change is downstream of the G-
protein coupled receptors, crucially at MLC phosphorylation (Daniel et al., 1984).  
The activation of MLC phosphorylation can occur through two routes; firstly, by a 
Ca2+/calmodulin dependent pathway, mediated by MLCK, and secondly, by a Ca2+ 
independent pathway mediated by the GTPase RhoA and its effector Rho Kinase 
(ROCK) pathway (Paul et al., 1999).  
 
To investigate the two pathways that can lead to platelet shape change, 
experimental conditions were performed in which either the cytosolic Ca2+ and/or the 
Rho-dependent pathway was inhibited. In the first instance, confirming the reported 
effects of NO on platelet intracellular Ca2+ levels, as recent studies indicate that the 
SOC component, TRPC1/3 can be regulated by NO in smooth muscle (Chen et al., 
2009). Figure.3.5 shows the possible effects of thrombin stimulation upon increases 
in cytosolic Ca2+though the formation of IP3 causing a release of Ca2+ from the 
intracellular stores via the IP3R,  and the effects of the inhibitors used to prevent this 
in a Ca2+ free buffer. Treatment of platelets with 1, 2-Bis (2-aminophenoxy) ethane-
N, N, N, N-tetraacetic acid tetra (acetoxymethylester) ((BAPTA)(cell permeable Ca2+ 
chelator)) at 20µM was used to inhibit any cytosolic Ca2+ increases due to release 
from intracellular stores and resulted in a 89% inhibition of Ca2+ rise compared to 
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addition of thrombin (0.05U/ml) alone. Preincubation with S-Nitrosoglutathione 
((GSNO) (PKG targeting the IP3R and SOC proteins)) at 10µM similarly inhibited any 
rise by 86%, demonstrated in Figure.3.5 while both experiments used ethylene 
glycol tetraacetic acid (EGTA) at 1mM, which prevents platelet aggregation by 
chelating extracellular divalent cations that are required for the stabilisation and 
function of the fibrinogen receptor integrin αIIbβ3 (Cicmil et al., 2000).  
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Figure.3.5. Changes in intracellular calcium in response to thrombin. 
 
WP (1x108) were stimulated with thrombin (0.05U/ml) in the absence of extracellular 
Ca2+ and analysed at peak Ca2+ transit with preincubation with the Ca2+ chelator 
[BAPTA (20µM for 20mins)] or GSNO (10µM for 1min). This figure is representative 
of three independent experiments. Data=mean±SEM. **P<0.01 vs. agonist 
stimulation. 
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3.2.3 Influence of NO on calcium mediated MLC phosphorylation 
An elevation of cytosolic free Ca2+ concentration is a major component of the signal 
transduction pathway to the activation of platelets following stimulation by thrombin 
(Davies et al., 1989). This elevation of Ca2+ leads to the subsequent activation of 
MLCK and therefore the phosphorylation of MLC, a key marker in platelet activation 
and the reorganisation of the cytoskeleton necessary for shape change and 
secretion (Hathaway & Adelstein, 1979; Kamm & Stull, 2001). With the inference that 
the initial Ca2+ elevation was due to store-operated Ca2+ channels and that NO can 
negatively regulate this Ca2+ dependent pathway. 
 
Platelet activation and subsequent Ca2+ elevation leads to the activation of the 
enzyme MLCK, involved in the phosphorylation of Ser19 upon MLC (Somlyo & 
Somlyo, 2003) and Figure.3.6a shows its concentration dependent inhibition via the 
cytosolic Ca2+ chelator BAPTA (1-20µM). The elevation of Ca2+ occurs by release 
from internal stores, the proposed candidates for this regulation is via the TRP 
channels. Figure.3.6b shows the addition of a SOC and TRPC blocker, 2-APB 
(80µM) inhibiting Ca2+ mobilisation upon addition of thrombin and Figure.3.6c 
similarly using SKF-96365 (25µM) a SOC inhibitor, demonstrated significant 
inhibition of Ca2+ mobilisation, both compared to the GSNO (10µM) a potent inhibitor 
of intracellular Ca2+ release and cation influx in human platelets.  
  
  
 
 
 
 
 
 
 
 
 
 
Figure.3.6 Intracellular effects of cyto
in response to thrombin 
 
(A) WP (5x108) were treated with BAPTA (1, 5, 10 and 20µM for 20mins)] and 
stimulated with thrombin (0.05U/ml) for 1 minute. Reactions were stopped 
addition of and equal volume of 2xLaemmeli buffer. Proteins (30µg) were separated 
in a 10% gel and immunoblotted for anti
representative of three independent experiments. 
with the SOC inhibitor [2-APB (80µM for 3mins)] or GSNO (10µM for 1min) before 
stimulation with thrombin (0.05U/ml). The figure is representative of three 
independent experiments. (C) 
[SKF-96365 (25µM for 3mins)] or GSN
thrombin (0.05U/ml). The figure is representative of three independent experiments.
Data = mean±SEM. **P<0.01 vs. agonist stimulation.
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3.3 Discussion 
The store-operated Ca2+ channels (SOC) are the main mechanism for Ca2+ entry into 
non-excitable cells, and also regulating Ca2+ entry into cells; the Ca2+ homeostasis it 
maintains within cells controls a diversity of cellular processes such as morphological 
changes, exocytosis, enzyme control, gene regulation, cell growth and proliferation 
(Parekh et al., 2005). In platelets the initial response to thrombin induced stimuli is 
represented by shape change, which reportedly results in the reorganisation of 
cytoskeletal structure after subsequent phosphorylation of contractile proteins, in this 
case namely MLC (Johnson et al., 2007). In this study it has been demonstrated that 
that this phenomenon can occur in both the presence and absence of cytosolic Ca2+ 
in response to stimulation with thrombin, confirming the findings of previous studies 
(Rink et al., 1982; Negrescu et al., 1995). In Figure.3.6.a BAPTA treatment 
significantly inhibits thrombin induced MLC phosphorylation, acting on the Ca2+ 
dependent pathway, confirmed by the use of fluorimetric studies on intracellular Ca2+ 
mobilisation and in agreement with (Trepakova et al., 1999) that NO blocks 
intracellular Ca2+ mobilisation upon stimulation seen in Figure.3.5. The inhibition of 
the Ca2+ route alone is not sufficient to completely inhibit MLC phosphorylation as 
demonstrated with BAPTA, suggesting that the inhibition exerted by the inhibitors on 
the Ca2+ dependent pathway did not affect the Rho-Kinase dependent one. 
 
One of the candidates proposed for SOC are the TRPC channels, which have been 
identified in many cell types; the CNS and in peripheral tissues such as bone, heart 
and prostate (Riccio, 2002), also smooth muscle (Xu et al., 2006) and platelets 
(Galan et al., 2009). 
 
  
89 
 
Demonstrated in this study, is that TRPC, Orai and Stim channels are highly 
expressed in both the mRNA and in protein form in the human ovarian cancer cell 
line SKOV3. Following the establishment of their expression, their possible role in 
SOC was investigated in Figure 3.3. This indicates that the possible effect of 2-APB 
is due to the inhibition on the SOC which is further supported by the use of another 
SOC blocker, SKF-96365. Since 2-APB is a broad-spectrum TRPC channel blocker 
and cannot distinguish the contribution of individual TRPC isoforms, the silencing of 
TRPC1, 3, 4, 6 with TRPC isoform-specific siRNA was untaken to confirm that they 
are an active component within the SOC and proliferation (Figure.3.4).  
 
To substantiate initial findings regarding the role of SOC in the model SKOV3 cell 
line, the contribution of the SOC in the regulation of agonist induced elevation of 
cytosolic Ca2+ in platelets was analysed via the use of fluorimetric study. In this, 2-
APBwas used to block the SOC (Figure.3.6.b), significantly inhibiting internal Ca2+ 
elevation upon agonist stimulation. To support the mechanism via which cytosolic 
Ca2+ elevation occurs in platelets, SKF-96365 another SOC and Orai1/Stim1 
inhibitor (Liou et al., 2005) was used (Figure.3.6.c), again confirming the model of 
Ca2+efflux via SOC. 
 
However due to the limited time available, the potential contribution of the subunits of 
SOC, such as TRPC, Stim and Orai proteins (Putney, 2007; Koslowski et al., 2008), 
studied in the SKOV3 model, could not be applied to the investigation of platelet 
activation. 
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However, recent TRPC1 extraction from human platelets has shown that it was 
phosphorylated by either PKA or PKG, and this phosphorylation decreased upon 
activation of platelets by thrombin (Authi, 2007). This suggests that the 
microenvironment around TRPC1 contains proteins that are substrates for PKA and 
PKG. Thereby in circulation when platelets are exposed to prostacyclin or nitric oxide 
leading to activation of PKA and/or PKG, respectively, their kinases would play an 
important regulatory role in maintaining low cytosolic Ca2+ levels via possible 
inhibitory phosphorylation of SOC proteins and the IP3R regulating the IP3 mediated 
intracellular Ca2+ release (Schwarz et al., 2001), a critical step in the signal 
transduction pathway that leads to full platelet activation (Jackson et al., 2003). 
 
Collectively, the data presented in this chapter shows the inhibitory influence of NO 
upon cytosolic Ca2+elevation; possibly through phosphorylation of key signalling 
proteins. The data also shows that the calcium dependent regulation of platelet 
activity is not the exclusive activatory pathway, with the presence of a calcium 
independent RhoA/ROCK dependent mechanism involved in the phosphorylation of 
the contractile protein, MLC.  
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CHAPTER 4 REGULATION OF PLATELET 
FUNCTION BY NITRIC OXIDE (NO) 
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4. Introduction 
4.1 Regulation of platelet function by nitric 
oxide 
Nitric oxide is a gaseous free radical messenger (NO·), which is synthesised from 
the amino acid L-arginine by various isoforms of NOS. NO is important in the 
endothelial dependent regulation of blood flow and pressure though also a key 
regulator of platelet function. Blood flow pushes platelets to the periphery of the 
vessel wall placing them next to the endothelium where they can respond rapidly to 
vascular damage.  This blood flow also activates the release of the endothelial 
derived NO (Naseem, 2005).NO diffuses into platelets and via its close interaction 
with iron containing proteins binds to its intracellular receptor, the haem-containing 
enzyme called soluble guanylyl cyclase (sGC), activating it to 200 fold increase in 
producing the signalling molecular cyclic guanosine monophosphate (cGMP) 
(Schmidt et al., 1993), endothelial release of NO was linked to cGMP dependent 
platelet inhibition (Mellion et al., 1981), the cyclic nucleotide now can activate protein 
kinase G (PKG), the major mediator of NO (Feil et al., 2003). Defects in platelet 
cyclic nucleotide signalling may play a role in diseases such as ischemic heart 
disease, heart failure and diabetes, where platelet hyperactivity is due to reduced 
sensitivity of platelets to NO and thereby inhibition (Chirkov et al.,2007).  
 
It has been shown that NO is able to block many aspects of platelet activation 
including early activatory signals such as the release of Ca2+ from the intracellular 
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stores, subsequent store operated Ca2+ entry, platelet adhesion, granule release, 
aggregation and apoptosis (Rukoyatkina et al.,2011; Schwarz, 2001; Nesbitt et al., 
2003). Though as yet the exact signalling mechanisms involved in NO mediated 
inhibition are only partly understood. In the previous chapter the ability of NO to 
inhibit Ca2+ mobilisation was confirmed, although shown for the first time is an aspect 
of platelet signalling, that is, that phosphorylation state of MLCSer19 can be regulated 
in a Ca2+independent manner. In the present chapter experiments were designed to 
characterise the effects of NO on platelet function followed by a more detailed 
evaluation of the signalling mechanisms regulating MLC.  
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4.2 Results 
4.2The regulation of platelet function by nitric 
oxide 
4.2.1 Agonist induced platelet aggregation 
 
The first experimental series was designed to investigate the actions of platelet 
agonists, via the use of thrombin and collagen typical agonists to ensure that the 
platelet isolation procedure produced a functionally responsive cell population. It was 
important to ascertain the most appropriate conditions for the use of the agonist. 
Thrombin and collagen were added to WP in aggregation tubes under continuous 
stirring ensuring an even suspension of platelets and their response to the addition 
of the agonists was measured using an aggregometer. These two agonists were 
chosen because they activate platelets by two distinct mechanisms. 
 
Platelet preparations did not undergo spontaneous aggregation upon stirring. The 
addition of thrombin (0.005-0.1U/ml) to platelets induced a concentration-dependent 
increase in platelet aggregation. The initial effective aggregation was observed at 
0.005U/ml to 8.3±4.7% and the maximum at the highest concentration used at 
0.1U/ml is 71±2.1% (Figure.4.1a). At concentrations of 0.05U/ml and above classical 
shape change could be observed. 
 
Next the effects of the matrix protein collagen (0.1-2µg/ml), which promotes 
aggregation through tyrosine kinase linked receptors such as glycoprotein VI, was 
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examined. The initial dose responsible for activating aggregation was 0.1µg/ml 
5.6±2.3%and maximum aggregation at 2µg/ml 70±2.5%(Figure.4.1b). While higher 
concentration collagen caused maximal aggregation there was a significant lag 
phase compared to thrombin. 
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Figure.4.1 Agonist induced platelet aggregation 
 
WP (2.5x108) was incubated at 37°C and aggregation measured as described in 
section 2.1.4.Platelets were stimulated with varying concentrations of (A) thrombin 
and (B) collagen. Aggregation traces were recorded using a dual channel 
aggregometer and expressed as a % aggregation. Traces are representative of three 
independent experiments.   
A B 
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4.2.2 Influence of Nitric Oxide (NO) on platelet aggregation 
4.2.2.1 Nitric Oxide inhibits platelet aggregation in a dose dependent manner 
Having established concentrations of agonist required to induce aggregation the 
functional effects of the inhibitory pathway was tested. The NO-donor, S-
nitrosoglutathione (GSNO), was used to stimulate the cGMP/PKG pathway.  
Platelets were incubated with GNSO (1-100µM) for 1 minute before addition of 
thrombin (0.05U/ml). The agonist alone caused 50±2.2% aggregation, which was 
then reduced to 49±9.2%, 27±3.2% (P<0.05), 13±1.9% (P<0.05) and 1.7±0.33% 
(P<0.05) in a concentration dependent manner in respect to 0.1, 1, 10, 100µM 
GSNO. Significant threshold inhibitory effects occurred by 1µM with 23±5.8% 
(P<0.05) inhibition, maximum inhibition was 100µM GNSO, resulting in 1.7±0.33% 
(P<0.05) aggregation (Figure.4.2a). Importantly using 10µM and above completely 
abolished shape changes and therefore for further experiments GSNO was used at 
concentrations of 10µM and thrombin for 0.05U/ml. 
Next to be examined was the affect of GSNO upon collagen agonist stimulated 
platelet aggregation. WP were again treated with GSNO (0.1-100µM) for 1 minute 
under continuous stirring then stimulated via the addition of collagen (1µg/ml). 
Figure.4.2b shows that collagen caused 60±0.33% aggregation, then upon addition 
of GSNO was reduced to 54±1.3% (P<0.05), 34±6.7% (P<0.05), 13±1.2% (P<0.05) 
and 2.3±0.88% (P<0.05) in a concentration dependent manner to GSNO at 0.1, 1, 10 
100µM.Significantthreshold inhibitory effects occurred by 0.1µM with 5.3±1.7% 
(P<0.05) inhibition, maximum inhibition was 100µM GSNO, resulting in 2.3±0.88% 
(P<0.05) aggregation. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure.4.2 GSNO inhibits platelet aggregation in a dose dependent manner
 
WP (2.5x108) were stimulated with either 
(1µg/ml) or pretreated first with GSNO at the indicated concentrations prior to 
stimulation with the afore mentioned agonists. 
indicated times and expressed as % aggregation. Traces are representative of three 
experiments. As is quantified in the graph 
*P<0.05 vs. agonist alone sample.
A 
C 
 
(A) thrombin (0.05U/m
Responses were recorded for the 
(C), P value compared to agonist alone. 
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l)(B) collagen 
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4.2.2.2 Nitric Oxide inhibits platelet aggregation in a time dependent manner 
The next aspect to be examined was the effectiveness of GSNO as a platelet 
inhibitor as a function of time. WP was incubated with an intermediate concentration 
of GSNO (10µM) from 30 seconds to 60 minutes before stimulation with the agonist 
of interest. Figure.4.3a shows that after 1 minute of incubation of GSNO, 
aggregation was inhibited by 84% upon addition of thrombin. The level of inhibition 
was reduced to 68% after 5 minutes and to 60% by 15 minutes. At 30 minutes 56% 
and for 60 minute the level of inhibition was negligible and comparable to addition of 
thrombin alone. 
 
The effectiveness of GSNO as an inhibitor of collagen-mediated aggregation was 
tested using was collagen (1µg/ml) and 10µM of the inhibitor. Figure.4.3b shows 
that the maximum level of inhibition was reached at 1 minute with 67%, then to 26%, 
11%, 8% and negligible for the times for 5, 15, 30 and 60 minutes respectively. The 
time courses allow us to demonstrate the changing platelet activity as a result of the 
degradation of GSNO over time and thereby its decline in the protective effects 
against agonist activation, though also the differing rates of inhibition regarding 
collagen and thrombin stimulation. 
 
4.2.2.3 Nitric Oxide inhibits platelet aggregation via cGMP pathway 
The key enzyme in the NO/PKG inhibitory pathway is soluble guanylyl cyclase 
(sGC). NO exerts its effects predominantly via activation of the sGC, which leads to 
the formation of cyclic guanosine mono-phosphate (cGMP) (Schaferet al., 2010). 
Therefore it was investigated if GSNO uses this sGC pathway to inhibit agonist-
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induced aggregation. This was evaluated by the use of a selective sGC inhibitor (1H-
[1, 2, 4] oxadiazolo [4, 3-a] quinoxalin-1-one) ODQ (Moroet al., 1996).  
 
Preincubation of platelets with GSNO (10µM) for 1minute before the addition of 
thrombin (0.05U/ml) reduced aggregation from 58.3±3.4% to 14±4.6% (P<0.05). 
Incubation of platelet with ODQ (20µM) alone failed to affect aggregation induced by 
thrombin.  However, when platelets were treated with ODQ before the addition of 
GSNO and thrombin, the NO-donor failed to inhibit aggregation. Under these 
conditions, thrombin induced 58±3.4% aggregation, which remained at 56±4.4% in 
the presence of ODQ and GSNO shown in Figure.4.4. Next platelets were 
stimulated with collagen after treatment with GSNO, the inhibitory effect is apparent; 
we see in Figure.4.4 that GSNO causes a reduced aggregation from 57±6.01% to 
19±4% (P<0.05). Incubation of platelets with only ODQ failed to affect aggregation 
induced by collagen, although when platelets were treated with ODQ before the 
addition of GSNO and collagen, again the NO-donor failed to inhibit aggregation. 
Under these conditions, collagen induced 57±6.01% aggregation, which in the 
presence of ODQ and GSNO 59±1.4%. 
  
  
 
 
Figure.4.3 GSNO inhibits platelet aggregation in a time 
 
WP (2.5x108) was incubated with GSNO (10µM) for up to 1 hour. At the indicated 
times the platelets were stimulated with 
(1µg/ml) for 3minutes. Aggregation traces were recorded on dual channel 
aggregometer and expressed as % aggregation. Traces represent two experiments.
 
 
 
 
 
 
 
 
 
Figure.4.4 GSNO inhibits platelet aggregation via cGMP pathway
WP (2.5x108) was pre-incubated with sGC 
WP were then treated with GSNO (10µM) and stimulated with thrombin 0.05U/ml 
and collagen 1µg/ml. The graph
Data = mean±SEM. *P<0.05 vs. agonist stimulation.
A 
dependent manner.
(A) thrombin (0.05U/ml
inhibitor [ODQ (20µM)] for 20 minutes. 
 is representative of three independent
 
B 
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 experiments. 
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4.2.3 Nitric Oxide induced phosphorylation of Vasodilator 
Stimulated Phosphoprotein (VASP) 
4.2.3.1 NO induces a concentration and time dependent increase in VASP at 
serine 239 
Stimulation with NO leads to the activation of cGMP dependent protein kinase G 
(PKG) and subsequent phosphorylation of various proteins, one of these is VASP, a 
major substrate for cyclic nucleotide dependent kinases, to be located in focal 
adhesions, stress fibres, cell–cell contacts, and highly dynamic membrane regions 
(Reinhard et al., 2001). In platelets, it is present in particularly high concentrations 
(Eigenthaler et al., 1992). Phosphorylation of this protein can be taken as an 
indicator of PKG activity. Three phosphorylation sites have been identified in VASP 
(Ser157, Ser239 and Thr278), although Ser239 is preferentially phosphorylation by PKG 
(Smolenski et al., 1998). Furthermore VASP phosphorylation correlates with 
vasodilator induced inhibition of platelet activation and aggregation (Horstrup et al., 
1994). Therefore taking VASP as a marker, the previous conditions were analysed 
for correlation with inhibition of aggregation via the western blotting technique.  
 
In unstimulated platelets no phosphorylation of VASP was observed. Treatment of 
WP with incremental higher doses of GSNO (0.1-100µM) for 1 minute incubation led 
to similar increase in phosphorylation of VASPSer239 (Figure.4.5a), from the 1µM to a 
maximum at 100µM (highest concentration tested). This phosphorylation of 
VASPSer239 correlated directly with the inhibition of aggregation shown in Figure.4.2 
upon addition of the agonist. Incubation of platelets with the sGC inhibitor ODQ prior 
to GSNO resulted in the inhibition of VASPSer239 phosphorylation, confirming that the 
inhibitory pathway and its subsequent marker of effect are both mediated by the 
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cGMP/PKG pathway. Having established a dose dependent increase in VASPSer239 
phosphorylation, an intermediate concentration of GSNO (10µM) was selected and 
the time dependent phosphorylation of VASPSer239 analysed in Figure.4.5b. Initial 
phosphorylation of the residue was detected within 30 seconds and was maintained 
for 15 minutes hereafter the inhibitory phosphorylation triggered by GSNO declines 
and by 60 minutes is no longer present.  
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Figure.4.5 GSNO induces a concentration and time dependent increase in 
VASP at serine 239 
 
(A) WP (5x108) was incubated with varying doses of GSNO for 1 minute in the 
presence or absence of the sGC inhibitor [ODQ (20µM].Each sample was treated at 
37°C with stirring (1000rpm). Reactions were stopped with an equal volume of 
2xLaemmli buffer. Proteins (30µg) were separated in 10% gradient gels and 
immunoblotted for anti-phospho-VASPSer239. 
(B) WP (5x108) was incubated with GSNO (10µM) for differing times. Reactions were 
stopped with an equal volume of 2xLaemmli buffer. Proteins (30µg) were separated 
in 10% gradient gels and immunoblotted for anti-phospho-VASPSer239. Blots are 
representative of three independent experiments.  
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4.2.4 Inhibition of PAR 1 and 4 induced platelet aggregation via 
Nitric Oxide 
4.2.4.1 Inhibition of Protease Activated Receptors (PARs) 1 and 4 via a dose 
and time dependent manner 
The multifunctional serine protease thrombin is generated at the sites of vascular 
injury during the coagulation cascade and activates various types of cells in the 
vasculature like platelets and endothelial cells (Macfarlane et al., 2001; Hirano, 
2007), and plays a key role in haemostasis and thrombosis. Unlike all other ligands 
that are involved in platelet activation that act by binding in a reversible manner to 
their receptors, thrombin activates its PAR receptors by cleaving an N-terminal part 
at a consensus site (Vu et al., 1991), and is rapidly inactivated by uncoupling from its 
signalling pathway, then internalised and degraded in lysosomes (Trejo et al., 1998). 
The activation of human platelets is predominately mediated through PAR-1, a high 
affinity receptor for activation at low concentrations of thrombin and also PAR-4 
induced platelet responses which are less pronounced and is it a low affinity 
receptor, signalling at primarily high thrombin concentrations (Andersen et al., 1999). 
To address the signal transduction surrounding thrombin induced aggregation and 
how this was affected by cGMP signalling, the action of the PAR receptors was 
examined upon exposure to GSNO.  
 
The activation of PARs is achieved by the proteolytic unmasking of a tethered 
peptide ligand that resides in the receptor’s N-terminal exodomain containing the 
recognition sequence. The synthetic peptides mimic this sequence and function as 
agonists that activate PARs independent of receptor cleavage (Kataoka et al., 2003). 
In the first instance appropriate concentration of the PAR agonists were determined 
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utilising previous work (Bilodeau et al., 2007; Kataoka et al., 2003). PAR-1 agonist 
with a sequence of H-Ser-Phe-Leu-Leu-Arg-Asn-NH2/SFLLRN-NH2at 6µM giving 
58% aggregation and PAR-4 agonist with a sequence of H-Ala-Tyr-Pro-Gly-Lys-Phe-
NH2/AYPGKF-NH2at 60µM for 51% aggregation (Figure.4.6a-b). 
 
Upon preincuabtion of platelets with GSNO (1µM) for 1 minute before the addition of 
PAR-1 (6µM), this reduced aggregation seen in Figure.4.6a from 58±7.5% 
to14±7.5% (P<0.05) to 4.3±2.2% (P<0.01) and then 2.1±2.4% (P<0.01) for 10µM 
and 100µM GSNO respectively. Incubation of platelet with ODQ (20mM) alone failed 
to affect aggregation induced by PAR-1.  However, when platelets were treated with 
ODQ before the addition of GSNO (10µM) and the PAR-1 agonist, the NO-donor 
failed to inhibit aggregation. Under these conditions, PAR-1 induced 58±7.5% 
aggregation, which remained at 54±19% in the presence of ODQ and GSNO shown 
inFigure.4.6c. 
 
Similarly, Figure.4.7b with the PAR-4 (60µM) incubation with GSNO (1µM) for 1 
minute reduced aggregation from61±10.5% to 14±10%to 2.5±2.5% (P<0.05) and 
then to 3±1% (P<0.05) for 10µM and 100µM GSNO respectively. Incubation of 
platelet with ODQ (20mM) alone failed to affect aggregation induced by PAR-4.  
However, when platelets were treated with ODQ before the addition of GSNO 
(10µM) and PAR-4 agonist, the NO-donor failed to inhibit aggregation. Under these 
conditions, PAR-4 induced 61±10.5% aggregation, which remained at 54±6% in the 
presence of ODQ and GSNO shown in Figure.4.6d. 
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Next to be examined was if the effectiveness of GSNO at inhibiting PAR-1 induced 
platelet aggregation was dependent on the time of incubation, in order establish the 
time of peak inhibition following its addition. WP was incubated with an intermediary 
concentration of GSNO at 10µM for allotted time intervals before stimulation with the 
agonist of interest. Figure.4.7ashows that after 30seconds of incubation of GSNO 
(10µM) before PAR-1 (6µM) aggregation was reduced from 52.7±6.4% to 0.3±0.3% 
(P<0.01). The maximum level of inhibition of aggregation was reached at 30seconds, 
then remained at 0.6±0.5% (P<0.01) and 1±1.4% (P<0.01) aggregation for the times 
1 and 5minutes until the duration of 15 minutes incubation with GSNO, 3.7±3.2% 
(P<0.01) aggregation and for 30minutes 15.7±7.8% (P<0.05), 60minutes 48.5±6.5%. 
 
Figure.4.7b demonstrates that following 30secondsof GSNO incubation, PAR-4 
agonist induced aggregation is reduced from 68.3±2.4% to 24.7±9.2% (P<0.05), and 
subsequently to 6.7±4.1% (P<0.01), 5.3±2.9% (P<0.01), 0.5±0.5% (P<0.01) and 
18.7±12.2% (P<0.05) for 1, 5, 15 and 30 minutes respectively, and for 60 minutes 
the level of aggregation had recovered to 39±14.6% suggesting distinct signalling 
differences between PAR1 and 4 upon addition of GSNO and its differing rates of 
inhibition over time.  
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Figure.4.6 Inhibition of Protease Activated Receptors agonists 1 and 4 via 
GSNO 
 
WP (2.5x108) were stimulated with either (A) PAR-1 (B) PAR-4 agonists or 
pretreated first with GSNO at the indicated concentrations prior to stimulation with 
the aforementioned agonists. Responses were recorded for the indicated times and 
expressed as % aggregation. Traces are representative of three experiments. WP 
(2.5x108) were preincubated with sGC inhibitor [ODQ (20µM)] for 20 minutes. WP 
were then treated with GSNO (10µM) and stimulated with (C) PAR-1 (D) PAR-4. 
Responses were recorded and expressed as % aggregation. Traces are 
representative of three experiments. The graph (E) is representative of the above 
experiments. Data = mean±SEM. *P<0.05 vs. agonist stimulation.  
A 
C 
B 
D 
E 
  
 
 
 
Figure.4.7 GSNO inhibits PAR 1
dependent manner 
 
WP (2.5x108) was incubated with GSNO (10µM) for up to 1 hour. At the indicated 
times the platelets were stimulated with 
3 minutes. Aggregation traces were recorded on dual channel aggregometer and 
expressed as % aggregation. 
PAR-1 (D) PAR-4 are representative of three
mean±SEM. *P<0.05 **P<0.01 vs. agonist stimulation.
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C 
 
 
 
 
 
 
 
 
 
-4 induced platelet aggregation in a time 
(A) PAR-1 at 6µM and (B) PAR
Traces represent three experiments.
 independent experiments. Data = 
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4.3 Discussion 
NO acts as an important paracrine signalling molecule in the cardiovascular system 
(Radomski et al., 1987). By the diffusion across the plasma membrane of platelets it 
is able to alter intracellular enzyme activity, with its main receptor being NO sensitive 
guanylyl cyclase receptor leading to the production of cyclic guanosine 
monophosphate (cGMP) from the nucleotide guanosine triphosphate (GTP) 
substrate. Cyclic GMP is present in almost all cells (Hardman et al., 1969), and is a 
secondary messenger which regulates many signalling events; activation of protein 
kinases, ion channels and phosphodiesterases (PDEs). Increased levels of cGMP 
increases the activity of the cGMP-dependent protein kinase (PKG), this being the 
NO dependent mechanism of platelet regulation (Schwarz, 2001). Cyclic GMP is a 
strong negative regulator able to interfere with platelet adhesion, activation, 
aggregation, secretion and shape change. Though there are also cGMP independent 
effects that are mediated by reactive nitrogen species produced as a result of the 
interaction of NO with oxygen (O2), the superoxide radical (O2·¯ ) or metals which can 
lead to tyrosine nitration and nitrosylation of numerous proteins, including 
transcription factors and signalling molecules (Friebe et al., 2003). The present study 
is focussed on the mechanisms by which NO and cGMP inhibited platelet function.  
 
The NO donor chosen an S-Nitrosothiol, to investigate this process is present in vivo 
as major redox form of NO in the plasma (Stamler et al., 1992) with the most 
abundant intracellular RSNO the low molecular weight; S-nitrosoglutathione (GSNO) 
(Stamler et al., 1992), this has the ability to inhibit platelet function, and as NO, 
stimulate guanylyl cyclase thereby producing intracellular levels of cGMP and 
attenuating platelet function primarily via this mechanism. With release of NO from 
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GSNO occurring via enzymatic GSNO reductase activity, by catalytic redox effects of 
transition metals (Cu+, Cu2+, Fe2+) or protein disulphide isomerase(Hogg, 2002;Xiao 
et al., 2011). 
 
To begin to address the mechanisms by which NO and cGMP inhibited platelet 
function, the relationship by which NO induces the inhibition of agonist stimulation 
mediated by agonists such as collagen and thrombin was examined. 
 
Consistent with previous studies using a range of GSNO concentrations, from 
threshold inhibitory responses at 0.1µM to where maximum inhibition was achieved 
at 100µM, we confirmed that GSNO at the 10µM concentration significantly inhibits 
platelet aggregation by thrombin (0.05U/ml) and collagen (1µg/ml)(Roberts et al., 
2009). Demonstrated here is the platelet response upon addition of NO to inhibit 
agonist induced platelet aggregation in a concentration and time-dependent manner 
via the use of aggregometry.   
 
Many of the cellular effects of thrombin are initiated by the protease activated 
receptors (PARs), which are GPCR whose activation occurs via proteolytic 
generation of a tethered ligand. PARs were selectively activated by synthetic 
peptides (Vu et al., 1991; Faruqi et al., 2000) and subsequently intracellularly 
activate Gq and G12pathways (Offermanns, 2006). The results reflect that individual 
PAR agonist can activate platelet aggregation in the same dose and time dependent 
manner as thrombin. It is also known that thrombin has a higher affinity for PAR1 
than PAR4 and that more PAR1 are expressed on platelet surface compared with 
PAR4 (Offermanns, 2006). Due to the high PAR1 affinity, lower concentrations of 
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thrombin and its mimic are required for activating PAR1 (Covic et al., 2000).As the 
cleavage of human PAR-4 required a higher concentration of thrombin than does 
cleavage of PAR-1, it is likely thatPAR-1 is the predominant signalling receptor at low 
thrombin concentrations (Shapiro et al., 2000). Demonstrated here is the fact that 
PAR1 and PAR4 are sensitive to cGMP dependent actions which is consistent with 
the current signalling models for these receptors and indeed a common pathway of 
activation and signal transduction of that established by thrombin, its inhibition by 
GSNO and reversal by ODQ (Holinstat et al., 2007; Murugappa et al., 2006). 
 
In a wider context, the results demonstrate here the efficiency of the anti-aggregatory 
effects of NO linked to the activation of GC, and that ceasing the addition of the NO 
donor and subsequent decline in cGMP production over time, allow the pro-
aggregatory agonist, thrombin, to reverse the otherwise anti-aggregatory pathways. 
The reversibility of NO mediated platelet inhibition has been shown to correlate with 
a cGMP decrease, thereby allowing platelet pro-aggregatory signals to become 
dominant and also the relaxation of smooth muscle (Smolenski, 2012; Rivero-Vilches 
et al., 2003; Nakamura et al., 2007; Kitazawa et al., 2009). 
 
Although the inhibitory effect of NO on agonist induced aggregation, adhesion and 
Ca2+ mobilisation is certain, whether the inhibitory function was of a cGMP-
dependent or independent was uncertain. Data on cGMP-independent signalling 
uses mainly the NO-GC inhibitor ODQ, relying on oxidation of the central iron of the 
enzymes prosthetic haem from Fe2+ to Fe3+ preventing NO binding (Schrammel et 
al., 1996).The data here suggests that the action of the NO donor GSNO inhibits 
human platelet activation in main part via a sGC dependent mechanism. Though 
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high concentrations of the NO donor SNAP (100µM) can partially overcome this 
(Moro et al., 1996; Schrammel et al., 1996).In NO-CG deficient mice, at the high NO 
concentrations suggested for cGMP-independent effects, NO donors, such as DEA-
NO (100µM-4mM), SNP (0.8mM) including GSNO (100µM-4mM) failed to inhibit 
knock out platelet aggregation by agonists such as thrombin (Dangel et al., 2010). 
Furthermore the inhibitory actions of GSNO and ODQ are determined by the platelet 
preparation used, although ODQ effectively blocks the inhibitory actions of NO 
donors in washed platelet preparation, the effect in platelet rich plasma is reduced or 
abolished (Crane et al., 2005; Sogo et al., 2000), due to ODQ binding to plasma 
proteins and thus a reduction in the concentration to inhibit GC. The platelet rich 
plasma also contains free nitrosothiols at concentrations of 1-3µM (Stamler et al., 
1992) and micromolar concentrations of nitrosated proteins that serve to transmit NO 
bioactivity and regulate protein function via mechanism corresponding to 
phosphorylation (Naseem et al., 1996). 
 
To uncover the effect of GSNO upon vasodilator-stimulated phosphoprotein (VASP) 
in platelets, as one of the major regulatory substrates for activated PKG is VASP, we 
sought to determine the effect of GSNO upon Ser239 phosphorylation in a dose and 
time dependent manner. Revealing that the phosphorylation of VASP on Ser239 
results in a mobility shift which was detected as a double band, with the upper 
50KDa band corresponding specifically with phosphorylated Ser239 VASP and the 
lower 46KDa band corresponding to dephosphorylated Ser239VASP, serving as an 
indicator of VASP phosphorylation state (Horstrup et al., 1994). Our data 
demonstrate that GSNO stimulation induces rapid phosphorylation and subsequent 
dephosphorylation over time due to the limited half-life of the NO-donor of Ser239on 
  
114 
 
VASP in human platelets. This rapid phosphorylation has been shown to be 
cGMP/PKG-dependent, and dephosphorylation is dependent on the down-regulation 
of PKG, suggesting that VASP and its phosphorylation on Ser239 are important 
elements in the mechanism of human platelet aggregation (Lindsay et al., 2007; 
Brindle et al., 1996). 
 
The aggregation traces detail human platelets with exposures to NO prior to agonist 
stimulation provide a good match to the concentration and time dependent response 
for VASP phosphorylation. Up to duration of 1 minute after the addition of NO the 
inhibitory action continues to increase in agonist induced aggregation, though the 
negative regulation of platelet activity gradually declines after this time due to the 
decline in the NO signal along with the actions of phosphodiesterases (PDEs) 
terminating cGMP signalling (Schwarz et al., 2001). PDE5 specifically degrades 
cGMP, providing negative feedback on cGMP levels by being activated by cGMP 
and additionally phosphorylated by PKG, activating PDE5 catalytic activity and long 
term desensitisation of an NO induced cGMP response (Mullershausen et al., 2003). 
The tight regulation of the cGMP level is thereby required to maintain the sensitivity 
of the response to the incoming signal and rapid adjustment to changes in that signal 
(Francis et al.,2010). 
 
This phosphorylation of VASP corresponds to the vasodilator induced inhibition of 
platelet activation and aggregation upon residue Ser239, affecting actin-filament 
mediated cytoskeletal reorganisation required for platelet aggregation and spreading 
(Harbeck et al., 2000). Previous studies showed that a lack of the PKG target VASP 
results in megakaryocyte hyperplasia and enhanced agonist induced action of P-
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selectin expression and fibrinogen binding (Hauser et al., 1999) as well as enhanced 
collagen induced activation and impaired inhibition via cGMP dependent inhibition of 
platelet aggregation (Aszodi et al., 1999) 
 
In conclusion, these results demonstrate that GSNO exerts its inhibitory effects via a 
sGC dependent mechanism in turn generating the cyclic nucleotide cGMP and 
subsequent activation of PKG leading to protective effect against agonist induced 
aggregation. Subsequent phosphorylation of VASP and the IP3 receptor by PKG 
results in the reduced rearrangement of the cytoskeletal proteins and reduced Ca2+ 
release from internal stores; in the absence of sGC GSNO has no effects (Friebe et 
al., 2003). 
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CHAPTER 5 REGULATION OF MYOSIN LIGHT 
CHAIN PHOSPHORYLATION BY NITRIC OXIDE 
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5. Introduction 
5.1 Regulation of myosin light chain 
phosphorylation by nitric oxide 
Platelets mediate haemostasis via amplifying an initial agonist stimulus and 
aggregating at the site of injury. Activated platelets change shape, secrete α-
granules and dense granules, and release positive feedback mediators (Holmsen, 
1994). When platelets are initially stimulated, the first event is a rearrangement of the 
cytoskeletal proteins (actin and myosin), and the inert disc-shaped platelets change 
into spheres with filopodia (Wurzinger, 1990). Activation of phospholipase A2 
releases arachidonic acid from membrane phospholipids, which is converted into 
thromboxane A2. Serotonin and ADP, released from dense granules, and 
thromboxane A2 function as positive feedback mediators, which recruit more 
platelets into a primary haemostatic plug (Shattil et al., 1997). 
 
During platelet shape change, a prerequisite for secretion and platelet aggregation, 
changes are driven by the rearrangement of the actin-myosin cytoskeleton and the 
contraction of actin filaments, with myosin, a hexamer ATPase motor protein, playing 
a central role in the regulation of actin filaments contraction (Hartwig, 1992).  
Phosphorylation of the myosin light chain (MLC) on Serine19 (MLCSer19) regulates the 
ATPase activity of myosin which upon ATP hydrolysis generates a mechanical force 
the causes actin filaments contraction (Johnson et al., 2007). MLC phosphorylation 
is regulated in a Ca2+/Calmodulin-dependent manner by myosin light chain kinase 
(MLCK) and in a Ca2+ independent manner by RhoA/Rho-Kinase (ROCK) (Bauer et 
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al., 1999). Activation of the later pathway leads to the inhibition of myosin light chain 
phosphatase (MLCP) allowing MLC phosphorylation to take place (Kimura et al., 
1996). NO/cGMP inhibits platelet shape change, though the mechanism remains 
unclear. In smooth muscle cells the NO/cGMP pathway decreases the 
phosphorylation of the MLC and increases phosphorylation of MLCP resulting in 
vasorelaxation (Wooldridge et al., 2004). In the previous chapter the data indicated 
that NO completely abolished shape change. Therefore it was possible that NO may 
influence the biochemical mechanisms regulating this morphological process. In this 
chapter the mechanism by which NO modulated platelet shape change is examined 
in detail.  
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5.2Results 
5.2 Regulation of Myosin Light Chain 
phosphorylation by NO 
5.2.1 Platelet shape change 
Shape change is mediated through two separate pathways, Ca2+ dependent and 
independent. To examine the potential role of NO on these two pathways, inhibitors 
were used to isolate the pathways in the presence and absence of NO. Platelets 
were stimulated with thrombin, in the presence of apyrase (1U/ml), indomethacin 
(10µl/ml) and EGTA (1mM) to prevent secondary signalling though underwent shape 
change but not aggregation.  Shape change through the pathway that was 
independent of an increase in cytosolic Ca2+, that is in the presence of BAPTA, was 
delayed though the maximal response was not reduced. The role of the RhoA/ROCK 
pathway was investigated by preincubation of platelets with Y-27632 (10µM) shown 
to specifically inhibit the kinase activity of p160ROCK purified from platelets (Uehata 
et al., 1997). Under these conditions shape change was weakly inhibited upon 
addition of thrombin. However, pre-treatment with both the Y-27632 and BAPTA, 
completely inhibited shape change, suggesting that thrombin stimulates both 
pathways and that Ca2+ and Rho-kinase pathways play independent roles in the 
initiation of this morphological response. In contrast, GSNO alone abolishes shape 
change completely. 
 
  
120 
 
The inhibitors were then used in the presence of NO and thrombin induced shape 
change was investigated. Figure.5.1shows that when platelets were preincubated 
with either BAPTA in combination with GSNO, leading to complete inhibition of 
shape change. Similarly, the combination of Y-27632 with GSNO also ablated shape 
change. Together these data indicate that NO has the capacity to target the Ca2+ 
dependent and ROCK dependent pathways independently of each other.  
  
  
 
 
 
 
 
 
 
 
Figure.5.1 Platelet shape 
 
WP (2.5x108) stimulated with thrombin (0.01
Ca2+ chelator [BAPTA (20µ
20mins)], GSNO (10µM for 1min) before stimulation of Apyrase
Indomethacin (10µl/ml) treated platelets. The figure is representative of three 
independent experiments. 
 
change in response to thrombin 
-0.05U/ml) or pre-incubated first with 
M for 20mins)], Rho-kinase inhibitor [Y-
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5.2.2 Thrombin induces a dose and time dependent MLC 
phosphorylation in platelets 
Actin and myosin interactions have a critical role in platelets (Daniel, 1984) and their 
interactions are regulated via the MLC and its phosphorylation by agonist stimulation 
upon the residues Ser19 and Thr18 (Itoh et al., 1992). In this study we focused upon 
the MLCSer19 phosphorylation site, as it has been shown to be phosphorylated 
downstream of both the Ca2+ dependent Gq activation and  Ca2+ independent G12/13 
pathways, while the residue Thr18 phosphorylation occurs subsequent to former 
residue and is principally phosphorylated via the Ca2+ independent G12/13 pathway 
(Getz et al.,2010). After addition of thrombin platelets undergo shape change as 
demonstrated in Figure.5.1 and can subsequently aggregate, during which it is 
reported that phosphorylation of MLCSer19takes place (Buaer et al 1999).  
 
As part of the study it was important to establish the effect of NO signalling on MLC 
phosphorylation. However, prior to this, the conditions for MLC phosphorylation in 
response to platelet activation had to be determined.  No phosphorylation of MLC 
was observed under basal conditions. The phosphorylation of MLCSer19 occurs in a 
dose dependent manner upon addition of increasing concentrations of thrombin 
(Figure.5.2). Initial phosphorylation was observed at concentrations as low 
0.025U/ml thrombin, with more robust phosphorylation observed at 0.05U/ml and 
0.1U/ml. Selecting an intermediate dose of thrombin (0.05U/ml), the phosphorylation 
state of MLC was examined over a period. This revealed a time dependent 
phosphorylation which was observed as early as 15secondspeaking at 1minute after 
stimulation thereafter returning to basal conditions.  
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Figure.5.2 Effect of thrombin on MLC phosphorylation 
 
(A) WP (5x10 8) stimulated with varying doses of thrombin for 1minute. Each sample 
was treated at 37°C with stirring (1000rpm). Reactions were stopped with an equal 
volume of 2xLaemmli buffer. Proteins (30µg) were separated in 10% gradient gels 
and immunoblotted for phospho-MLCSer19. Blot is representative of three individual 
experiments, and (C) densitometric analysis of these immunoblots. **P<0.01 vs. 
basal sample. (B) WP (5x108) were incubated with 0.05U/ml of thrombin for up to 5 
minutes. Each sample was treated at 37°C with stirring (1000rpm). At the indicated 
times the reactions were stopped with an equal volume of 2xLaemmli buffer. 
Proteins (30µg) were separated in 10% gradient gels and immunoblotted for anti-
phospho-MLCSer19.Blot is representative of three individual experiments, and (D) 
densitometric analysis of these immunoblots. *P<0.05, **P<0.01 vs. basal sample. 
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5.2.3 Thrombin induces MLC phosphorylation via biphasic
 mechanism 
It has been previously shown in Figure.5.1 that thrombin induced platelet shape 
change is mediated by both ROCK and Ca2+dependent pathways and that thrombin 
in Figure.5.2 affects the phosphorylation state of MLC (Bauer et al., 1999). Having 
confirmed that stimulation of platelets with thrombin induced MLC phosphorylation 
on Ser19the pathways regulating this phosphorylation event were examined. Firstly, 
to determine whether the agonist-mediated phosphorylation of the residue is Ca2+ 
dependent, platelets were incubated with BAPTA (20µM) prior to stimulation with 
thrombin. Thrombin induced MLC phosphorylation was significantly reduced, 
indicating that phosphorylation is mediated, at least in part, in Ca2+ dependent 
manner. To delineate the Ca2+independent signalling pathway upstream of MLC 
phosphorylation platelets were incubated with Y-27632, a ROCK inhibitor (Uehata et 
al., 1997). Similarly to BAPTA, thrombin-induced MLC phosphorylation was partially, 
but significantly reduced under conditions of ROCK inhibition. Importantly, incubation 
of platelets with both inhibitors prior to stimulation with thrombin completely 
abolished MLC phosphorylation. This data suggests that MLC phosphorylation in 
response to thrombin is dually regulated byCa2+ and ROCK dependent mechanisms. 
The dual regulation of MLC phosphorylation by ROCK and Ca2+ in platelets is in 
agreement with other studies using different agonists, such as ADP, thromboxane 
analogue U46619 and convulxin (Wilde et al., 2000; Bauer et al., 1999). 
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Figure.5.3 Effect of ROCK inhibition by Y-27632 and chelation of cytosolic 
calcium by BAPTA on thrombin induced MLC phosphorylation 
 
(A)WP (5x108) stimulated with thrombin (0.05U/ml) or pre-incubated first with the 
Ca2+ chelator [BAPTA (20µM for 20mins)], Rho-kinase inhibitor [Y-27632 (10µM for 
20mins] before stimulation. After 1 minute incubation with agonist the reactions were 
stopped with addition of an equal volume of 2xLaemmli buffer. Proteins (30µg) were 
separated in 10% gradient gels and immunoblotted for phospho-MLCSer19. Blot is 
representative of three individual experiments and (B) densitometric analysis of 
these immunoblots. **P<0.01 vs. TBN (Thrombin) sample. 
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B 
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5.2.4 Reversible phosphorylation via the action of NO 
The aim of the next series of experiments was to determine the effect of GSNO on 
thrombin induced phosphorylation of MLCSer19. Figure.5.4a shows the agonist 
stimulation of platelets with thrombin after preincubation for 1 minute with increasing 
concentrations of GSNO (1-50µM) the phosphorylation of MLCSer19. Phosphorylation 
of the MLCSer19was increased significantly upon addition of thrombin. Preincubation 
of platelets with GSNO (0.1-50µM) inhibited phosphorylation of the MLC triggered by 
the agonist and maintained the basal phosphorylation state; this occurred at all 
concentrations tested. Within the same samples the phosphorylation of VASP was 
also examined. Minor phosphorylation of VASP was observed at 1µM; with maximal 
phosphorylation observed at 10µM.The mechanism of action of GSNO was 
investigated via the use of a soluble guanylyl cyclase (sGC) inhibitor ODQ.  In the 
presence of this inhibitor the action of GSNO is blocked, that is, thrombin was still 
able to induce phosphorylation of MLC.  The confirmation that ODQ is blocking 
cGMP mediated signalling is evidenced by the lack of VASP phosphorylation under 
these conditions, this data indicative of a cGMP dependent mechanism. 
 
The first series of experiments highlighted the ability of NO to prevent thrombin 
stimulated phosphorylation of MLC. In the next series of experiments, the ability of 
NO to potentially dephosphorylate MLC that had been phosphorylated in response to 
thrombin was investigated. To achieve these platelets were treated with Thrombin for 
1min followed by the addition of GSNO for 1min. Figure.5.4b shows that stimulation 
of thrombin for 1minute led to the phosphorylation of MLCSer19. However, the addition 
of GSNO after thrombin reversed the phosphorylation of MLC; at all concentrations 
of GSNO tested.  The paired examination of VASP phosphorylation demonstrated 
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that cGMP signalling was activated. Though it was noticeable that GSNO induced 
dephosphorylation of MLC was maximal at lower concentrations than required to 
induce maximal phosphorylation of VASPSer239. The potential dephosphorylation of 
MLC was cGMP dependent, since when sGC activity was blocked by ODQ, the level 
of MLC phosphorylation return that that found with thrombin alone.  
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Figure.5.4 Effect on NO mediated inhibition of MLC phosphorylation 
 
(A)WP (5x108) pre-incubated with increasing concentrations of GSNO for 1minute 
prior to stimulation with thrombin (0.05U/ml) for 1minute or pre-incubated first with 
the sGC inhibitor [ODQ (10µM for 20mins]. After 1 minute incubation with thrombin 
the reactions were stopped with addition of an equal volume of 2xLaemmli buffer. 
Proteins (30µg) were separated in 10% gradient gels and immunoblotted for anti-
phospho-MLCSer19 and anti-phospho VASPSer239. Blot is representative of three 
individual experiments and (C) densitometric analyses of these immunoblots. 
**P<0.01 vs. TBN (Thrombin) sample.(B) WP (5x108) stimulated with thrombin 
(0.05U/ml) for 1minute then increasing concentrations of GSNO incubated for 1 
minute post stimulation, or pre-incubated first with the guanylyl cyclase inhibitor 
[ODQ (10µM for 20mins]. After 1 minute incubation with GSNO the reactions were 
stopped with addition of an equal volume of 2xLaemmli buffer. Proteins (30µg) were 
separated in 10% gradient gels and immunoblotted for anti-phospho-MLCSer19 and 
anti-phospho VASPSer239. Blot is representative of three individual experiments and 
(D) densitometric analysis of these immunoblots. **P<0.01 vs. TBN (Thrombin) 
sample.  
C 
A B 
D 
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5.2.5 Dissection of the pathways regulating NO mediated regulation 
of MLC phosphorylation 
Following on from the actions of NO was the requirement to explore the pathways 
that are regulated by NO, and the subsequent effects upon the phosphorylation state 
of MLCSer19.  Having confirmed in section 5.2.3that MLC phosphorylation required 
two independent pathways; we examined the effect of NO on theCa2+ 
dependent/MLCK route through the use of the Ca2+ chelator BAPTA and the Ca2+ 
independent/ROCK route via the inhibitor Y-27632. First, the individual effects of the 
inhibitors were examined, and then in combination with NO to gauge if the alternate 
pathway was also abolished. Figure.5.5a shows that following stimulation by 
thrombin there was a large increase in phosphorylated MLCSer19. Incubation with 
BAPTA, which prevents the rise in cytosolic Ca2+ concentration, resulted in a 
dramatically reduced phosphorylation compared with agonist alone stimulated 
platelets, although phosphorylation was not abolished suggesting a role for ROCK 
activity in Ca2+ independent MLC phosphorylation. Consistent with this 
Figure.5.5bshowsY-27632 (10µM) pre-treatment also exhibits significant inhibition of 
thrombin-induced phosphorylation. Again the phosphorylation was not abolished by 
Y-27632 indicating that phosphorylation is not entirely ROCK dependent.  
 
In contrast to the pathway specific inhibitors, GSNO completely abolished MLC 
phosphorylation, suggesting that it targeted both pathways. Importantly the 
combination of either BAPTA or Y27632 with GSNO (10µM) abolished 
phosphorylation remaining when using the inhibitor alone. The protective effect of 
NO against phosphoMLCSer19was prevented by incubation of platelets with the 
inhibitor ODQ, confirming that its protective effect is via cGMP signalling and this 
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principally occurs through dual inhibition of the cytosolic Ca2+ increases and 
RhoA/Rho-kinase activity in platelets thus reducing MLC phosphorylation, platelet 
shape change and ultimately aggregation. 
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Figure.5.5 Influence of NO on MLC phosphorylation 
 
WP (5x108) stimulated with thrombin (0.05U/ml) for 1minute. (A) Pre-incubated first 
with the Ca2+ chelator [BAPTA (20µM for 20mins)], the guanylyl cyclase inhibitor 
[ODQ (10µM for 20mins] or GSNO for (10µM for 1minute) before stimulation. (C) 
Densitometric analysis of these immunoblots. **P<0.01 vs. TBN (Thrombin) sample. 
(B) After 1 minute thrombin stimulation addition of GSNO for (10µM for 1minute)and 
or preincuabtion with the Rho-kinase inhibitor [Y-27632 (10µM for 20mins] and 
guanylyl cyclase inhibitor [ODQ (10µM for 20mins]. Reactions were stopped by 
addition of2xLaemmli buffer. Proteins (30µg) were separated in 10% gradient gels 
and immunoblotted for phospho-MLCSer19 and anti-phospho VASPSer239. Blot is 
representative of three individual experiments and (D) densitometric analysis of 
these immunoblots. **P<0.01 vs. TBN (Thrombin) sample.  
  
A 
C D 
B 
  
132 
 
5.2.6 NO modulation of the RhoA-mediated pathway 
Platelet stimulation via thrombin is mediated through G-protein coupled receptors 
which activate Gq, G12/13 and Gi (Offermanns et al., 1994).  G12/13 is the primary 
signalling pathway to RhoA activation (Getz et al., 2010). This enables the activation 
of Rho guanine nucleotide exchange factors, leading to the switching from the 
inactive GDP form to RhoA-GTP bound active state that are interconvertable by 
GDP-GTP exchange and GTPase reaction. Stimulation of ROCK results in MLCSer19 
phosphorylation, increasing actomyosin contractility and regulation of microtubule 
coils during shape change and dense granule secretion (Offermanns, 2006). Data 
presented in section 5.2.5 suggested that GSNO can inhibit the ROCK pathway that 
leads to phosphorylation of MLC, however, it was still unclear how NO modulated the 
pathway. The classic model of Rho protein regulation involves a cycle between 
active GTP-bound and inactive GDP-bound conformations (Etienne-Manneville et 
al., 2002). Various agonists induced signals, such as G protein-coupled receptor 
agonists, activate guanine nucleotide exchange factors and increase the level of 
GTP-RhoA. Activated GTP-RhoA is readily prenylated at its carboxy terminus and 
then translocated to the cell membrane, where it interacts with effector proteins like 
ROCK to generate downstream signalling. Ser188 phosphorylation of RhoA is thought 
to uncouple this cycle and to terminate RhoA signalling by allowing the guanine 
dissociation inhibitors to bind and sequester GTP RhoA in the cytosol (Lang et al., 
1996; Rolli-Derkinderen et al., 2005). Previous studies demonstrate that PKG 
phosphorylates RhoA at Ser188 in vitro and in cultured cells (Ellerbroek et al., 2003; 
Sauzeau et al., 2000; Sawada et al., 2001). Figure.5.6 demonstrates in platelets that 
increasing doses of GSNO (1-50µM) lead to a concentration dependent increase in 
phosphorylation of RhoA at Ser188. The level of phosphorylation at Ser188 on RhoA 
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closely parallels that of VASP phosphorylation at Ser239, the site selectively 
phosphorylated by PKG (Smolenski et al., 1998). The results indicate that PKG 
phosphorylates RhoA at Ser188 in human platelets, with phosphorylation initiated at 
1µM and maximal at 50µM, making this consistent with the profile for the inhibition of 
RhoA. The ability of GSNO to drive the phosphorylation of RhoA is blocked by ODQ. 
Thus, activation of the NO/PKG pathway leads to inhibition of RhoA dependent 
functions, potentially through the inhibitory phosphorylation.  
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Figure.5.6 NO mediated inhibition of Rho-mediated inhibitory pathway 
 
WP (5x108) was stimulated with Thrombin (0.05U/ml) for 1 minute or incubated first 
with the guanylyl cyclase inhibitor [ODQ (10µM for 20mins] or GSNO for (1, 5, 10 
and 50µM for 1 minute) before the reactions were stopped with addition of an equal 
volume of 2xLaemmli buffer. Proteins (30µg) were separated in 10% gradient gels 
and immunoblotted for phospho-RhoASer188 and phospho-VASPSer239. Blot is 
representative of two individual experiments.  
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5.3  Discussion 
Platelets respond to various stimuli by rapid changes in shape followed by 
aggregation and subsequent secretion of granule contents. Platelet shape change is 
the earliest functional response following activation with physiological agonists, 
which is accompanied by the rearrangement of the cytoskeleton (Daniel et al., 1984). 
Cytoskeletal rearrangements such as filament assembly, surface membrane folding 
and centralization of secretory granules are thought to be mediated by the 
phosphorylation of Myosin IIA (Siess, 1989). The phosphorylation of the MLC results 
in an increased development of actin-activated ATPase activity and reflects the 
contractile activity of actomyosin (Getz et al., 2010).Previous studies have 
demonstrated that platelet shape change can occur both in the presence and in the 
absence of an increase of cytosolic Ca2+ concentration in response to thrombin, 
ionomycin and the thrombin receptor activating peptide (Negrescu et al., 1995). In 
contrast to thrombin, the thromboxaneA2analogue U46619 was not able to induce a 
rise of intracellular Ca2+ concentration in Gq deficient platelets and the addition of the 
ROCK inhibitor Y-27632inhibited the U46619-induced MLC phosphorylation in Gq-
deficient mouse platelets. These observations led the authors to conclude that a 
Rho/Rho kinase pathway regulating MLC phosphorylation operated in platelets and 
that ROCK mediates the Ca2+independentpathway. These data suggested that a 
dual regulation of platelet activation and aggregation is present; thereby extension 
also requires a reversible inhibition of these pathways to allow rapid platelet 
responses to changing internal environment. The intracellular mechanism remains 
undetermined, though shown here is the inhibitory capability of NO to potentially 
target both pathways. 
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The dual regulation of MLC phosphorylation and shape change by ROCK and Ca2+ 
elevation inhuman platelets is demonstrated here via thrombin through PAR 
receptors which couple to both heterotrimeric G proteins Gq and G12/13. The 
activation of Gq and ultimately PLCβ, resulting in the mobilisation of intracellular Ca2+ 
and MLCK activity resulting in platelet shape change was prevented via the addition 
of BAPTA, as shown in the fluorimetric data in Figure.3.6, thus leading to delayed 
shape change and reduced MLC phosphorylation. Consistent with a role of NO in 
modulating intracellular Ca2+ concentrations, we demonstrate that thrombin induced 
Ca2+ mobilisation can be inhibited by GSNO. However, as seen in Figure.5.1 and 
5.3inhibition of the Ca2+ mobilisation alone is not sufficient to completely inhibit 
shape change and MLC phosphorylation. In the presence of BAPTA approximately 
50% of thrombin induced phospho MLC is lost, clearly indicating an additional 
pathway.  The inhibition of ROCKbyY-27632 only slightly affected shape change and 
again did not completely inhibit MLC phosphorylation induced by thrombin; a 
complete inhibition of shape change was only achieved when both pathways were 
simultaneously inhibited by Y-27632 and BAPTA. This confirmed a biphasic 
stimulation by thrombin involved in shape change and that there is dual regulation of 
MLC phosphorylation, one via the Ca2+ dependent MLCK and the other by the Ca2+ 
independent ROCK.  
 
Circulating platelets are exposed to endothelium-derived NO and also low levels of 
thrombin(Shimokawa et al., 1995) and alterations in NO concentrations might 
influence this balance, as evidenced by increased susceptibility to thrombosis in 
patients with impaired NO production (Freedman et al., 1996). Data in this thesis 
demonstrated that there is the dual inhibitory effect of NO upon both of the pathways 
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required for initiation of shape change, MLC phosphorylation and subsequent 
aggregation. The cGMP pathway negatively regulates cytosolic Ca2+ elevation 
including all types of Ca2+ oscillations that have been observed under flow conditions 
(Mazzucato et al., 2002). Some of these effects are thought to be mediated by direct 
phosphorylation of IP3-R (Tertyshnikova et al., 1998) or by the phosphorylation of 
IRAG on intracellular stores (Hofmann, 2005; Schwarz et al., 2001). Though Ca2+ 
levels are further regulated by the transient receptor potential channel 6 (TRPC6) in 
platelets (Hassock et al., 2002), which is involved in store-operated Ca2+ entry, and 
forms a complex with type II IP3R in platelets (Redondo et al., 2008). 
 
The data presented in this section of the work show for the first time the ability of NO 
via PKG, to block the Ca2+ independent Rho-pathway.  This is a critical observation 
in understanding the mechanisms by which NO regulates platelet function. Since 
Ca2+ mobilisation is so central to platelet activity it has often been assumed that NO 
mediates its major effects by blocking Ca2+. However, our data demonstrates that 
regulation of platelets by NO requires other targets.  The mechanism by which 
NO/PKG inhibits RhoA activation is unclear, but could involve the inhibitory 
phosphorylation of RhoASer188, inactivating RhoA. This phosphorylation event in other 
cells is thought to prevent the translocation of the active GTP-bound RhoA to the 
membrane and interactions with the kinase present there necessary for activation of 
the ROCK and all subsequent downstream affects (Totsukawa et al., 2000). ROCK 
activation is required indirectly for the phosphorylation of MLC, since it will cause the 
inhibitory phosphorylation of MYPT1 substrate, which in turn allows MLC kinase to 
phosphorylate MLC unhindered. Thus, it is possible that PKG regulation of shape 
change is due to its ability to block RhoA/Rock inhibition of MLCP, thus ultimately 
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allowing for reversible dephosphorylation of the MLC phosphorylation state by the 
MLCP. 
 
Shown here is that NO prevents and reverses the thrombin induced platelet shape 
change and MLC phosphorylation via a pathway dependent on cGMP/PKG 
activation, confirmed by the action of the sGC inhibitory ODQ, which consequently 
led to abolition of the protective NO dependent pathway upon thrombin stimulation. 
The effects of NO on platelets have been previously demonstrated to be rapidly 
reversible and at concentrations produced by stimulated endothelial cells (Kanai et 
al., 1995). Therefore circulating platelets should thus be able to respond to 
fluctuations in concentrations of NO with a rapid and reversible shape change. More 
importantly we identify RhoA as a novel target for PKG signalling and potentially a 
new mechanism of regulation of platelets by the cyclic nucleotide regulated pathway. 
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CHAPTER 6 THE REGULATION OF MYOSIN 
LIGHT CHAIN PHOSPHATASE (MLCP) 
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6.  Introduction 
6.1 The regulation of myosin light chain 
phosphatase 
Myosin Light Chain Phosphatase (MLCP) is responsible for dephosphorylation of the 
phosphorylated MLC and was identified as the major serine/threonine phosphatase 
component in the platelet-cytoskeleton fraction (Kiss et al., 2002). MLCP from 
human platelets is composed of three subunits, a 38kDacatalytic subunit of type 1 
protein phosphatase PP1c, 130-kDamyosin phosphatase target subunit 1 MYPT1 
and a 20kDa subunit of unknown function (Nakai et al., 1997), as is also the case for 
MLCP present in smooth muscle, cerebral arteries (Kitazawa et al., 2009; Neppl et 
al., 2009) and endothelial cells (Hartel et al., 2007). MYPT1 targets PP1c to its main 
substrate myosin and thus is involved in the formation of the active MLCP complex. 
Inhibition of MLCP can occur though phosphorylation of inhibitory sites: MYPT1; 
Thr696/853 result in inhibition of PP1c activity. Both sites mentioned are major 
phosphorylation sites for Rho-Kinase (Feng et al., 1999). The activation of the MLCP 
can occur through phosphorylation of Ser695 in response to PKG activity, which also 
prevents the phosphorylation of the inhibitory site Thr696 (Wooldridge et al., 2004) via 
ROCK, thereby blocking inhibition. Having already explored the relationship between 
NO/cGMP signalling and regulation of MLC, this relationship between these two was 
further explored by examining MLCP activity and its role in MLC phosphorylation. 
  
  
141 
 
6.2 Results 
6.2 The regulation of myosin light chain 
phosphatase 
6.2.1 Rho-Kinase dependent inhibition of MLCP 
Having examined the action of thrombin and GSNO induced responses, the 
mechanisms that lead to assembly and activity of the phosphatase complex were 
now probed through the controlling phosphorylation at residues Thr696 and Thr853 
upon the MYPT1 subunit. 
 
In Figure.6.1 treatment of WP with thrombin (0.05U/ml) resulted in robust 
phosphorylation of both MLCP inhibitory residues Thr696/853 and at MLCSer19. 
However, pre-incubation with the ROCK inhibitor, Y-27632 (10µM) prevented the 
inhibitory phosphorylation and decreased phospho MLCSer19residues, confirming that 
all lie downstream of ROCK signalling. To explore the effect of Ca2+ elevation, ML-7 
(5µM) was used to inhibit the Ca2+ sensitive MLCK. In the presence of ML-7, 
thrombin phosphorylation of MLCSer19 was reduced, while the inhibitory 
phosphorylation of MLCP was maintained. These data confirm that MLC 
phosphorylation is under the control of MLCK and potentially ROCK dependent 
regulation of MCLP.  
 
 
  
142 
 
6.2.2 Agonist triggered phosphorylation of MYPT1 residues 
Upon agonist stimulation intracellular Ca2+ concentration is elevated and GDP-Rho 
converted to GTP-Rho leading to its activation. In parallel activation of RhoA/ROCK 
phosphorylates the MYPT1 subunit of the MLCP at Thr696/853 (Kitazawa et al., 2009). 
Utilising thrombin (0.05U/ml) the contribution of MYPT1 phosphorylation was 
explored focusing upon the inhibitory threonine residues. Figure.5.2 has previously 
shown that phosphorylation of the MLC is time dependent, now we determine if the 
inhibitory phosphorylation of MYPT1 residues has a similar behaviour. Treatment of 
the WP with thrombin (0.05U/ml) resulted in a time dependent phosphorylation of the 
inhibitory sites on the MYPT1, although there were differences in the kinetics. Thr696 
was maximally phosphorylated at 5seconds post thrombin and maintained for 
30seconds before undergoing full dephosphorylation by 60 seconds. The Thr853 is 
phosphorylated at 5seconds, but is maximal at 30seconds before declining to basal 
by 60seconds, possibly indicating preferential targeting by ROCK activity for Thr696.  
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Figure.6.1 Thrombin initiated MLCP inhibitory phosphorylation via Rho-Kinase 
 
WP (5x108) stimulated with thrombin (0.05U/ml) for 30seconds or pre-incubated first 
with Rho-kinase inhibitor [Y-27632 (10µM for 20mins], and or the MLCK inhibitor 
[ML-7 (5µM for 20mins)]. Reactions were stopped by addition of 2xLaemmli buffer. 
Proteins (40µg) were separated in 10% gradient gels and immunoblotted for anti-
phospho MLCPThr853, anti-phospho-MLCPThr696, anti-phospho-MLCPSer695, anti-
phospho VASPSer157 and phospho-MLCSer19. Blot is representative of two individual 
experiments. 
 
 
 
 
 
 
Figure.6.2 Thrombin triggered phosphorylation of inhibitory residues 
 
WP (5x108) was incubated with thrombin (0.05U/ml) for differing times. Reactions 
were stopped with an equal volume of 2xLaemmli buffer. Proteins (40µg) were 
separated in 10% gradient gels and immunoblotted for anti-phospho-MLCPThr696 and 
anti-phospho-MLCPThr853. Blots are representative of two independent experiments. 
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6.2.3 Influence of NO on platelet MLCP phosphorylation 
A downstream target of RhoA/ROCK and NO/PKG pathways, MLCP activity is 
represented though phosphorylation and dephosphorylation of the MYPT1 (Kitazawa 
et al., 2009; Hartel et al., 2007). The NO/PKG pathway results in the reactivation and 
disinhibition of MLCP (Wu et al., 1998) via two possible routes, one, phosphorylation 
at Ser188 on RhoA inhibits its activity and subsequently ROCK mediated 
phosphorylation of MYPT1 at inhibitory site Thr853, or two, PKG mediated 
phosphorylation of MYPT1 at Ser695, which may interfere with phosphorylation of the 
adjacent Thr696, thus potentially removing the inhibition of MLCP thereby reactivating 
the MLCP (Nakamura et al., 2007). The ability of NO/cGMP signalling to modulate 
MLCP activity was investigated. Treatment of WP with 10µM GSNO (Figure.6.3), a 
concentration that blocks MLC phosphorylation, elicited a time dependent increase in 
phosphorylation. This increase in MYPT1 phosphorylation at Ser 695 is consistent 
with previous studies of (Nakamura et al., 2007) and (Wooldridge et al., 2004) 
following treatment elevating cGMP levels in smooth muscle. Concomitant increases 
in VASP phosphorylation at Ser239in response to GSNO treatment suggest that PKG 
phosphorylates both MYPT1 and VASP at the sites examined in human platelets, 
with initial phosphorylation of the Ser695 residue occurring after 15 seconds with 
maximum being reached after 60 seconds incubation. These strongly suggest that 
PKG is the kinase responsible for phosphorylating these serine sites when active 
and possibly suggesting that the MYPT1Ser695 can be used as a marker of a 
functional endothelial NO/cGMP signalling (Neppl et al., 2009). 
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Figure.6.3 NO triggered activatory phosphorylation of MLCP 
 
WP (5x108) was incubated with GSNO (10µM) for differing times. Reactions were 
stopped with an equal volume of 2xLaemmli buffer. Proteins (40µg) were separated 
in 10% gradient gels and immunoblotted for anti-phospho-MLCPSer239 and anti-
phospho-VASPSer239. Blots are representative of two independent experiments. 
  
  
146 
 
6.2.4 Reversible phosphorylation of MLCP upon influence of NO 
In sections 6.2.2 and 6.2.3 the action of thrombin and NO upon their respective 
phosphorylation residues on MYPT1 was observed, and the consequent action on 
the phosphorylation of MLCSer19. The data suggested that the phosphorylation of 
MLCSer19 can be reversed by the action of the NO/PKG pathway specifically by the 
activity of the MLCP. The ability of NO/cGMP signalling to modulate the 
phosphorylation state of MLCSer19 and the key controlling residues of MLCP activity 
was investigated. In Figure.6.4a WP were pre-incubated with thrombin before 
addition of GSNO (10µM) under increasing durations demonstrating the inhibitory 
action of the endothelium. Thrombin pre-incubation for 25 seconds before addition of 
GSNO demonstrated phosphorylation at the inhibitory residues of MYPT1 at 
Thr696/853 and also MLCSer19, though all diminished markedly as addition of GSNO for 
5 seconds. The dephosphorylation of the inhibitory residues continued in a NO time-
dependent manner, as did the dephosphorylation of MLCSer19.The phosphorylation of 
the MLCP activatory residue, Ser695 become apparent only upon NO alone 
incubation, indicating the strong inhibitory nature of thrombin possibly induced by 
phosphorylation of MLCPThr696 residue. In Figure.6.4b GSNO was first to be 
incubated with WP, this accurately replicates an in vivo system as platelets will be 
exposed to nitric oxide in blood vessels prior to encountering a site of potential injury. 
Incubation of WP with GSNO (10µM) for increasing time points strongly inhibited 
thrombin (0.05U/ml) induced phosphorylation. Pre-treatment with GSNO for 5 
seconds before addition of thrombin inhibited, inhibitory phosphorylation of the 
residues Thr853/696 and maintained activity of MLCP by Ser695 phosphorylation. This 
is evident through the lack of phosphorylation at MLCSer19, and the action and activity 
of PKG in this role confirmed via phosphorylation of VASPSer239.   
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Figure 6.4 Reversible phosphorylation of MLCP upon influence of NO 
 
(A)WP (5x108) stimulated with thrombin (0.05U/ml) for 30seconds or pre-incubated 
thrombin first then addition of GSNO (10µM) for increasing time periods after 
stimulation. After 30 seconds incubation with the thrombin GSNO mix the reactions 
were stopped with addition of an equal volume of 2xLaemmli buffer. Proteins (40µg) 
were separated in 10% gradient gels and immunoblotted for anti-phospho 
MLCPThr853, anti-phospho-MLCPThr696, anti-phospho-MLCPSer695, anti-phospho-
MLCSer19 and anti-phospho VASPSer239. Blot is representative of two individual 
experiments. (B) WP (5x108) stimulated with thrombin (0.05U/ml) for 30 seconds or 
pre-incubated first with GSNO (10µM) for increasing time periods before addition of 
thrombin. After 30seconds incubation with GSNO and thrombin mix the reactions 
were stopped with addition of an equal volume of 2xLaemmli buffer. Proteins (40µg) 
were separated in 10% gradient gels and immunoblotted anti-phospho MLCPThr853, 
anti-phospho-MLCPThr696, anti-phospho-MLCPSer695, anti-phospho-MLCSer19 and anti-
phospho VASPSer239. Blot is representative of two individual experiments. 
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6.2.5 Action of NO mediating MLC phosphorylation via MLCP 
To further investigate the mechanisms by which NO regulates MLC phosphorylation, 
its effects on the inhibitory phosphorylation of MLCP induced by thrombin were 
studied. Stimulation with thrombin (0.05U/ml) induced phosphorylation of the 
inhibitory residues Thr696/853 and subsequently at MLCSer19. Thrombin induced 
inhibitory MYPT1 phosphorylation was completely blocked by Y-27632, a direct 
inhibitor of ROCK, confirming that both phosphorylation sites are targeted by ROCK, 
though the remaining MLC phosphorylation occurring via the cytosolicCa2+ elevation 
as indicated in Figure.6.5. The addition of GSNO (10µM) prior to thrombin addition 
eliminated not only the Ca2+ dependent pathway, but also the inhibition of ROCK 
dependent phosphorylation of the inhibitory residues upon MYPT1, preventing 
phosphorylation of MLC at Ser19. The combination of Y-27632 with NO mirrored the 
affects of either agent alone upon the MLCP indicating the same role.  
 
To examine whether MLCP was active under basal conditions, the serine 
phosphatase inhibitor calyculin A (100nM) was used. Incubation of platelets with 
calyculin A prior to addition of thrombin led to a strong phosphorylation of MLC, 
indicating that MLCP is constitutively active in order to prevent phosphorylation of 
MLCSer19 or possibly suggesting an active kinase (Deng et al., 2001). Subsequently, 
it was examined whether NO acts though the regulation of the MLCP or MLCK. 
Inhibition of the phosphatase via prevention of the assembly of the MLCP subunits 
with calyculin A resulted in the inhibitory affects of NO been lost and phosphorylation 
of inhibitory residues, on MLCPSer695, and ultimately MLCSer19 phosphorylation, thus 
indicating that NO acts via the activity of MLCP and not MLCK, confirmed by addition 
of ML-7 (5µM) failing to cause effect in combination with NO.  
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Figure.6.5 NO prevents MLC phosphorylation via the MLCP  
 
WP (5x108) stimulated with thrombin (0.05U/ml) for 30seconds or pre-incubated first 
with NO [GSNO (10µM for 1 min)], the Rho-kinase inhibitor [Y-27632 (10µM for 
20mins)], the MLCK inhibitor [ML-7 (5µM for 20mins)], and or the MLCP inhibitor 
[Calyculin A (100nM for 20mins)] except for the dashed line in the thrombin underline 
indicating no addition. Reactions were stopped by addition of2xLaemmli buffer. 
Proteins (40µg) were separated in 10% gradient gels and immunoblotted for anti-
phospho MLCPThr853, anti-phospho-MLCPThr696, anti-phospho-MLCPSer695, anti-
phospho VASPSer239, and phospho-MLCSer19. Blot is representative of two individual 
experiments. 
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6.3 Discussion 
In the present chapter the effects of the NO signalling pathway on the regulation of 
MLCP were examined as a mechanism by which the pathway influences the 
phosphorylation of MLC.   It is established in both smooth muscle cells and platelets 
that G-protein coupled signalling pathways lead to the phosphorylation of MLCP on 
Thr696/853. Phosphorylation of MLCP by ROCK, although other kinases have been 
implicated, on these residues is associated with inhibition of the phosphatase 
activity. Our data suggests a key role of ROCK in the phosphorylation of these 
residues in response to thrombin.  The phosphorylation of both of these inhibitory 
residues was blocked by the ROCK inhibitor Y-27632. In contrast, phosphoMLCP-
Thr696/853 in response to thrombin was unaffected by the MLC kinase inhibitor ML7. 
This is consistent with previous reports suggesting MYPT1 phosphorylation of the 
Thr853, which has been shown to inhibit MLCP activity by reducing the affinity of 
MYPT1/MLCP towards myosin (Velasco et al., 2002), and the Thr696 site apposing 
the adjacent activatory Ser695 site which yields an inactive form of MLCP (Muranyi et 
al., 2005) are primarily regulated via ROCK (Feng et al., 1999) confirmed by the 
incubation of the specific ROCK inhibitor Y-27632. Our data also clear demonstrates 
that NO signalling regulates the ability of the thrombin to induce this inhibitory 
phosphorylation, which is consistent with previous reports in smooth muscle 
(Nakamura et al., 2007; Wu et al., 1996; Sawada et al., 2001; Kitazawa et al., 
2009).Moreover this seems to happen in two ways.  Firstly, the addition of the NO 
prior to the addition of thrombin can prevent the ability of thrombin to induce 
inhibitory phosphorylation of MLCP.  Secondly, addition of NO after thrombin also 
caused a rapid reduction in the phosphorylation of phospho MLCPThr696/853. These 
two sets of observations suggest that there may be multiple mechanisms at work. 
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The inhibition of RhoA that was observed in Figure.5.6 could probably be the ability 
of GSNO to prevent phosphorylation in response to thrombin, that is, blocking RhoA 
prevents activation of ROCK and therefore phosphorylation of MLCP. However, 
other mechanisms may also be present. In smooth muscle cells MLCP has been 
shown to be a direct substrate for PKG. The phosphorylation of MYPT1Ser695 by a 
PKG dependent mechanism (Wooldridge et al., 2004) has been described.  
Phosphorylation of this site is associated with increasing activity of MLCP.  The pre-
phosphorylation at Ser695 blocked the adjacent inhibitory phosphorylation of Thr696 by 
thrombin, preventing MLCP inhibition and also reducing the total phosphorylated 
Thr696 after agonist addition, reducing the inhibition of MLCP activity. The study also 
demonstrated that the prior phosphorylation of Ser695 affected the rate at which the 
inhibitory sites and adjacent site Thr696 was phosphorylated, consistent with previous 
reports that Ser695 phosphorylation can interfere with the subsequent 
Thr696phosphorylation (Wu et al., 1996).  However, this phosphorylation of MLCP at 
Ser696was thought to be primarily driven by PKG1α, an isoform not present in 
platelets. Data from this study clearly demonstrate that NO can cause the 
phosphorylation of this site, which was mirrored by the phosphorylation of VASP, 
indicating a cGMP dependent kinase that phosphorylated the site. Therefore it is 
possible that NO acts via two mechanisms to prevent the phosphorylation of MLC, (I) 
inhibition of RhoA, which prevents the activation of ROCK, and (ii) the direct 
phosphorylation of MLCP, which may prevent subsequent inhibitory phosphorylation. 
Furthermore the findings suggest that MYPT1Ser695 is an additional marker for 
NO/cGMP signalling in platelets, which has been verified in cerebral vessels and the 
pulmonary artery, where L-NAME treatment completely abolished Ser695 
phosphorylation (Neppl et al., 2009). 
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Under conditions where the activity of the MLCP is inhibited by the incubation of 
calyculin A, the protective action of NO was lost on Ser695, and ultimately MLCSer19 
phosphorylation. Previous reports indicate that this triggers a spatial redistribution of 
MYPT1 subunits, thereby being unable to de-phosphorylate the MLC (Lontay et al., 
2005). This indicates that NO acts via the activity of MLCP and not MLCK, that were 
confirmed by addition of ML-7 failing to cause effect in combination with NO, 
revealing that MLCP activity but not MLCK activity was affected by NO/PKG 
pathway, consistent with reports from smooth muscle cells (Nakamura et al., 2007; 
Lee et al., 1997). 
 
The ability of NO to cause the dephosphorylation of MLCP at Thr696/853 occurs 
through an unknown mechanism. There were two potential explanations that could 
account for these effects of GSNO, (I) there could be a phosphatase that regulates 
the phosphorylation of MLCP, which in turn could be activated by NO, or (ii) NO 
directly modifies MLCP to such a degree that it is more susceptible to phosphatase 
activity. It has previously been shown in vascular smooth muscle (Kitazawa et al., 
2009) that the regulation of MLCP activity by NO is associated with a reduction in the 
phosphorylation of the specific inhibitory protein CPI-17 at Thr38, thereby causing 
MLCP disinhibition. In endothelial cells cAMP/PKA plays a similar role (Aslam et al., 
2010). However the role of NO to influence CPI-17 phosphorylation and activity and 
the regulation of MLCP in platelets is unknown, therefore these possibilities require 
further investigation. 
 
Shown in this chapter for the first time is the influence of NO/PKG on RhoA signalling 
in relation to downstream phosphorylation of MLCP in platelets and the ability of NO 
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to induce phosphorylation of RhoA resulting in reduced inhibitory phosphorylation of 
MLCP and unveiled the novel ability of NO to induce disinhibitory phosphorylation of 
MYPT1. 
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CHAPTER 7 GENERAL DISCUSSION 
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7. General Discussion 
Platelets play a vital role in haemostasis, stopping haemorrhaging following vascular 
injury though their ability to rapidly adhere to the damaged endothelium and sub 
endothelia matrix proteins and to aggregate (Ruggeri, 2002). The processes of 
platelet adhesion and aggregation are promoted via differing factors.  VWF, thrombin 
and ADP activate multiple intracellular signal transduction mechanisms which lead to 
shape change.  This drives the formation of filopodia and lamellipodia, secretion of 
granule contents, aggregate formation and ultimately thrombus formation (Johnson 
et al., 2007). Acto-myosin driven contraction is initiated by the phosphorylation of 
regulatory MLC by a network of kinases, including the Ca2+/calmodulin-dependent 
MLCK and Ca2+-independent ROCK (Somlyo et al., 2003). The present study initially 
wished to examine how NO regulated different aspects of Ca2+ mobilisation in 
platelets. However, during the course of the investigation we discovered a novel and 
potentially important mechanism of platelet regulation by NO that did not involve its 
known effects on intracellular Ca2+ levels. 
 
Platelet activation is tightly regulated under physiological conditions by antagonists 
such as the endothelium derived inhibitor, NO, which the platelets encounter as they 
circulate at the periphery of the blood vessel. NO inhibits platelet activation, 
adhesion and aggregation in vitro and in vivo (Naseem et al., 2008). The NO donor 
chosen here, an S-Nitrosothiol, to investigate this process is present in vivo as major 
redox form of NO in the plasma (Stamler et al., 1992) with the most abundant 
intracellular RSNO being the low molecular weight S-nitrosoglutathione (GSNO) 
(Stamler et al., 1992). Release of the NO activates the haem containing enzyme 
sGC, elevating levels of cGMP and causing activation of PKG, which now 
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phosphorylates target proteins leading to the inhibition of platelet activation (Schwarz 
et al., 2001).  There are number of PKG substrates that have been identified 
including inositol trisphosphate (IP3) receptors (Cavallini et al., 1996), the focal 
adhesion protein vasodilator-stimulated phosphoprotein (VASP) (Halbrugge et al., 
1990), IRAG, RapIb (Danielewski et al., 2005) and the TxA2 receptor (Wang et al., 
1998).  However, what remains to be established is how the phosphorylation of 
these targets is linked to the inhibition of specific platelet functions. Moreover, many 
of these targets were identified using non-physiological activation of the cGMP 
system. Therefore it is important to determine more physiological targets to fully 
understand how NO regulates platelets. 
 
Platelets respond to various agonistic stimuli by rapid changes in shape followed by 
aggregation and subsequent secretion of granule contents. Platelet shape change is 
the earliest functional response following activation with physiological agonists, 
which is accompanied by the rearrangement of the cytoskeleton (Daniel et al., 1984). 
This investigation utilised thrombin to induce the phosphorylation of contractile 
proteins, in this case namely MLC (Johnson et al., 2007) resulting in the 
reorganisation of cytoskeletal structure and in shape change. The phosphorylation of 
the MLC results in an increased development of actin-activated ATPase activity and 
reflects the contractile activity of actomyosin (Getz et al., 2010). Thrombin’s 
intracellular signalling is mediated and confirmed through the use of PAR analogues 
of the PARs coupling to Gq and G12/13 families of GPCR, which ultimately activate 
signalling cascades leading to MLCK and ROCK activation (Macfarlane et al., 2001). 
Both of these pathways contribute to the regulation of the phosphorylation state of 
MLC. Ca2+/calmodulin acts through the MLCK mediated phosphorylation at 
  
157 
 
MLCSer19residue; ROCK contributes by both deactivating the MLCP and potentially 
directly phosphorylating the Ser19 residue (Somlyo, 2003; Yazaki et al., 2005).  
 
7.1.1 First key finding 
 
The major observation in this study was the ability of NO to inhibit the 
phosphorylation of MLC. 
 
The experimental approaches used the NO donor GSNO, but found that the 
inhibitory effect of GSNO was solely mediated via NO-GC and cGMP, as NO 
mediated effects were abolished under conditions of sGC inhibition, confirming it as 
the critical node in the NO signalling cascade in platelets (Riba et al., 2008). This 
was important since GSNO has been shown to have cGMP-independent effects on 
platelets (Irwin et al., 2010). These findings of a cGMP dependent mechanism that 
reduces MLC phosphorylation is consistent with previous findings suggesting NO 
role in smooth muscle and endothelial cells in inducing relaxation via this mechanism 
(Rivero-Vilches et al., 2003; Nakamura et al., 2007). 
 
7.1.2 Second key finding 
 
This study has confirmed ROCKs dual role in platelets and shown that this 
mechanism does not therefore increase phosphorylation directly but potentially 
decreases the dephosphorylation upon the MLC residue. 
 
Phosphorylation of MLC triggers activation of the contractile machinery, regulated by 
the Ca2+ dependent MLCK and Ca2+ independent Rho-Kinase (ROCK) (Goeckeler et 
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al., 1995; Garcia et al., 1995). In the context of the present study ROCK is of special 
interest. It was postulated that ROCK may have a dual role; this had previously been 
shown in smooth muscle firstly via the direct phosphorylation of the MLC (Amano et 
al., 1996), and secondly through the phosphorylation on MYPT1Thr696/853, resulting in 
the inhibition of MLCP catalytic activity, and its affinity to bind to myosin (Fukata et 
al., 2001; Velasco et al., 2002), thereby increasing in MLC phosphorylation.  
 
The crucial role of ROCK in mediating sustained MLC phosphorylation and in 
smooth muscle contraction has focused attention on the ability of NO to inactivate 
RhoA and its effector ROCK (Etter et al., 2001; Sauzeau et al., 2000). Previous 
studies on smooth muscle and NK cells have suggested the negative regulation of 
Rho-dependent signalling via PKA phosphorylating activated, membrane bound 
RhoA at the site Ser188, and accelerating its inactivation and its dissociation from its 
membrane bound substrates (Murthy et al., 2003).The data in this study shows for 
the first time that NO/PKG signalling pathways induce phosphorylation of RhoA on 
Ser188. This study demonstrates that NO/PKG phosphorylates RhoA, which inhibits 
its signalling probably by retaining RhoA in the cytosol or by terminating an already 
active RhoA signalling pathway in platelets (Murthy et al., 2003).   
 
7.1.3 Third key finding 
 
This study shows for the first time that NO/PKG can phosphorylate MYPT1 at Ser695 
in platelets. 
 
Though as PKG cannot dephosphorylate MLCSer19 directly, it was anticipated that it 
would act indirectly via altering activity of the MLCP or inhibition of the MLC kinase 
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(Bauer et al., 1999). The inactivation of RhoASer188 via addition of GSNO was thought 
likely to inhibit the activation of ROCK, which in turn may account for the 
observations that inhibitory phosphorylation of MYPT1 at the residues Thr853 and 
Thr696 in human platelets is reduced. These sites have also been shown to be 
governed by ROCK in endothelial cells (Ito et al., 2004).  
 
Although regulation of the MLCP via addition of NO has been demonstrated in 
endothelial, smooth muscle and porcine aorta (Hartel et al., 2007; Nakamura et al., 
2007; Eto et al., 1995), the exact regulation of MLCP by PKG in human platelets has 
not. As mentioned previously, this is the first study which shows that NO/PKG can 
phosphorylate MYPT1 at Ser695 in platelets. This is associated with reduced 
phosphorylation of the inhibitory residues Thr696/853 by ROCK, possibly by steric 
hindrance (Kitazawa et al., 2009), leading to MLC dephosphorylation. NO potentially 
reduces the ability of the agonist to inhibit phosphatase activity and when reversed, 
the pre-phosphorylation of Thr696 can be overturned. Phosphorylation of the residue 
Ser695 on MYPT1 demonstrates the mutual exclusion of the phosphorylation of the 
inhibitory residues by ROCK based on the fact of being adjacent to the inhibitory site 
and PKG upstream deactivation (Nakamura et al., 2007). 
 
7.1.4 Fourth key finding 
 
The prior phosphorylation of Ser695 affected the rate at which the inhibitory sites and 
adjacent site Thr696 was phosphorylated.  This was shown to be consistent with 
previous reports that Ser695 phosphorylation can interfere with the subsequent Thr696 
phosphorylation in smooth muscle (Wooldridge et al., 2004; Wu et al., 1996). 
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 GSNO significantly reduced MLCSer19 phosphorylation and diminished the ability of 
thrombin to activate the RhoA pathway thereby preventing inhibitory phosphorylation 
of MYPT1 residues. Though the pre-phosphorylation at the inhibitory sites upon 
MLCP affects that rate at which activatory phosphorylation at Ser695 accrues. 
 
These findings suggest that MYPT1Ser 695 is an additional marker for of NO/cGMP 
signalling which has been alternatively verified in cerebral vessels and endothelial 
denudation of pulmonary artery, where L-NAME treatment completely abolished 
Ser695 phosphorylation (Neppl et al., 2009). 
 
The data produced here provides new insights into the mechanism by which GSNO 
induced PKG activation inhibits Ca2+ elevation required for MLCK activity, blocks the 
two Rho dependent pathways; phosphorylation of MLC and inhibitory 
phosphorylation of MYPT1. While phosphorylating the Ser695 site resulting in an 
increase in MLCP activity leading to the dephosphorylation of the MLC, thus 
inhibiting cytoskeletal rearrangement and platelet shape change, though critically in 
the study we have identified two novel substrates for PKG signalling in platelets. 
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8. Further Work 
This further work to be carried out will reinforce the preliminary data that has already 
been accumulated; to advance our understanding of the mechanisms which NO 
regulates MLCP activity in platelets. 
 
 The modulation of RhoA/ROCK mediated inhibition of MLCP by NO/PKG 
Aim: To examine if NO activates MLCP through inhibition of RhoA/ROCK. 
NO inhibits shape change mediated by RhoA/ROCK. Since RhoA/ROCK 
mediate their effects though inhibitory phosphorylation of MYPT1, the data 
here suggests a link between NO inhibition of shape change and the 
phosphorylation of MLCP. The influences of NO/PKG on RhoA signalling in 
relation to downstream phosphorylation of MLCP will be further investigated. 
 
• The influence of NO on RhoA/ROCK mediated inhibition of MLCP. 
 
o The activity of RhoA in agonist and NO treated platelets will 
be established using a GST-pull down assay. 
 
o To determine if inhibition of RhoA influences the activity of 
MYPT1 performed using Sensolyte fluorimetric phosphatase 
assay with immunoprecipitated MLCP. 
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• The influence of NO on RhoA/ROCK/MLCP interactions and 
subcellular localisation. 
Activation of smooth muscle RhoA requires translocation from the 
cytosol to the membrane (Gong et al., 1997) where it interacts with 
ROCK and potentially MLCP. It will be established the effect of NO 
on this process in platelets. 
 
o Determine if NO can influence either the translocation of 
RhoA to the membrane or accelerate its translocation back 
to the cytosol utilising differing fractions that will be 
immunoblotted for RhoA in its native or phosphorylated form 
over several time points. 
 
o Examine if these proteins form a multi-protein complex and if 
NO inhibits this association to prevent inhibition of MYPT1. 
 
 
• Does PGI2/PKA modulate RhoA/ROCK mediated inhibition of 
MLCP? 
RhoA is phosphorylated, inhibited and relocalised from the 
membrane to cytosolic compartments by PKA in numerous cell 
types (Murthy et al., 2003). 
 
o Although study focus on NO, it is fundamentally important to 
examine if PGI2 influences the activity of MYPT1. 
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 The role of phosphorylation in the regulation of platelet MYPT1 activity 
by NO/PKG 
Aim: To determine how NO/PKG signalling influences phosphorylation of 
MYPT1, downstream activity and subcellular localisation of MLCP. 
This will characterise the effects of NO on the multiple phosphorylation sites 
of MYPT1 and how these post-translational modifications influence MLCP 
activity, structure of the haloenzyme and cellular localisation. 
 
• Characterisation of phosphorylation of MYPT1 Ser695 by NO 
signalling: to confirm that the phosphorylation of MYPT1 on Ser695 
increases MLCP activity. 
 
• The influence of NO on inhibitory phosphorylation of MYPT1. 
Examine the interplay between the activatory and inhibitory 
phosphorylation sites, and the influence of NO on the 
phosphorylation sites and MLCP activity. 
 
o To determine the influence of MYPT1 phosphorylation on 
enzyme activity. 
 
• Is MYPT1 phosphorylation associated with changes in cellular 
location? 
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Stimulation of smooth muscle leads to the translocation of MLCP 
from the cytosol to the membrane by ROCK dependent 
mechanisms (Shin et al., 2002: Lontay et al., 2005), leading to 
potential inhibition of the enzyme. The cellular location and potential 
translocation of platelet MLCP under NO treatment requires 
clarification. 
 
o If translocation is required for inhibitory phosphorylation of 
MLCP or the reverse. 
 
o If the different phosphorylation states reflect differences in 
cellular location. 
 
• How does NO influence the structure of the MLCP holoenzyme. 
Under resting conditions platelet MLCP exists as a 130kDa 
heterotrimer (Suzuki et al., 1999), although it is unclear if this is 
maintained under activatory conditions. 
 
o Is the MLCP maintained as a heterotrimer or dissociate into 
different cellular fractions according to its phosphorylation 
state? 
 
 NO regulation of MLCP activity through modulating CPI-17 
Aim: To examine the ability of NO and PGI2 to modulate CPI-17 mediated 
inhibition of MLCP. 
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CPI-17 is an important endogenous regulator of MLCP (Ito et al., 2004). 
However the ability of both cGMP/PKG and cAMP/PKA to influence CPI-17 
regulation of MLCP in platelets is unknown and so the influence of NO and 
PGI2 on platelet CPI-17 shall be characterised. 
 
• Does NO influence the phosphorylation and activity of CPI-17? 
 
o Does ROCK phosphorylate CPI-17 or multiple pathways? 
 
o Influence of NO on CPI-17, if NO prevents and/or induces 
dephosphorylation of CPI-17 and its effects on MLCP 
activity. 
 
 
o If CPI-17 affects the interaction between PP1c and the 
MLCP 
 
• Does PGI2/PKA influence the phosphorylation and activity of CPI-
17? 
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Appendix I 
1-Isolation of human platelets via pH method 
Buffers 
 
• Acid Citrate Dextrose (ACD) pH 6.5 
 
COMPOUND MOLARITY 
(mM) 
Glucose 113.8 
Tri-Sodium citrate 29.9 
Sodium Chloride 72.6 
Citric Acid 2.9 
 
• Wash Buffer pH 6.5 
 
COMPOUND MOLARITY 
(M) 
Citric Acid 0.036 
EDTA 0.010 
Glucose 0.005 
Potassium 
Chloride 
0.005 
Sodium 
Chloride 
0.09 
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• Tyrodes Buffer pH 7.4 
 
COMPOUND MOLARITY 
(mM) 
Sodium 
Chloride 
150 
HEPES 
sodium salt 
5 
NaH2PO4anh 0.55 
NaHCO3anh 7 
Potassium 
Chloride 
2.7 
Magnesium 
Chloride 
0.5 
Glucose 5.6 
Equipment 
 
 
• Falcon Tubes (15 and 50ml)……………………………………Sarstedt 
 
• Centrifuge 
 
• Butterfly-21 Venisystems……………………………………….Abbot Labs 
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2-Calculation of platelet count 
Buffer 
- Ammonium Oxalate; (1%w/v) in dH2O 
Equipment 
• Neubauer cell counter 
 
• Inverted light microscope 
3-Determionation of protein content 
Buffer (Ratio-1:1) 
 
• Tyrodes Buffer 
COMPOUND MOLARITY 
(mM) 
Sodium 
Chloride 
150 
HEPES 
sodium salt 
5 
NaH2PO4anh 0.55 
NaHCO3anh 7 
Potassium 
Chloride 
2.7 
Magnesium 
Chloride 
0.5 
Glucose 5.6 
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• Lysis Buffer 
 
COMPUND MOLARITY (mM) 
Sodium Chloride 150 
Tris-base 10 
EGTA 10 
EDTA 1 
 
Assay Kit 
 
• DC Protein Assay………………………………………………..BioRad 
 
Equipment 
 
 
• 96-well cell culture plate…………………………………………Sarstedt 
 
• Multiplate reader with 750nm filter 
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4-Measurment of platelet aggregation 
Buffers 
• Tyrodes Buffer 
 
COMPOUND MOLARITY 
(mM) 
Sodium 
Chloride 
150 
HEPES 
sodium salt 
5 
NaH2PO4anh 0.55 
NaHCO3anh 7 
Potassium 
Chloride 
2.7 
Magnesium 
Chloride 
0.5 
Glucose 5.6 
 
 
Equipment 
 
• Aggregation module-duel channel ……………………………….Payton 
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4-Sample preparation for Sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) 
 
Buffer 
 
• Laemmeli buffer (2x) – pH6.8 
 
COMPOUND MOLARITY 
SDS 4%w/v 
2-Mercaptoethanol 10%v/v 
Glycerol 20%v/v 
Tris-Base 50mM 
Bromophenol blue Trace 
 
 
 
Equipment 
 
• Aggregation module-duel channel ……………………………….Payton 
• Aggregation cuvettes 
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5-Methods for SDS-PAGE 
 
Buffers 
 
• Buffer 1 pH 8.8 
 
COMPOUND MOLARITY 
Tris-Base 0.5M 
SDS 0.4%w/v 
 
• Buffer 2 pH 6.8 
 
COMPOUND MOLARITY 
Tris-Base 1.5M 
SDS 0.4w/v 
 
Equipment 
 
• Miniprotean 3 cell…………………………………………………BioRad 
• Gradient mixer…………………………………………………….BioRad 
• Peristaltic pump 
• Butterfly-21 Venisystems………………………………………..Abbot Labs 
• Plastic tubing 
• Biotin protein ladder ………………………………………………Cell signalling 
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Gradient gel (10-18%) composition for 1.5mm casting plates 
 
COMPOUND 10% Running Gel 18% Running Gel 3% Stacking Gel 
dH2O 1.418ml 0.708ml 4.87ml 
Buffer 1 0.886ml 0.886ml  
Buffer 2   1.87ml 
30% Acrylamide 1.182ml 1.961ml 0.75ml 
TEMED 2µl 2µl 10µl 
Ammonium 
Persulphate 10% 
18µl 18µl 75µl 
 
10% gel for 2x 1.5mm casting plates 
 
COMPOUND 10% Running Gel 3% Stacking Gel 
dH2O 6.48ml 4.87ml 
Buffer 1 4ml  
Buffer 2  1.87ml 
30% Acrylamide 5.3ml 0.75ml 
TEMED 5.3µl 10µl 
Ammonium Persulphate 
10% 
65µl 75µl 
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6-Western Immunoblotting 
 
Buffers 
• Transfer Buffer  
COMPOUND MOLARITY 
Tris-Base 25mM 
Glycine 0.2M 
Methanol 20% v/v 
 
• Tris Buffered Saline Tween (TBST0.1%) pH 7.4 
 
 
 
• ECL-1 
 
COMPOUND MOLARITY 
Luminol  250mM 
P-Coumoric 90mM 
Tris-Base(pH 8.5) 100mM 
 
COMPOUND MOLARITY 
Sodium Chloride 150mM 
Tris-Base 20mM 
Tween-20 0.1% v/v 
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• ECL-2 
 
COMPOUND MOLARITY 
H2O2 (30%) 0.2% v/v 
Tris-Base (pH 8.5) 100mM 
 
 
• ECL 1 & ECL 2 combined in 1:1 ratio before use 
 
• Developer solution; prepared in 1:5 ratio with dH2O 
 
• Fixer solution; prepared in 1:5 ratio with dH2O 
 
 
 
Equipment 
 
• Hybond-P PVDF membrane…………………………………...GE Health Care 
• Mini Trans-Blot electro transfer cell……………………………BioRad 
• Exposure cassette……………………………………………….Sigma 
• Hyper film…………………………………………………………GE Health Care 
• Microplate shaker 
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9-Platelet preparation for calcium assay 
 
 
Buffer 
 
 
• Calcium buffer pH 7.4 With the addition of CaCl2 (1mM) or EGTA (1mM) as 
required 
 
COMPOUND MOLARITY 
Sodium Chloride 145mM 
Potassium Chloride 5mM 
Magnesium Chloride 1mM 
HEPES 10mM 
Glucose 10mM 
 
 
 
Equipment 
• Fluorospectrometer…………………………….PhotonTechnology International 
• Fura-3……………………………………………………………..Molecular Probes
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Appendix II 
 
 
Inhibitors/Activators 
Compound Concentration Target 
2-APB 0.1-100µM SOC 
SKF-96365 0.1-100µM SOC 
Carbenoxolone 100-400µM GAP Junctional 
Channels 
Gd3+ 0.1-100µM TRPC4/5 
GSNO 0.1-100µM sGC 
BAPTA 20µM Intracellular Ca2+ 
EGTA 1mM Extracellular Ca2+ 
SFLLRN-NH2 6µM PAR-1 
AYPGKF-NH2 60µM PAR-4 
ODQ 20µM sGC 
Y-27632 10µM RhoA 
Thrombin 0.01-0.1U/ml PAR-1/4 
Calyculin A 100nM Ser/Thr Phosphatases 
ML-7 5µM MLCK 
Indomethacin 10µM TxA2 
Apyrase 1µ/ml ADP 
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Appendix III 
Antibody List 
Antibody Company 
Anti-rabbit IgG: HRP Amersham 
Anti-Biotin protein ladder Cell Signalling 
Anti-mouse IgG: HRP Amersham 
Anti-phospho VASP (Ser239) Cell Signalling 
Anti-β tubulin Upstate 
Anti-phospho RhoA (Ser188) Santa Cruz 
Anti-phospho MLC (Ser19) Santa Cruz 
Anti-phospho MLCP (Thr853) Cell signalling 
Anti-phospho MLCP (Thr696) Santa Cruz 
Anti-phospho MLCP (Ser695) Santa Cruz 
Anti-TRPC1 (T1E3) Leeds University 
Anti-TRPC4 (T45E3) Leeds University 
Anit-TRPC5 (T5E3) Sigma 
Anti-TRPC6 (T367E3) Leeds University 
Anit-TRPC6 (N-Termini) Alomone 
Anti-Stim1 Sigma 
Anti-Stim2 Sigma 
Anti-Orai1 Sigma 
Anti-Orai2 Sigma 
Anti-Orai3 Sigma 
Goat Anti-Rabbit-IgG: FITC Sigma 
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Appendix IV 
 
SiRNA List 
 
siRNA Company 
si-pool Sigma 
si-scramble Sigma 
si-TRPC1 Sigma 
si-TRPC3 Sigma 
si-TRPC4 Sigma 
Si-TRPC6 Sigma 
si-Bcl2 Sigma 
 
Appendix V 
 
Primer sequences for RT-PCR 
Gene 
Name 
 Primers (5’ to3’) 
β-actin F TTGTAACCAACTGGGACGATATG 
R GATCTTGATCTTCATGGTGCTGG 
GAPDH F CCATCCACAGTCTTCTGG 
R CCCTCCAAAATCAAGTGG 
TRPC1 F TGGTATGAAGGGTTGGAAGAC 
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(T1) R GGTATCATTGCTTTGCTGTTC 
TRPC3 
(T3) 
F TGACTTCCGTTGTGCTCAAATATG 
R CCTTCTGAAGTCTTCTCCTTCTGC 
TRPC4 
(T4) 
F TCTGCAGATATCTCTGGGAAGGATGC 
R AAGCTTTGTTCGAGCAAATTTCCATTC 
TRPC5 
(T5) 
F TGAGAACGAGAACCTGGAG 
R TACTCGGCCTTGAACTCATTC 
TRPC6 
(T6) 
F TACGATGGTCATTGTTTTGC 
R TCTGGGCCTGCAGTACATATC 
TRPC7 
(T7) 
F ATCTTCGTGGCCTCCTTCAC 
R AACGCTGGGTTGTATTTGGC 
STIM1 (S1) F TGTGGAGCTGCCTCAGTATG 
R AAGAGAGGAGGCCCAAAGAG 
STIM2 (S2) F CAGCCATCTGCACAGAGAAG 
R AGGTTCGTGCACTGCTATCC 
ORAI1 
(O1) 
F AGGTGATGAGCCTCAACGAG 
R CTGATCATGAGCGCAAACAG 
ORAI2 
(O2) 
F CATAAGGGCATGGATTACCG 
R CGGGTACTGGTACTGCGTCT 
ORAI3 
(O3) 
F GGCTACCTGGACCTCATGG 
R GGTGGGTACTCGTGGTCACT 
 
Note: F forward, R: reverse. 
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